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Figure 1. The enzymes and reactions of the (de)ubiquitination pathway. Image adapted from17.  
Post-translational modification
When RNA translation has completed and the 
proteins have been properly folded, most proteins 
are subject to a diverse range of post-translational 
modifications that affect their function. It is an 
important cellular strategy that enables the cell to 
react dynamically to intracellular or environmen-
tal changes caused by exposure to stress factors, 
growth stimuli or differentiation signals. Proteins 
are modified by methylation, acetylation, hydroxyl-
ation, phosphorylation or conjugated to ubiquitin 
(Ub) and ubiquitin-like (Ubl) proteins. The post-
translational modification with Ub of proteins has 
emerged to play an essential role in the regulation 
of virtually all aspects of cell biology 1,2.
Ubiquitination pathway
Protein ubiquitination was discovered in the 1980s 
as a post-translational modification in which lysine 
residues of a target protein are modified with the 
addition of Ub. This small protein is a highly con-
served 76 amino-acid polypeptide of ~8500 Da3. 
The crystal structure of Ub revealed a distinctive 
fold, the β-grasp fold, which is also present in a 
group of proteins with distinct functions: ubiqui-
tin-like (Ubl) proteins4-6.
 Through the sequential action of three 
enzymes a target protein is modified by covalent 
ligation to Ub (Figure1). In the first step of the 
ubiquitination pathway, Ub is activated by a spe-
cific activating enzyme (E1) UBA1. UBA1 first 
binds MgATP and Ub and catalyzes Ub C-terminal 
acyl-adenylation. Secondly, the catalytic cysteine 
residue in the E1 attacks the ubiquitin-adenylate
to form the activated ubiquitin-E1 complex via 
a high-energy thioester bond. In the second step 
of the ubiquitination pathway, the Ub loaded E1 
engages one of up to tens of related E2 conjugat-
ing enzymes and then transfers the activated Ub 
to an active site cysteine residue of the E2. Finally 
the Ub is covalently linked by its C-terminus in an 
amide isopeptide linkage to an ε-amino group of a 
lysine residue of a target protein, which is catalyzed 
through the coordinated function of E3 Ub ligases. 
There are three different types of E3 ligase, RING 
(the Really Interesting New Gene), U-box and 
HECT (Homologous with E6-associated protein 
C-Terminus) domains and contain binding sites for 
both charged E2s and ubiquitinated substrates. For 
the largest class of E3s the RING family and the 
RING-related U-box family an ε-amino group of a 
lysine residue in the associated substrate attacks the 
thioester of the transiently associated charged E2 to 
make an isopeptide bond with Ub. The discharged 
E2 then dissociates from the -E3, allowing a second 
charged E2 to interact with the E3. This facilitates 
a second round of Ub transfer, either by attack of a 
lysine residue on Ub itself or by attack of a different 
lysine residue on the substrate7-11. 
 In addition, through a similar cascade 
of reactions catalyzed by evolutionary related en-
zymes, the Ubl proteins (URM1, ATG12, Nedd8, 
SUMO, FAT10, ISG15 etc.) can also be conjugat-
ed to target proteins9,11-16.
 Because Ub itself contains seven accep-
tor lysines that can be a target of Ub conjugation, 
different types and lengths of Ub chains can be 
formed. Thus target proteins not only are ubiqui-
tinated with a single Ub on a single lysine residue
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(mono-ubiquitination) or on multiple ly-
sine residues (multi-mono-ubiquitination), 
but they are also modified with different 
types of poly-ubiquitin chains (Figure 2). 
           In addition Ub chains can be assembled in 
a head-to-tail or linear configuration through the 
α-amino  group at the N-terminus. An important 
difference between linear and lysine-linked chains is 
the chemistry of the linkage (isopeptide compared 
with peptide bond). To add to the complexity of 
ubiquitination, quantitative studies have shown 
the existence of branched Ub chains, although the 
specific pathways in which these more complex 
poly-ubiquitin chains are involved remain poorly 
understood18-21.
Deubiquitination pathway
Protein ubiquitination, similar to other regulated 
targeting pathways, is a reversible process and in the 
last decade protein deubiquitination has emerged as 
an important regulatory step in the ubiquitin-de-
pendent pathways. In this deubiquitination process 
the isopeptide bond between Ub and a target pro-
tein or between Ub molecules in a poly-ubiquitin 
chain, is hydrolyzed by proteases named deubiqui-
tinases (DUBs) (Figure 1)22-25.
Proteases
Proteases likely arose at the earliest stages of protein 
evolution as simple destructive enzymes necessary 
for protein catabolism and the generation of amino 
acids in primitive organisms. However, many years 
of studies on proteases have shown their relevance 
in the control of multiple biological processes in all 
living organisms. Thus proteases regulate the fate, 
localization and activity of many proteins, modu-
late protein-protein interactions, create new bioac-
tive molecules and generate, transduce and amplify 
molecular signals. Because of their essential roles in 
different cellular processes, alterations in the struc-
ture and expression patterns of proteases underlie 
many human pathological conditions such as can-
cer, neurodegenerative disorders, and inflammatory 
and cardiovascular diseases26-29.
 Based on the mechanism of catalysis, 
proteases are classified into six distinct classes: as-
partic, glutamic, metalloproteases, cysteine, serine 
and threonine proteases. The first three classes 
utilize an activated water molecule as a nucleo-
phile to attack the peptide bond of the substrate. 
 In contrast to the remaining protease 
classes, the nucleophile is an amino acid residue 
(Cys, Ser or Thr) located in the active site30. Most 
proteases hydrolyse the α-peptide bonds between 
naturally occurring amino acids, but there are some 
proteases that perform slightly different reactions. 
In particular, the DUBs are able to hydrolyze the 
isopeptide bonds in Ub and Ubl protein conju-
gates.
DUBS
The human genome encodes more than 100 puta-
tive DUBs that are predicted to be active31. Even 
though there is a lack of knowledge about the regu-
lation and roles of many DUBs, several generaliza-
tions have emerged in recent years.
 Most DUB activity is cryptic. That is 
DUBs require substrate association or a scaffolding 
protein to achieve competent conformation. So like 
most other proteases, their activity is carefully con-
trolled to prevent unnecessary cleavage of non-sub-
strates32. Other DUBs are covalently modified by 
phosphorylation, ubiquitination or sumoylation, 
which are likely to influence activity, localization 
and half-life.
 In addition to their active-site core do-
mains, most DUBs contain insertions within the 
catalytic domain and N- and C-terminal exten-
sions, which participate in the substrate binding 
and recognition and direct the assembly of multi-
protein complexes that localize DUBs and assist 
in substrate selection. These extensions contain 
predicted ubiquitin-binding domains (UBDs), in-
cluding the zinc finger ubiquitin-specific protease 
domain (ZnF-UBP domain), the ubiquitin-inter-
acting motif (UIM) and the ubiquitin-associated 
domain (UBA domain)33,34. The presence of one or 
multiple Ubl domains is also widely predicted35. 
 DUB activities fall into three major 
functional categories (Figure 2). First, Ub can be 
transcribed from several genes as a linear fusion of 
multiple Ub molecules or with ribosomal proteins, 
such that the generation of free Ub requires DUB 
activity (Figure 2a). Second, DUBs can remove Ub 
chains from post-translationally modified proteins, 
leading to reversal of Ub signaling or to protein 
stabilization by rescue from degradation (Figure 
2b, c). However, once proteins are targeted for 
degradation, associated DUB activities can prevent 
degradation of Ub and maintain Ub homeostasis 
(recycle of Ub) (Figure 2d,e)36,37. Third, DUBs can
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Figure 2. Schematic diagram of DUB function. Image adapted from38.
be used to edit the form of Ub modification by 
trimming Ub chains and thereby help to exchange 
one type of Ub signal for another (Figure 2f )38,39.
 The DUB family can be classified into 
five distinct subfamilies: ubiquitin C-terminal 
hydrolases (UCHs), ubiquitin-specific prote-
ases (USPs), ovarian tumor proteases (OTUs), Jo-
sephins and JAB1/MPN/MOV34 metalloenzymes 
(JAMMs). The UCH, USP, OTU and Josephin 
subfamilies are Cys proteases, whereas the JAMM 
family members are zinc metalloproteases. A more 
comprehensive view on these five subfamilies of 
DUBs will be given in chapter 2: A genomic and 
function inventory of deubiquitinating enzymes.
Ubiquitin signaling
Types of ubiquitination
Depending on the type of Ub modification (at-
tachment of a single Ub molecule or a Ub chain), 
a target protein can undergo different cellular fates 
(Figure 3). Multi-mono-ubiquitination has been 
shown to be involved in triggering the internaliza-
tion of cell-surface receptors and their subsequent 
degradation in lysosomes or recycling to the cell 
surface40. Mono-ubiquitination is also involved in
the DNA-damage response pathway, where histones 
or the DNA sliding clamp, PCNA (Proliferating-
Cell Nuclear Antigen), are mono-ubiquitinated41,42.
 The most well studied example of Ub sig-
naling is the Ub chain conjugation through the lysine 
at position 48 of Ub which leads to the proteasomal 
degradation of the modified target protein7,43-45.
 Also, proteins modified with K11-linked 
poly-ubiquitin chains are targeted for degradation 
by the proteasome. In addition proteins from di-
verse cellular processes were identified as being 
modified and regulated by K11-linked chains, sug-
gesting that K11 is employed in many different 
pathways (e.g. in ERAD (Endoplasmic-Reticulum-
Associated Degradation) and in the cell cycle regu-
lation21,46,47). 
 Another degradation signal is the K29-
linked poly-ubiquitination. Proteins conjugated 
with K29-linked chains are degraded by lysosomal 
rather than proteasomal degradation pathways48,49. 
K29-linked poly-ubiquitin chains are also impli-
cated in the UFD (Ubiquitin Fusion Degradation) 
pathway, in which the N-terminus of target pro-
teins are attached to a Ub leading to the extension 
with a K29- or K48-linked Ub chain, resulting in 
efficient degradation of the fusion protein50. Besides
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playing a role in protein degradation pathways, the 
K29-linked poly-ubiquitination also is involved in 
kinase modification, blocking their activity51.
 In contrast to the degradation signals of 
K11-, K29- and K48-linked Ub chains, K63-linked 
poly-ubiquitin chains participate in endocytosis, in 
DNA repair and in signaling kinase complexes52-59. 
 While several reports show K6-linked 
poly-ubiquitination, mediated by the heterodi-
meric RING E3 ligase complex, BRCA1/BARD1, 
might be involved in DNA repair60-62.
 Although mass spectrometry proteomics 
did find K27- and K33-linked Ub chains, no clear 
cellular role has been associated with these types of 
Ub chains21. A U-box E3 ligase, Ufd2, was found 
to catalyze the formation of K27- and K33-linked 
Ub chains, which suggests a role in the UFD path-
way63. The K33-linked Ub chains have also been 
shown to be involved in kinase modification51.
 The most recently described type of Ub 
polymer is the linear Ub chains, which are assem-
bled by a specific ligase complex called the linear 
Ub-chain assembly complex (LU BAC) and are 
crucial for NF-κB signaling19,64-66. 
 Mass spectrometry proteomics has also 
shown that Ub chains can have more complex to-
pologies. Doubly modified Ub peptides indicative 
of branched Ub chains have been detected67. The 
ubiquitination of lysine residues in close proximity 
of each other as a product of in vitro reactions were 
detected and the K27/K29 forks have been found 
in yeast cells68. It is still unclear which type of sig-
nals these branched Ub chains mediate, however 
they show the complexity of the Ub system. 
 The function, structure and physiological 
roles of K48- and K63-linked chains in ubiquitina-
tion have been studied and published extensively. 
However, relatively only a few reports deal with 
the remaining chain types, some of which have not 
been studied at all. A likely reason is that only K48- 
and K63-linked chains have been available and 
protocols for generation of these Ub chains have 
been published69-72. El Oualid and colleagues re-
cently published the chemical synthesis of all types 
of di-ubiquitin73, which in chapter 4 are utilized 
for investigating the differential modulation of the 
activity of a sub-family of DUBs.
Figure 3. Different types of ubiquitination. Image adapted from20.
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Reading out of ubiquitin signals in different 
cellular processes
In all the processes described above, Ub acts as a 
signaling component that can trigger molecular 
events. This is achieved by operating as a reversible 
and highly versatile regulatory signal for ubiqui-
tin-binding domains (UBDs) in cellular proteins.
The effects of protein ubiquitination are mediated 
through a class of specific UBDs, with more than 
twenty different families identified to date. UBDs 
are diverse modules in a protein that can bind, 
and often distinguish, different types of Ub modi-
fications. The UBDs differ both in structure and 
in the type of Ub recognition that they use. Most 
commonly, they fold into α-helical structures that 
bind a hydrophobic patch in the β-sheet of Ub. 
Other UBDs bind Ub through two discontinuous 
α-helices. It is currently unknown why so many vari-
ations of helical structures have evolved to interact 
with Ub and regulate its downstream signaling34,74.
The structures of many UBDs in complex with mo-
no-ubiquitin have been determined revealing inter-
actions with multiple surfaces on Ub and not just 
the Ile44 hydrophobic patch region. The affinities 
of the mono-ubiquitin binding of these domains 
span a wide range (Kd= 1-100µM). As a crude gen-
eralization binding domains in enzymes with activi-
ties in or regulated by ubiquitination tend to have 
affinities in the low micromolar range. Adaptors 
that bind ubiquitinated proteins contain domains 
that typically bind mono-ubiquitin with affinities 
of about 100µM or lower74-77. 
 Linkage-specific Ub recognition contrib-
utes to the diverse set of functional cellular process-
es associated with ubiquitination. Although some 
UBDs showed little discrimination between differ-
ent Ub chain types, others do prefer certain ubiq-
uitin-linkages. Several UBDs can selectively bind to 
K63-linked Ub chains. For example, NZF domains 
of TAK1-binding protein 2 (TAB2; also known as 
TRAF-binding protein domain) preferentially bind 
to K63- over K48-linked Ub chains78. 
a single K63 linkage, thus defining selectivity. As 
mentioned in the previous paragraph, the linear 
Ub chains have been implicated in the activation 
of NF-κB signaling pathway. Several proteins that 
regulate this pathway, including NF-κB essential 
modulator (NEMO), A20-binding inhibitor of 
NF-κB proteins (ABIN) and optineurin, contain 
the Ub binding in ABIN and NEMO domain 
(UBAN domain), which specifically binds to linear 
Ub chains66,81,82. Specific mutations of NEMO that 
block interactions with linear Ub chains impair the 
activation of IκB kinase (IKK) and NF-κB in re-
sponse to tumor necrosis factor-α (TNF-α) stimu-
lation. 
UBDs in DUBs
As stated previously, also DUBs contain UBDs, 
which might directly regulate their activity or 
specificity. USP25 for example requires UIMs to 
efficiently hydrolyze poly-ubiquitin chains83. UIMs 
can also play a role in Ub linkage specificity. The 
UIM of ATXN3 for instance is necessary for K63 
selectivity84. Another common UBD found in 
DUBs is the ZnF-UBP domain, which in the case 
of USP5, binds to proximal Ub in the chain and 
induces an allosteric conformational change leading 
to an increased catalytic rate for Ub chain process-
ing85. Additionally, USP5 also possess two UBA do-
mains, which are involved in binding two different 
poly-ubiquitin chains, linear and K48-linked86,87.
Recently, the crystal structure of the yeast 
Ubp8 (USP22) in complex with the SAGA 
(Spt-Ada-Gcn5 acetyltransferase) module was 
solved showing how the ZnF-UBP domain acts 
as a scaffold for complex assembly by hold-
ing all subunits of the module together88,89.
New classes of UBDs are continuously being re-
ported, revealing new information not only about 
their functionality but also about the mechanisms 
of intermolecular regulation. The accumulated 
knowledge of Ub-UBD interactions will also have 
an impact on pharmacological and medical appli-
cations, as several UBDs have now been linked to 
various human pathologies, including cancer and 
immune deficiencies, thus becoming interesting as 
putative drug targets.
 Linker regions in tandem repeats of 
UBDs can also define linkage specificity. For ex-
ample, the receptor associated protein 80 (RAP80) 
targets BRCA1 to DNA damage-induced foci 
through its two UIMs, which bind K63-linked 
Ub chains, but not K48-linked ones62,79,80. The se-
quence between the two UIMs of RAP80 promotes 
an appropriate protein conformation such that the 
UIMs are positioned for efficient binding across
Cancer and disease
Implication of ubiquitination
It has been recognized that the ubiquitination of
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cellular proteins is a major post-translational modi-
fication that can have profound effects on protein 
stability, localization or interaction pattern. These 
changes in the fate of individual proteins can cause 
alterations in cell signaling, which regulate cell 
cycle, proliferation or apoptosis77. Tampering with 
the ubiquitination machinery has been observed in 
various cancers and neurological diseases90,91. Mul-
tiple Ub pathway proteins, which directly control 
stability of key signaling molecules, have been iden-
tified as tumor suppressors or oncogenes77,92. 
 The best studied example in which the 
deregulation of ubiquitination plays an important 
role in tumorigenesis and cell death is the p53 
signaling pathway. It is a highly complex, multi-
component signaling network that is of fundamen-
tal importance in tumor biology. p53, commonly 
known as ´the guardian of the genome´, is a tumor 
suppressor that is capable of inducing cell-cycle ar-
rest, cell senescence and apoptosis93. Loss of p53 
expression causes cells to lose pivotal signaling 
responses to DNA damage events, hypoxia and 
aberrant oncogene expression as seen in a large 
percentage of human tumors. The proliferation of 
oncogenic cells results in the repression of p53 ex-
pression and activation. P53 is predominantly reg-
ulated through the ubiquitin-proteasome pathway 
and maintained at low protein levels during normal 
homeostasis. The major player in controlling p53 
levels is Mdm2. Mdm2 is a RING finger domain 
containing protein that exhibits E3 ubiquitin-pro-
tein ligase activity and is capable of regulating its 
own protein levels through auto-ubiquitination93. 
Genotoxic stress can induce high levels of p53 
promoting the expression of many proteins associ-
ated with apoptosis and cell-cycle arrest to coun-
teract the stressors causing DNA damage. On the 
contrary, if p53 is overactive, the cell will die, so 
the p53-mediated increase in Mdm2 level helps to 
regulate p53 levels by polyubiquitination and tar-
geting p53 for proteasomal degradation. Besides 
Mdm2 a few more E3 ligases have been reported 
to have similar activities in regulating p53 levels. 
COP1, Pirh2 and ARF-BP1 directly interact with 
p53 and target p53 for proteasome-mediated deg-
radation94-99. Decreased p53 levels and mutations in 
p53 have been linked to high incidences of cancer, 
thus p53 levels being elevated act as a mechanism 
of tumor suppression100. Mdm2-dependent and in-
dependent ubiquitinations that target p53 for deg-
radation are considered oncogenic and prevent p53
from regulating the cell cycle or inducing apoptosis. 
 Recent examples of the implication of 
ubiquitination in cancer include TRAF6-mediated 
K63-linked poly-ubiquitination of the kinase Akt, 
which is required for the membrane localization 
and activation of this proto-oncogene. Mutations 
in Akt in tumor cells, have shown to enhance its 
non-degradative ubiquitination and thus promote 
oncogenic signaling101. Another example of the im-
plication of the ubiquitination machinery in cancer 
is the NF-κB signaling pathway. The NF-κB tran-
scription factor is activated through K63-linked 
poly-ubiquitination and its anti-apoptotic activity 
has been associated with tumor progression, che-
motherapy resistance and metastasis102-104. The key 
event in NF-κB activation is the degradation of the 
inhibitor of NF-κB (IκB) which releases NF-κB 
from its sequestration in the cytoplasm. Various 
pro-inflammatory stimuli, including TNF-α, IL-1, 
and DNA damage activate the IKK (IκB kinase) 
complex that phosphorylates IκB and recruits the 
SCF Ub ligase. In turn, this SCF Ub ligase mediates 
the IκB ubiquitination and proteasomal degrada-
tion. The recruitment of the IKK complex depends 
on the K63-linked poly-ubiquitination of adaptor 
proteins TRAF2 and RIP, where TRAF2 is the re-
sponsible E3 ligase. Respectively, NK-κB signaling 
can be terminated via either deubiquitination of 
the adaptor proteins or their regulated degradation. 
Deregulation of either mechanism can lead to tu-
mor formation. Thus, SCF E3 ligase, which ubiqui-
tinates IKKβ and down regulates NF-κB signaling, 
has been found mutated in a high percentage of hu-
man malignancies.
 Mediation of DNA repair is another 
established function of non-degradative Ub sig-
naling. And it has been shown that non-repaired 
DNA lesions can lead to tumorigenesis and defects 
in the DNA repair system are common in several 
cancer predisposition syndromes. BRCA1 is a tu-
mor suppressor whose mutation leads to a high 
incidence of breast and ovarian cancers105. And 
together with BARD1, BRCA1 forms a heterodi-
meric E3 ligase, which synthesizes poly-Ub chains 
of different topology. This activity of BRCA1 plays 
an important role in the homologous recombina-
tion (HR) DNA repair pathway106. In the absence 
of BARD1, BRCA1 is destabilized and degraded 
by the proteasome. UBE2T, the E2 conjugat-
ing enzyme, and HERC2, the E3 ligase enzyme, 
are the newly identified factors that mediate pro-
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teasomal degradation of BRCA1107,108. HERC2 is 
also the E3 ligase that is necessary for the Ub sig-
naling at the DNA damage sites. It forms a complex 
with other Ub ligases, RNF8 and RNF168 (mu-
tated in the RIDDLE syndrome) thereby facilitat-
ing the recruitment of the E2 conjugating enzyme 
Ubc13 to the sites of DNA damage109. After detec-
tion of DNA damage, the Ubc13/RNF8 complex 
initiates poly-ubiquitination of histone H2A, there-
by promoting the recruitment of Ub-binding pro-
teins, including RAP80 and RNF168. RNF168, 
amplifies histone ubiquitination increasing the 
local concentration of K63-linked Ub chains and 
ensuring the recruitment of other DNA repair fac-
tor, such as BRCA1 and 53BP1 to the sites of DNA 
damage110,111. 
 More recently, the Ub machinery has 
been implicated in the other major degradation sys-
tem: autophagy. Autophagy is an evolutionary con-
served lysosomal degradation pathway that targets 
bulky cargos, such as protein aggregates and mito-
chondria112. Tumors resort to the autophagy to sur-
vive hypoxia and lack of nutrition. Yet, in normal 
mammalian cells, autophagy is more important for 
cell cleansing of aggregated proteins and damaged 
organelles113. Inhibition of autophagy in healthy 
tissues leads to accumulation of ubiquitinated 
protein aggregates and damaged mitochondria. 
This process has been linked to neoplastic trans-
formation, which has shown to be associated with 
enhanced mutagenesis and deregulated cell signal-
ing114. The inhibition of autophagy in cancer cells, 
besides limiting their survival in the face of hypoxia 
and starvation, could lead to accumulation of dam-
aged mitochondria and protein aggregates due to 
the inhibition of the selective, Ub-regulated forms 
of autophagy. This could sensitize tumor cells to 
cancer therapies that aim at inducing apoptosis115.
 It has become clear that the deregulation 
of the Ub-proteasome system (UPS) plays a vital 
role in the most important age-related neurodegen-
erative diseases, Alzheimer’s disease. In Alzheimer’s 
disease, hyper-phosphorylation of the microtubule-
associated protein tau results in the accumulation of 
paired helical tau filaments involved in the forma-
tion of neurofibrillary tangles and neuritic plaques. 
Relative dysfunction or inhibitory overloading of 
the UPS may contribute to the abnormal accumu-
lation of phosphorylated and ubiquitinated tau116. 
Interestingly, a frameshift mutant of Ub, Ub+1, 
found in some sporadic and hereditary Alzheimer 
disease patients, inhibits the UPS and enhances the 
toxic protein aggregation in a yeast model117.
Implication of DUBs
There is a growing recognition of DUBs that are 
mutated in human cancers playing an important 
role as oncogenes and tumor suppressors. As men-
tioned previously, stabilization of p53 activates 
downstream targets to initiate cell-cycle control, 
DNA repair mechanisms and apoptosis. This p53 
stabilization can be achieved by inhibiting Mdm2-
mediated ubiquitination. Alternatively stabilization 
can also be achieved by deubiquitination catalyzed 
by DUBs to reduce ubiquitination of p53. Sev-
eral USPs, including USP7 (HAUSP), USP2 and 
USP10, have been reported to regulate p53 and/
or Mdm2118-121.
 HAUSP was the first USP identified 
to deubiquitinate p53, with over-expression of 
HAUSP resulting in p53 stabilization leading to 
the induction of p53-dependent cell growth re-
pression and apoptosis118. However, depletion of 
HAUSP in cells doesn’t decrease p53 levels as pre-
dicted, but rather increases p53 levels, apparently 
because of HAUSPs ability to bind and deubiq-
uitinate Mdm2119,122. The relationship of HAUSP 
and cancer was complicated by the demonstration 
of HAUSP mediated regulation of Akt antagonist 
PTEN123. Reduced nuclear localization of PTEN is 
a common feature in aggressive cancers, including 
advance stage prostate cancer. PTEN nucleo-cyto-
plasmic shuttling is regulated by PTEN ubiquiti-
nation. HAUSP, which is overexpressed in prostate 
cancer, was shown to deubiquitinate PTEN leading 
to reduced nuclear localization. These data suggest 
that HAUSP may in some instances act as a tumor 
suppressor by stabilizing p53 or as an oncogene by 
stabilizing Mdm2 and re-distributing PTEN.
 In a yeast-two hybrid screen, USP2 was 
found to complex with Mdm2. USP2 deubiquiti-
nates Mdm2 leading to its stabilization120. Onco-
mine data suggest that many cancers have reduced 
expression of USP2 including cancers of the colon, 
pancreas and head/neck124. Interestingly, USP2 was 
linked to prostate cancer through a study to isolate 
androgen sensitive DUBs from a prostate cancer 
cell line125. USP2 was found to bind and stabilize 
fatty acid synthase, a protein that is often found 
overexpressed in aggressive prostate cancers125,126.    
 USP10 is overexpressed in breast can-
cer tissue compared to adjacent normal tissue and
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in glioblastoma samples127,128. Recently, USP10 was 
identified as a DUB for p53. In unstressed cells, 
USP10 mainly localizes in the cytoplasm and regu-
lates p53 homeostasis. After DNA damage, USP10 
translocates to the nucleus and contributes to p53 
activation. Increased USP10 expression in mutant 
p53 background increases p53 levels and promotes 
cancer cell proliferation, while downregulation of 
USP10 inhibits cancer cell growth. Increased ex-
pression of USP10 could be another mechanism 
responsible for increased mutant p53 expression in 
human cancers121.
 Another example of the implication of 
DUBs in cancer is the familial cylindromatosis tu-
mor suppressor gene, CYLD. Patients with familial 
cylindromatosis have the predisposition for devel-
oping multiple skin tumors of the head and neck. 
Germline mutations in the CYLD gene were identi-
fied in patients and most likely abolish the catalytic 
activity of CYLD129,130. CYLD negatively regulates 
NF-κB signaling through its deubiquitinating ac-
tivity. As noted above, several intermediates of the 
NF-κB pathway become K63-linked poly-ubiqui-
tinated. By removing these K63-linked Ub chains, 
CYLD dampens the NF-κB signaling131-134.
 The importance of the DUB activity 
in tumor progression is also illustrated by the re-
cent findings that USPs are often overexpressed in 
tumors to stabilize oncogenic potential. USP9X 
for example was found overexpressed in various 
hematological malignancies. Initially USP9X in 
mammals was found to have a variety of functions 
including important intersections with cancer path-
ways: the Wnt and TGFβ pathway135-138. Whether 
USP9X mediated deubiquitination plays a role in 
tumorigenesis remained unclear, and one could 
predict that overexpressed USP9X would enhance 
tumorigenesis by enhancing the Wnt and TGFβ 
signaling. Recent findings by Schwickart and co-
workers support this idea and found USP9X over-
expressed in various hematological malignancies139. 
USP9X overexpression leads to the promotion of 
cell survival by removing K48-linked poly-ubiqui-
tin chains that would otherwise target the pro-sur-
vival BCL-2 member, MCL1, for proteasomal deg-
radation. This contributes to the disease progression 
and chemoresistance139 .
 Other USPs have been identified to 
be involved in tumorigenesis, however how these 
USPs are implicated remains unclear. The in-
crease of USP6 transcription has been shown
to lead to the development of bone tumors140. 
USP1 has been identified as a negative regula- tor of 
FANCD2 (an important factor in Fanconi Anemia) 
mono-ubiquitination and DNA repair and was also 
found to deubiquitinates PCNA, an important 
component of the trans-lesion synthesis (TLS) re-
pair pathway141-143. The Oncomine database reveals 
the overexpression of USP28 in primary colon and 
breast cancer samples124. USP28 has been identified 
to deubiquitinates Myc, a central player in many 
forms of cancer, thereby salvaging it from protea-
somal degradation144,145. 
It is clear that the ubiquitination and 
deubiquitination pathway is tightly regulated and 
the deregulation in both processes has been shown 
to play a direct or indirect role in tumorigenesis and 
several inherited neurological diseases. 
USP family
The ubiquitin-specific protease subclass represents 
the largest of the DUB family encoded by the 
human genome146. In the last decade the crystal 
structures of the catalytic domain of several USPs, 
with or without Ub bound, have been solved (Fig-
ure 4 ) (USP8CD [PDB code: 2GFO], USP7CD 
[1NB8 & 1NBF], USP14CD [2AYN & 2AYO], 
USP2CD [2HD5], USP21CD [3I3T], Ubp8 
[3M99 & 3MHH] and CYLD [2VHF])88,89,147-150. 
The catalytic domain structures revealed several 
common structural features between the different 
USPs. First, despite the low sequence similar-
ity the overall structure of the catalytic domain is 
highly conserved. Three well-defined sub-domains: 
the ‘Fingers’, the ‘Thumb’ and the ‘Palm’ domain 
form a structure that resembles a right-hand (Fig-
ure 4). Secondly, the catalytic centre resides at 
the interface between the Thumb and the Palm 
regions. The Thumb is predominantly α-helical 
and contains the Cys Box, a motif that includes 
the active site cysteine. The Palm is composed of 
β-strands supported by α-helices and contains 
the remaining active site residues that form the 
catalytic triad: a His and an Asp or Asn residue. 
The junction between the Thumb and the Palm 
domains forms a cleft that accommodates the C-
terminal tail of Ub and the active site residues in-
volved in the catalysis. Third, the Finger domain is 
composed of four β-strands and in USP8, USP2 
and USP21 it contains a CXXCXnCXXC motif 
that chelates one zinc ion and form the so-called
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Figure 4. Crystal structures of the catalytic domains of USPs.
USP4-D1D2 [2Y6E] 
CYLD [2VHF] USP7 [1NB8] USP7_Ub [1NBF]
USP8 [2GFO] USP14 [2AYN] USP14_Ub [2AYO] 
Ubp8 [3M99, 3MHH] USP2_Ub [2HD5]USP21 [3I3T] 
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Zinc Finger ribbon147,150. Although not all of the 
solved structures contain this motif, the overall fold 
of the Finger domain is maintained. The CXX- 
CXnCXXC motif is lacking in nine of the 54 puta-
tive human USPs, suggesting that the zinc binding 
ability is dispensable for the integrity of the Finger 
domain fold146. The role of the Finger domain is to 
serve as a scaffold that contacts the globular body of 
Ub and the Zinc Finger ribbon does not appear to 
be involved in catalysis151. Interestingly, the Finger 
domain of CYLD is significantly smaller due to the 
shortening of the β-strands. CYLD also differs from 
the other USPs by the insertion of a Zn binding 
domain that closely resembles a B-box. The B-box 
is not required for deubiquitinating activity, but in-
stead appears to be important for the cytoplasmic 
localization of CYLD134.
 Furthermore multiple studies have 
demonstrated that the catalytic activity of USPs is 
regulated by substrate- or scaffold-induced confor-
mational changes. For example USP7 in the unli-
ganded form has a misaligned catalytic triad con-
figuration. The active site cysteine is approximately 
10Å away from the active site histidine, too far 
for catalysis to occur. Upon binding to Ub a ma-
jor conformational change occurs in the catalytic 
core domain causing the active site cysteine and 
histidine to be positioned within hydrogen bond 
distance from one another, rendering the enzyme 
catalytically competent148.
 The structure of USP14 in the presence 
and absence of Ub reveals a different type of activa-
tion mechanism. Unlike USP7, the catalytic triad 
of the free USP14 is productively aligned, indicat-
ing that the active site is catalytically competent. 
However, the binding groove that accommodates 
the C-terminal tail of Ub is blocked by two sur-
face loops that undergo significant conformational 
changes upon Ub binding149.
 A third conformational change is 
thought to occur in USP8. In the structure of the 
unliganded form, the tip of the Zinc finger ribbon 
of USP8 is positioned inward toward the Palm re-
sulting in a closed conformation that leaves insuf-
ficient room for Ub. Unlike the other USPs, USP8 
and USP2 have a unique α-helix juxtaposed to the 
finger and this helix may be involved in stabilizing 
the closed conformation147,150. Although there is no 
structure available of USP8 in complex with Ub, 
the closely related catalytic domain of USP2 has 
been solved in the presence of Ub. In this structure 
the Finger domain is displaced outward to adopt 
the conformation observed in the other USPs150. 
It is possible that upon target protein binding, the 
Finger domain of USP8 moves to the position ob- 
served in the other USPs, allowing the activation of 
the protease and subsequent binding to Ub. 
 Recently, the crystal structure of the yeast 
Ubp8 (USP22) in complex with the SAGA module 
was solved both in presence and absence of Ub. The 
structures showed that the Finger domain that binds 
Ub in the complex remains in an open conforma-
tion in the apo form. The Finger domain doesn’t 
collapse and occlude the Ub-binding pocket as seen 
in USP8. Furthermore, the active site residues are 
in their catalytically competent orientation in both 
the presence and absence of Ub. Interestingly, sev-
eral residues located adjacent to the Ub C-terminus 
are disordered in the absence of Ub and a small loop 
containing the active site cysteine (Cys-loop) move 
inward toward the Ub tail-binding groove. Both 
the Cys-loop and the disordered region contain res-
idues that contact Ub directly. Ubp8 is activated by 
binding of the Sgf11 subunit of the SAGA module 
to the catalytic domain of Ubp8 near the active site, 
supporting the construction of a competent cata-
lytic center of the enzyme88,89.
 The USP family members have modular 
domain architecture and besides having the con-
served catalytic domain they also feature additional 
protein-protein and localization domains. A num-
ber of domains outside the catalytic domain have 
been identified and characterized, for example the 
TRAF-like domain of USP7, the DUSP (domain 
in USPs) domain of USP15 and as described previ-
ously several UBDs  found in USPs87,152,153. Inter-
estingly, Ubl domains were recently predicted in a 
subset of USPs35.
Ubl domain
In a sequence analysis integrated ubiquitin-like 
(Ubl) domain were identified in a large number of 
USPs35. The integrated Ubl domain is a member of 
a subfamily of the Ub superfold family. Despite the 
poor sequence conservation for all members of the 
Ub superfold family, they all share the conserved 
β-grasp fold6,154. The integrated Ubl folds are stretch-
es of 45-80  amino acids and are found in a wide 
array of eukaryotic proteins. Only a small number 
of these integrated Ubl domains have been studied 
and characterized functionally. These integrated
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Ubl domains are present in proteasomal shuttle fac-
tors like Rad23 and Dsk2 and are believed to play a 
role in recruitment of ubiquitinated proteins to the 
proteasome. Integrated Ubl domains in other pro 
teins such as Parkin and USP14 can also be recruit- 
ed to the proteasome. However, the integrated Ubl 
folds not only function in recruitment but also play 
a role in enzymatic activities of certain immune-
response inducible kinases, such as IKKβ155,156. 
 The Ubl domains found in the USP fam-
ily are located at the N-terminus, within or at the 
C-terminus of the catalytic domain. Till recently 
only the Ubl domain at the N-terminus of USP14 
has been characterized. It has been shown to be in-
volved in proteasome binding, which promotes the 
DUB activity of USP14149. In chapter 5 a Ubl do-
main located within the catalytic domain of a USP 
is described and its effect on DUB activity.
USP4
Like USP14, USP4 has a Ubl domain N-terminal 
of its catalytic domain, but more interestingly it 
has a second Ubl domain within the catalytic do-
main. Furthermore, the DUSP domain is located 
N-terminal of the first Ubl domain. Not much is 
known about the structure and function of USP4, 
previously known as UNP for ubiquitous nuclear 
protein. It has been identified as a proto-oncogene 
related to tre-2/tre-17 (USP6) by its ability to trans-
form NIH3T3 cells and lead to increased tumori-
genesis in nude mice157,158. In a study of primary 
human lung tumor tissue, USP4 was observed to 
have a consistently elevated gene expression levels 
in small cell tumors and adenocarcinomas of the 
lung, suggesting a possible causative role for USP4 
in neoplasia159. 
 Besides the described domains of USP4, 
it also possesses functional nuclear import/export 
signals, the basis of its ability to shuttle between 
nucleus and cytoplasm160. Because of this ability, 
USP4 seems to have different cellular functions 
depending on its localization. When located in the 
cytoplasm, it has been reported that knockdown of 
USP4 activates the β-catenin-associated transcrip-
tion161. By interacting with two known Wnt signal-
ing components Nemo-like kinase and T-cell factor 
4, USP4 may play a role in the Wnt signaling path-
way in a variety of physiological conditions. 
 Interestingly, Song and co-workers show 
that USP4 is recruited to the spliceosome by form-
ing a complex with Sart3162. The N-terminal DUSP 
domain and the adjacent DUF1055 domain (ami-
no acids 27-216) of USP4 is primarily responsible 
for this interaction with Sart3. The Sart3 protein 
is a recycling factor of the U4/U6 spliceosomal 
snRNP, which promotes the re-annealing of U4 
and U6 snRNPs. The crystal structure of the N-
terminus of USP4 (PDB: 3JYU) shows that the 
DUF1055 domain is actually a Ubl domain which 
interacts extensively with the DUSP domain. It 
is likely that binding to the Sart3 protein might 
abolish this interaction and hence recruit USP4 
to the spliceosome complex where it preferentially 
deubiquitinates K63-linked chains on the U4 com-
ponent Prp3. The deubiquitination of Prp3 most 
likely facilitates the release of Prp3 from the spliceo-
some during maturation of its active site162.
 In addition to its cytoplasmic roles, re-
cent evidence shows that USP4 also plays impor-
tant nuclear roles. Fan and co-workers show that 
the tumor necrosis factor-α (TNFα), a pro-inflam-
matory cytokine, induces association of USP4 with 
the transforming growth factor-β-activated kinase 
1 (TAK1), which leads to the deubiquitination of 
Lys63-linked polyubiquitinated TAK1 and thereby 
down-regulating the TAK1-mediated NF-κB acti-
vation163. 
 Furthermore, Zhang and co-workers re-
cently identified a new important role for USP4. 
They show  that USP4 interacts directly with and 
deubiquitinates ARF-BP1, leading to the stabiliza-
tion of ARF-BP1 and subsequent reduction of p53 
levels164. ARF-binding protein 1 (ARF-BP1; also 
known as HUWE1) was recently identified as an-
other critical E3 Ub ligase in regulating p53 levels99. 
ARF-BP1 is a HECT domain-containing E3 Ub li-
gase, which interacts directly and ubiquitinates the 
p53 protein. This p53 ubiquitination is strongly 
repressed by the binding of ARF to ARF-BP1. The 
inactivation of ARF-BP1 stabilizes p53 and induces 
apoptosis.
 It seems that USP4 plays several impor-
tant cellular roles depending on its location in the 
cell. And it is therefore interesting to see what fu-
ture research will unveil on how USP4 function is 
being regulated. Chapter 5 shows how the catalytic 
activity of USP4 is being regulated.
Structural genomics
In the 21st century with the rise of new efficient 
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genome sequencing techniques, microarray experi- 
ments and new proteomics technologies, biology 
has seen huge increase in DNA sequence, gene 
expression and proteomics data. The Human Ge-
nome and other genome sequencing projects con- 
tinue to deliver new protein sequences in a rapid 
pace. New protein families are being discovered in 
newly sequenced genomes, for which a large frac-
tion of these new protein families we virtually don’t 
have any functional or structural data.
 To counteract this trend a number of 
structural genomics (SG) programs were created 
with the aim to determine rapidly a large number 
of novel structures in order to expand structural 
and functional knowledge for proteins found in 
genomes. The largest SG centers are funded by Ja-
pan (RIKEN), the United States [Protein Structure 
Initiative] (PSI and PSI2) and by an international 
consortium of governments, charitable foundations 
and industry  [the Structural Genomics Consor-
tium] (SGC), while in Europe The Structural Pro-
teomics In Europe (SPINE and SPINE2) was set-
up. These SG centers are using different approaches 
to structurally characterize the protein world165-168. 
RIKEN and the SGC focuses on the human pro-
teome165, while PSI and PSI2 target the repre-
sentative members of the largest protein families, 
proteins from human parasite and Mycobacterium 
tuberculosis168,169. SPINE and SPINE2 introduced 
high-throughput proteomics in a wide collabora-
tive platform in which SPINE initially was focused 
on targets of medical relevance. SPINE2 continued 
and extended these methodologies to study macro-
molecular complexes170.
 Additionally, most SG centers have 
dedicated a significant part of their efforts in the 
development of high-throughput methods, which 
may now also be used for fast and more accurate 
determination of structures by both X-ray crystal-
lography and NMR techniques in laboratories not 
involved in SG efforts. The work on thousands of 
target proteins has led to the development of effi-
cient protocols for each of the steps of the structure 
determination process167,171. New experimental pro-
tocols that were developed through SG efforts have 
shifted over time the so-called ‘bottlenecks’ in the 
pipeline and it seems that at present the analysis of 
3D structures in the context of all biological and 
bioinformatics information is the slowest step of 
the whole process. 
 As part of the SPINE network, we did
our share of work in developing new tools and ef- 
ficient protocols to aid the initial steps of structure 
determination and are described in chapter 3.
Outline of this thesis
Ubiquitination is a reversible protein modification 
that plays a central role in many important cellular 
functions. The enzymes involved in this ubiquiti-
nation process have been the main focus of many 
studies for several decades. However, deubiquitin-
ases (DUBs), responsible for the removal and pro-
cessing of ubiquitin, have been shown to be equally 
important. Over the last decade a lot of progress 
has been made in the characterization of this large 
family of isopeptidases. Because of their roles in key 
regulatory processes, these DUBs are actively pur-
sued as new drug targets. The aim of this thesis was 
to study the structure and function of members of 
the ubiquitin-specific protease family.
In Chapter 2 we give a comprehensive 
overview of putative DUBs encoded by the human 
genome. Furthermore, the function, specificity and 
the regulation of DUB activity is discussed.
In order to study a large number of USPs 
in parallel, high-throughput tools and methods 
needed to be developed. In Chapter 3 a description 
of a set of protein expression vectors for ligation-in-
dependent cloning is given and their use on a large 
number of the USP family members.
 In Chapter 4 a set of twelve USPs in 
presence and absence of modulators have been 
analyzed for their enzyme activity using synthetic 
reagents. Among these reagents are all seven wild-
type lysine-linked di-ubiquitins and the first com-
prehensive analysis comparing Ub chain preference 
is given.
 In Chapter 5 we present the crystal 
structure of the catalytic domain of USP4 and we 
show a new function of its Ubl domain located 
within the catalytic core.
A summary of the findings, concluding 
remarks and implications for future research are 
presented in Chapter 6. 
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Abstract
Posttranslational modification of proteins by the small molecule ubiquitin is a key regulatory event, 
and the enzymes catalyzing these modifications have been the focus of many studies. Deubiquiti-
nating enzymes, which mediate the removal and processing of ubiquitin, may be functionally as 
important but are less well understood. Here, we present an inventory of the deubiquitinating en-
zymes encoded in the human genome. In addition, we review the literature concerning these en-
zymes, with particular emphasis on their function, specificity, and the regulation of their activity.
Introduction
Over the last few decades, protein modification by 
ubiquitin (Ub) and ubiquitin-like (Ubl) molecules 
has emerged as a critical regulatory process in vir-
tually all aspects of cell biology. Indeed, the 2004 
Nobel Prize in Physiology or Medicine was awarded 
for the discovery of Ub-mediated proteolysis.
 More than a dozen different Ub and Ubl 
modifications have been described, and up to 20% 
of yeast proteins are conjugated to Ub under stan-
dard culture conditions1,2. In yeast, potentially all 
seven conserved lysines of Ub itself (K6, 11, 27, 29, 
33, 48, and 63) are used as branching sites for the 
generation of Ub polymers.
 The topic of ubiquitination, the proteins 
involved, and their functions in various pathways 
and signaling networks has been well reviewed3,4. 
Here, we discuss the enzymes that remove Ub from 
polypeptides. These deubiquitinating enzymes 
(DUBs) play key regulatory roles in a multitude of 
processes from hereditary cancer to neurodegenera-
tion. Despite the importance of DUBs, our knowl-
edge of their mode of regulation and substrate 
specificity is surprisingly scant. A detailed annota-
tion of individual family members of this enzyme 
group is an important step toward elucidating the 
molecular functions of DUBs in health and disease. 
To this end, we provide a comprehensive overview 
of putative DUBs encoded in the human genome. 
In addition, we discuss the lacunae in our under-
standing of these enzymes by drawing on examples 
from yeast and higher eukaryotes.
 In our attempt to classify these en-
zymes, we have made some arbitrary decisions 
as to which genes to include or exclude as po-
tential DUBs. Therefore, we present three cave-
ats to this list. First, we cannot exclude the fact 
that proteins or protein families not included 
in this overview can remove Ub from polypep-
tides. For instance, a recent in silico effort to pre-
dict new Ub signaling components suggested a 
previously undetected family of Ub peptidases5. 
Second, protein domain prediction based on gene 
transcripts depends on consensus sequences. Thus, 
divergent but true family members can be missed 
due to low homology scores. Finally, we wish 
to emphasize that it is unlikely that all predicted 
DUBs are truly specific for Ub: some will display 
additional activity or exclusive activity toward Ubl 
molecules.
DUBs Are Proteases
DUBs belong to the superfamily of proteases, of 
which an estimated 561 members are present in the 
human genome6. Based on the mechanism of catal-
ysis, proteases are divided into five classes—aspar-
tic, metallo, serine, threonine, and cysteine prote-
ases—and further subdivided based on phylogeny. 
Two classes of proteases (cysteine and 
metallo) contain DUBs, although most DUBs are 
cysteine proteases. By definition, the enzymatic ac-
tivity of cysteine proteases relies on the thiol group 
of a cysteine in the active site. Deprotonation of this 
cysteine is assisted by an adjacent histidine, which is 
polarized by an aspartate residue. These three resi-
dues make up the catalytic triad. During catalysis, 
the cysteine performs a nucleophilic attack on the 
carbonyl of the scissile peptide bond, which, in the 
case of DUBs, is between the target and Ub. The 
intermediate, which contains an oxyanion, is stabi-
lized in the so-called oxyanion hole. This oxyanion 
hole is generally provided by a glutamine, gluta-
mate, or asparagines residue and the main chain of 
the catalytic cysteine. The result of the reaction is 
release of the target protein and formation of a co-
valent intermediate with the Ub moiety. Reaction 
of this intermediate with a water molecule results in 
the release of the free enzyme and Ub.
In contrast to cysteine proteases, me-
talloproteases generally use a Zn2+ bound po-
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Figure 1. Structures of the Catalytic Domains of the Five Subclasses of Ub-Specific Proteases (Yellow) with Ub (Blue) Structures 
show the remarkable variability in secondary structure between the DUB classes. Catalytic centers are shown as Van der Waals spheres 
(carbon, gray; nitrogen, blue; oxygen, red; sulfur, orange; zinc, purple) and have been aligned for easy comparison. The OTU domain of 
OTU2 lacks the conserved Asp in the catalytic center and the Asn/Glu/Gln that is normally used to stabilize the oxyanion hole in these 
proteases. For detailed structural information see Amerik and Hochstrasser (2004). Protein Databank (PDB) codes: USP7, 1nbf; UCH-
L3, 1xd3; OTU2,1tff; Ataxin-3, 1yzb; JAMM, 1r5x.
larized water molecule to generate a noncovalent 
intermediate with the substrate. The metal atom is 
primarily stabilized by an aspartate and two histi-
dine residues7. The intermediate is further broken 
down by proton transfer from a water molecule 
causing the release of the DUB.
The Human DUB Genes
The cysteine protease DUBs can be further orga-
nized into four subclasses based on their Ub-pro-
tease domains: ubiquitin-specific protease (USP), 
ubiquitin C-terminal hydrolase (UCH), Otubain 
protease (OTU), and Machado-Joseph disease pro-
tease (MJD). All DUBs that are metalloproteases 
have a Ub protease domain called JAMM (JAB1/
MPN/Mov34 metalloenzyme). The structures of 
the catalytic domains of the different subclasses of 
DUBs reveal an impressive diversity in secondary 
structure (Figure 1).
 We used the ENSEMBL human genome 
database (v32, July 2005) to retrieve all putative 
DUBs from the human genome by selecting genes 
whose transcripts encode one of the five Ub pro-
tease domains. Our search identified all known 
DUBs except two DUBs with OTU domains 
(Otubain-1 and Otubain-2). This analysis indicated 
that the human genome encodes approximately 95 
putative DUBs, including many that have not been 
previously reported. These can be broken down 
into 58 USP, 4 UCH, 5 MJD, 14 OTU, and 14 
JAMM domain-containing genes, many of which 
are associated with multiple transcripts (see Table 
S1 in the Supplemental Data available with this 
article online). For six unnamed genes, we have 
submitted gene names to the HUGO gene no-
menclature committee (HGNC) (Table S1). To 
determine whether the putative DUB genes are 
expressed, we searched NCBI human-expressed 
sequence tag (EST) databases for transcripts corre-
sponding to the predicted protein sequence. We ob-
tained further evidence for expression of a number 
of genes with relatively low numbers of ESTs from 
additional sources (such as SAGE and UniGene). 
For five predicted DUBs, we could not find any 
convincing data supporting transcription.
 Next, we generated sequence alignments 
to ensure conservation of the catalytic residues and 
made an inventory of DUBs reported to display 
Ub protease activity. This indicated that of the 90 
putative DUBs that are expressed, 11 are unlikely 
to display Ub-protease activity. Together, these data 
indicate that humans express approximately 79 pu-
tative DUBs that are functional (Table S1).
 To investigate sequence homology be-
tween the various putative DUBs, we used two 
strategies. We used CLANS (Cluster analysis of se-
quences) software to visualize pairwise all-against-
all sequence BLAST matches8. As expected, very 
few positive BLAST results were found between 
the five subclasses, whereas the members within the 
subclasses clustered together (Figure 2A). This anal-
ysis revealed that within the subclasses some rela-
tively divergent members are present (for example, 
Otubain-1 and Otubain-2, USP55, and CYLD). 
Similar results were obtained using the CLUSTAL 
alignment algorithm (Figure 2B).
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The Five DUB Subclasses
Three-dimensional structures of DUB catalytic do-
mains from all subclasses, some of them in complex 
with Ub derivatives, have been solved (Figure 1). 
These studies reveal intriguing similarities and dif-
ferences between the four cysteine protease subclass- 
es. This topic, including the structure of a JAMM 
domain, has recently been extensively reviewed by 
Amerik and Hochstrasser9. Here, we comment on 
the new structural features of the DUB subclasses.
Ubiquitin C-Terminal Hydrolases (UCHs)
The human UCH subclass of DUBs consists of four 
proteins that share close homology in their catalytic 
domains. Structural and biochemical studies have 
indicated that the UCH subclass of DUBs prefers 
to cleave relatively small protein substrates (up to 
20– 30 amino acids) from Ub9. This size limit is 
thought to be imposed by a loop that partially oc-
cludes the active site of these enzymes. However, 
recent biochemical and structural studies show that 
certain large substrates can nevertheless be accom-
modated10.
 Although UCHs were the first 
described DUBs, their specific functions re-
main poorly understood. UCHs are thought 
to mainly act in the recycling of Ub when 
Ub is inappropriately conju- gated to intra-
cellular nucleophiles (for example, glutathi-
one, polyamines). They also may be involved 
in the processing of newly synthesized Ub, 
which is translated either as a polyubiquitin 
precursor or fused to ribosomal protein pre-
cursors. However, other DUBs also display in 
vitro activity toward linear Ub fusions, sug-
gesting that processing of newly synthesized 
Ub is performed by multiple DUBs.
 Some studies suggest a role 
for UCHs in specific Ub-regulated pro-
cesses. Mutations in UCH-L1 (a UCH 
Figure 2. Phylogenetic Map of Human DUBs (A) 
Graphic two-dimensional representation of sequence 
similarities between all Ub protease domains of DUBs 
using CLANS software. CLANS performs all-against-all 
BLAST searches and uses the significant high-scoring 
segment pairs (HSPs) to draw a three-dimensional graph 
represented here in two dimensions. Each node represents 
a Ub protease domain and each edge (line) represents a 
significant HSP (edges are shaded according to p value). 
DUB subclasses are highlighted in the graph. The start 
and end positions of the DUB Ub-protease domains, as 
defined by Interpro, were used to generate the protein 
sequences. Proteins with a partial or short and misalign-
ing DUB domain were excluded from the analysis. (B) 
Unrooted dendrogram of the DUBs using Clustal soft-
ware. Clustal generates a multiple sequence alignment file 
based on pairwise alignments. From this information a 
phylogenetic tree can be constructed. The robustness of 
the phylogenetic relations can be assessed by “bootstrap-
ping,” a mathematical technique that introduces noise in 
the alignment and measures how often the phylogenetic 
relationships reproduce. An asterisk indicates a bootstrap-
ping percentage <10% (lowest branch only). The numbers 
correspond to the genes in Table S1.
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specifically expressed in neurons) that re-
duce its DUB activity have been described 
in two siblings with Parkinson’s disease 
(PD), and a polymorphism in this gene has
been linked to reduced PD risk11,12. However, not 
all studies have found a strict relationship between 
UCH- L1 activity and PD. Furthermore, although 
mice that have a mutation in Uch-L1 exhibit neu-
rodegeneration, they do not display PD-like symp-
toms13.
Ubiquitin-Specific Proteases (USPs)
The USP subclass represents the bulk of the 
DUBs encoded by the human genome. As the 
number of Ub E3 ligases (the third factor in 
the ubiquitination cascade that determines tar-
get specificity) increased during evolution, so 
did the number of USPs, suggesting an intimate
relationship between the two resulting in their co-
evolution14.
 The catalytic domain of USPs contains 
two short and well-conserved motifs, called Cys 
and His boxes, which include the residues critical 
for catalysis. However, the size of the complete do-
main varies from approximately 300 to 800 amino 
acids due to the large unrelated sequences that are 
interspersed between the two motifs, which may 
serve a regulatory function (Figure 3).
 Upon closer examination of the catalytic 
domains of USPs, we noted that a subset (USP16, 
USP30, USP39, USP45, and USP52) lack catalytic 
residues previously thought to be critical for pro-
tease activity (Figure S1). USP30 and USP16 lack 
only the aspartate in the catalytic triad but retain 
enzymatic activity against a model substrate (Table 
S1 and M.P.A.L.-V. and T.K.S., unpublished data). 
This indicates that, as is the case for the Otubain-2 
protein, USP30 and USP16 may use a different res-
idue to stabilize the active site histidine. Additional 
structural information about USPs may shed light 
on this issue.
 USP39 (also known as SAD1) does 
not contain the conserved catalytic cysteine or 
histidine and does not cleave a model substrate 
in vitro, indicating that USP39 is not a bona fide 
DUB (M.P.A.L.-V. and T.K.S., unpublished data). 
However, USP39 plays a critical role in spliceo-
some maturation in both yeast and human cells, 
and many of the other residues within the cata-
lytic domain are conserved15,16. Therefore, it is 
tempting to speculate that USP39 can still inter-
act with Ub. An analogous situation exists in Ub 
conjugation. Here, a Ub interaction motif known 
as UEV (ubiquitin-conjugating enzyme variant) 
strongly resembles the catalytic domain of E2s 
(the second enzyme in the ubiquitination cascade) 
but lacks activity17. In keeping with this nomen-
clature, these catalytically inactive USP domains 
are hereby referred to as USPV (ubiquitin-specific 
protease variant). The functions of these variants 
with respect to Ub await further investigation.
Machado-Joseph Disease Protein Domain Proteases 
(MJDs)
A bioinformatics search for other classes of Ub pro-
teases identified Ataxin-3 and a number of Ataxin-
3-like proteins18. Experiments in vitro confirmed 
that wild-type Ataxin-3, but not a mutant with the 
active site cysteine mutated, could deubiquitinate a 
model substrate19. Sequence similarity between the 
catalytic domain of Ataxin-3 and other DUBs is 
low (Figure 2A), but recent NMR structures show 
that the overall arrangement of the catalytic triad is 
conserved (Figure 1)20,21.
Instability of a CAG nucleotide re-
peat in the Ataxin-3 gene leads to a hereditary 
neurological condition known as spinocer-
ebellar ataxia type-3 or Machado-Joseph disease
(OMIM 607047). Like other polyglutamine neu-
rodegenerative disease-associated genes, expansion 
of the CAG repeat in Ataxin-3 leads to protein mis-
folding, resulting in aggregation and cellular toxic-
ity. Some experimental evidence indicates that the 
normal function of Ataxin-3 involves transcription-
al regulation, but whether its DUB activity plays a 
role in this process remains unclear22. In evolution-
ary terms, MJDs likely represent a relatively late ad-
dition to the Ub system, as no homologs have been 
identified in yeast. However, protease activity of the 
other family members has not yet been demonstrat-
ed, and their biological functions remain unknown.
Ovarian Tumor Proteases (OTUs)
A bioinformatics approach also led to the identifi-
cation of the Ovarian Tumor (OTU) subclass of Ub 
proteases23. The otu gene is involved in the devel-
opment of the Drosophila melanogaster ovary where 
it may regulate the localization and translation of 
certain RNA transcripts24,25. Using the Drosophila 
otu gene and its homologs as a starting point, Ma-
karova and colleagues found sequence similarity be-
tween these genes and those encoding viral cysteine
ThesisVargas2.indd   34 9/28/2011   2:02:12 PM
 DUB OVERVIEW               35
2 
Figure 3. Comparison of the Domain Structures of Putative DUBs For each primary DUB transcript (the transcript associated with 
the HUGO or RefSeq ID), we retrieved information concerning domain architecture and signal motifs using ENSEMBL, SMART 
(simple modular architecture research tool; http://smart.embl-heidelberg.de/), Pfam (protein families database; http://www.sanger.ac.uk/
Software/Pfam/), and PROSITE databases. The USPs without additional domains are indicated as “generic USP.” Only JAMM and MJD 
domain proteins with predicted catalytic activity are shown. An asterisk indicates that the ENSEMBL-predicted translational start site is 
uncertain. Proteins and domains are plotted on an approximate scale. Select abbreviations: ZnF, zinc finger; NLS_BP, bipartite nuclear 
localization signal; MATH, meprin and TRAF homology; DUSP, domain in ubiquitin-specific proteases. For additional information 
concerning the indicated domains visit http://www.ebi.ac.uk/interpro/.
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proteases23. A recently solved OTU structure shows 
that, unlike other cysteine protease DUBs, the cata-
lytic triad is incomplete and is stabilized by a new 
method involving a hydrogen bonding network26.
 Otubain-1 and Otubain-2 were the first 
two OTU proteins found to display in vitro DUB 
activity27. Shortly thereafter, Cezanne, another 
OTU-domain containing protein, was found to in-
teract with poly-Ub in a yeast two-hybrid assay and 
to contain DUB activity in vitro, suggesting that 
this is a general OTU feature28. However, for most 
OTU proteases, their physiological role in vivo, in-
cluding their putative role as DUBs, remains to be 
investigated.
JAMM Motif Proteases
The JAMM domain is found in all three major 
kingdoms of life (bacteria, archaea, and eukarya). 
However, bacteria do not contain Ub protease ac-
tivity, and an analogous Ub-like conjugation sys-
tem has not yet been identified in prokaryotes. This 
suggests that JAMM domains have adopted new 
protease functions during evolution and indicates 
that at least some of the human JAMM proteases 
may be involved in more than Ub (or Ubl) pro-
cessing. Indeed, recent work has identified the 
protein product of the Mycobacterium tuberculosis 
gene mec+ as a JAMM domain peptidase involved 
in cysteine biosynthesis by cleaving cysteine from a 
peptide intermediate29. 
Sequence alignment of the JAMM-do-
main proteins revealed that seven of the 14 mem-
bers have at least one amino acid change in the 
conserved Zn2+ ion-stabilizing residues, indicating 
that they may not be functional proteases. Three 
family members (POH1, CSN5, and AMSH) will 
be briefly discussed in the section concerning DUB 
function.
DUB Specificity
Accumulating evidence indicates that most DUBs 
regulate a limited number of proteins and path-
ways, suggesting that they target specific substrates 
(Table 1). In the case of DUBs, specificity can 
refer to either the Ub or Ubl moiety itself (sub-
strate specificity) or the target protein to which the 
moiety is conjugated (target specificity). In real-
ity, it may not be possible to separate these types 
of specificities. It is likely that in many cases a 
combinatorial mechanism relying on recognition
 of both the target and the attached moiety deter-
mines overall DUB specificity. Additional mecha-
nisms, such as protein localization and interactions 
with binding partners, may further contribute to in 
vivo specificity. In the following sections, we will 
discuss current insights into DUB specificity.
Substrate Specificity: Ubiquitin Polymers
Protein ubiquitination comes in many different 
flavors that serve distinct functions2. Whereas poly-
Ub chains linked through the lysine residues of Ub 
at position 48 (K48) target proteins for proteasomal 
degradation, the attachment of a single Ub moiety 
(monoubiquitination) appears to regulate subcellu-
lar localization and recruitment of Ub binding pro-
teins. Besides mono- and K48-linked polyubiqui-
tination, other poly-Ub branches using alternative 
lysines on Ub have been described. The relevance 
and function of most of these different types of 
described for a number of mammalian proteins, 
including RIP, NEMO and TRAFs30. These signal-
ing molecules are involved in activation of NF-κB 
signaling, a pathway involved in inflammation, 
apoptosis, and tumorigenesis. As in the case of mo-
no-Ub, K63 polyubiquitination is required for the 
activation of downstream molecules, like kinases, or 
recruitment of other proteins. K63-linked Ub mol-
ecules differ remarkably from K48 chains in their 
three-dimensional structure, which probably ac-
counts for their distinct functions31. Furthermore, 
this suggests that certain DUBs may act on specific 
Ub branches. Indeed, the yeast DUB Ubp2 prefers 
K63 over K48-linked Ub chains as a substrate32. 
Conversely, examples of DUBs cleaving K48 but 
not K63- linked Ub polymers include USP8 and 
USP1433,34. Another DUB, UCH-L5 can cleave 
various types of branches but does not display ac-
tivity toward linear Ub dimers. Other examples 
further support the notion that DUBs cleave poly-
Ub variants with varying efficiency, at least in vivo. 
One such example is the protein product of the 
Cylindromatosis tumor-suppressor gene (CYLD), a 
DUB involved in inhibiting NF-κB signaling35-37. 
CYLD cleaves linear Ub fusions in vitro; yet in 
vivo it appears to be specific for non-K48-linked 
Ub chains. The basis for the specificity observed 
in vivo remains unclear, but phylogenetic analy-
sis indicates that the catalytic domain of CYLD 
is relatively divergent from other DUBs, as indi-
cated by its unique protease family identifier, C67 
(Table S1 and Figure 2). This information leads us
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to speculate that the architecture of the enzymatic
cleft contributes to its specificity. The OTU-type 
DUB A20  is another potent inhibitor of NF-κB 
signaling38. In vitro, A20 can cleave both K48- and 
K63-linked Ub polymers with similar efficiency. 
Yet in vivo, A20 deubiquitinates K63 but not K48 
polyubiquitinated RIP (the protein we mentioned 
previously that is involved in NF-κB activation). 
However, given that A20 also contains (K48) E3 
ligase activity toward RIP, it is not clear if the ap-
parent K63 DUB activity in vivo is due to true 
substrate preference or simply due to its ability to 
catalyze the addition of K48-linked Ub polymers.
 In at least some cases, domains outside 
the catalytic domain may contribute to Ub chain 
specificity39. Splice variants of USP2 and a mutant 
containing only the core catalytic domain of this 
DUB cleave both linear Ub fusions and K48-linked 
Ub polymers. However, their relative efficiency var-
ies considerably. The core domain prefers linear 
fusions, but full-length USP2b was most efficient 
in cleaving K48-linked Ub. Although USP2 does 
not contain an additional, known Ub-interaction 
motif, it is conceivable that sequences outside the 
catalytic domain contribute to selection and posi-
tioning of specific Ub chains. In fact, Ub- inter-
action motifs found in some E2 ligases have been 
implicated in determining linkage specificity. In-
deed, it was recently described that a previously 
unnoticed Ub-interacting Zinc finger domain in 
USP15 is needed for disassembling branched Ub 
polymers but not for cleavage of a linear Ub-GFP 
fusion40. Another recent study showed that ad-
dition of a UBA domain that recognizes K48-Ub 
chains to USP5 skewed its substrate preference to-
ward this type of Ub polymer41. Similarly, other Ub 
binding domains frequently encountered in DUBs, 
like UIM and ZnF-UBP (also called PAZ) may also
Figure 4. DUB Specificity and Regulation (A) DUB/E3 interactions. DUBs and E3 are often found in a com-
plex together. These interactions, which occur between USP7 and HDM2, for example, serve to reverse E3-me-
diated autoubiquitination (left panel) or allow the E3 to regulate the target and its DUB simultaneously as in 
the case of USP20 and pVHL (middle panel). Alternatively, DUB/E3 interactions confer specificity to the DUB,
as in the case of Ubp2 and Rsp5 (right panel). E3 Ub-ligase and Ub-protease activity is indicated with black arrows and red arrows, 
respectively. Ub conjugated to E2 is not shown for clarity. (B) DUB activity is regulated at various levels, including transcription (left 
panel), degradation, and binding to stimulatory or inhibitory cofactors (right panel). The exact mechanism whereby these cofactors 
regulate DUB activity is unknown but may occur at multiple levels (for example, phosphorylation, subcellular localization), stimulat-
ing conformational changes or conferring specificity.
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contribute to Ub chain selection (Figure 3).
Substrate Specificity: Ubiquitin and Ubiquitin-like-
Molecules
The vast majority of putative DUBs tested so far 
display Ub protease activity in vitro (Table S1). 
Nonetheless, some predicted DUBs may be active 
toward Ubl moieties. Therefore, when considering 
DUB specificity, we wish to extend our discussion 
to both Ub and Ubl moieties. USP21 and UCH-
L3 cleave both Ub and the Ubl molecule NEDD8. 
USP18 has been proposed to specifically cleave an-
other Ubl, ISG1542-44. Furthermore, although some 
circumstantial evidence indicates that CSN5 may 
contain Ub protease activity, its main proteolytic 
target is thought to be the Ubl NEDD845-47. For 
other Ubl molecules, distinct proteases have been 
identified. For instance, newly synthesized Ubl 
Atg8 is processed by a distinct protease (Apg4) of 
which five family members are found in the ge-
nome48. Likewise, protease activity toward SUMO 
(small ubiquitin-like modifier) has thus far been 
restricted to the SENP family of cysteine proteases, 
of which seven genes are present in the human ge-
nome. However, within this family proteolytic ac-
tivity is not limited to SUMO; SENP8 (also known 
as DEN1) is a NEDD8-specific protease49,50.
Our current knowledge of the motifs or residues in 
these proteases that are responsible for distinguish-
ing Ub from Ubl moieties is limited. Clearly, more 
in vitro and in vivo analysis of DUBs and Ubl prote-
ases, in- cluding structural information, is required.
Target Specificity and DUB/E3 Interactions
The recognition of targets by DUBs may be direct-
ed by sequences and motifs outside the conserved 
catalytic core. For instance, one of the Cap-Gly 
domains of CYLD mediates its interaction with 
NEMO, a potential CYLD substrate (Figure 3)51. 
However, like most enzyme/substrate interactions, 
DUB/target interactions are expected to be weak 
and transient in nature, making the identification 
of in vivo targets frustrating. A more stable complex 
between a DUB and its target may occur in the case 
when proteins are inappropriately K48 polyubiqui-
tinated (Figure 4A, left panel). These proteins need 
to be continuously deubiquitinated to protect them 
from unwanted degradation. Autoubiquitination 
by ring fingertype E3 ligases is a frequently observed 
phenomenon resulting from nonspecific ubiquiti-
nation of proximal lysines (careless gunplay). For
instance, the E3 ligase NRDP1 stimulates its own 
turnover as well as a number of cellular targets. The 
DUB USP8 associates with NRDP1 resulting in its 
deubiquitination and stabilization, suggesting that 
interaction with a DUB may simply serve to an-
tagonize this self-inflicted degradation52. Similarly, 
the interaction of USP7 with HDM2 and USP15 
with Rbx1 results in the stabilization of these E3 
ligases40,53-55. Interestingly, USP7 was also found to 
stabilize the herpes virus E3 ligase ICP0, indicat-
ing that viruses can hijack cellular DUBs to stabi-
lize viral proteins. The importance for controlling 
Ub dynamics in the herpes virus life cycle is further 
underscored by the recent finding that the herpes-
viridae contains a distinct class of cysteine protease 
DUBs without known mammalian homologs56.
 Not all DUB/E3 interactions strictly 
serve to regulate E3 ligase stability. The E3 tumor 
suppressor protein pVHL regulates the stability 
of HIF1 transcription factors that are important 
regulators of angiogenesis. USP33 interacts with 
this E357 and appears to regulate HIF1 stability by 
deubiquitination58. This suggests that, in this case, 
interaction of the DUB with the E3 allows the E3 
ligase to differentially regulate the primary protea-
somal target (HIF1) as well as its deconjugating en-
zyme (Figure 4A, middle panel).
 Kee and colleagues recently suggested a 
third type of DUB/E3 interaction32. They postu-
lated that in some cases the DUB may hitch along 
with the E3 ligase. They showed that the target 
specificity of the yeast DUB Ubp2 is strictly depen-
dent on the E3 ligase Rsp5, which is responsible 
for recognition of the substrate (Figure 4A, right 
panel). A remarkable variation on this theme is the 
previously mentioned protein A20. Here, E3 ligase 
and DUB activity reside in the same polypeptide38.
DUB Function
Gene deletion studies in yeast have indicated that 
none of the USPs are required for cell growth or 
viability9. Nonetheless, USPs and other DUBs in 
lower and higher eukaryotes including mammals 
have been implicated in regulating various critical 
cellular processes in a nonredundant manner. Hu-
man DUBs (or their murine homologs) of particu-
lar interest that have been linked to defined cellular 
processes or substrates are listed in Table 1.
The functions of DUBs at the pro-
teasome lid, in endocytosis and regulation of
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chromatin structure, are reasonably well under-
stood and are therefore discussed in some detail
in the following sections. In addition, we will pro-
pose some directions for future studies.
DUBs and Proteasome Function
Proteins that must undergo fast and dramatic 
changes in abundance are often regulated by 
proteolysis. These proteins are targeted to the 
proteasome by K48-linked polyubiquitina-
tion, where they are degraded. The 26S protea-
some consists of two 19S regulatory particles and
a 20S cylinder-shaped multiprotein complex pos-
sessing the proteolytic activity59. The 19S subunit 
restricts access to the interior of the 13 Å cylinder 
of the proteasome, which is where the catalytic 
residues for proteolysis are located. Deubiquitina-
tion of proteins arriving at the proteasome allows 
recycling of Ub and is required for protein degrada-
tion. In fact, deubiquitination, protein unfolding, 
translocation into the proteasome and degradation 
are intimately linked processes. A number of DUBs 
from various subclasses have been found in complex 
with the 19S proteasome regulatory component, 
including the JAMM protease POH1 (Rpn11 in 
yeast), UCH-L5, and USP14 (Ubp6 in yeast)46,60-62. 
Interestingly, residents of a paralogous multiprotein 
structure known as the COP9 signalosome are the 
JAMM protein CSN5 and USP1563,64. Like the 
proteasome, the COP9 signalosome has been im-
plicat- ed in a diverse array of biological processes. 
At least some of these functions can be explained by 
its ability to inhibit the activity of the cullin family 
of ubiquitin E3 ligases by CSN5-mediated dened-
dylation.
The main DUB activity at the proteasome 
appears to be generated by POH1, since deletion of 
the gene that encodes this enzyme results in defective 
proteasomal degradation and is lethal in yeast. The 
functions of the other DUBs may be partially redun-
dant with POH1, only playing a role in the deubiq-
uitination of specific substrates, or in “Ub editing.”
The Ub-editing concept was postulated as a mecha-
nism to rescue proteins that have been mistakenly 
ubiquitinated (as recognized by having short Ub 
chains) from destruction. The suggested Ub-editing 
mechanism would remove Ub polymers, starting 
at the distal end, independently of the substrate 
moiety61. Although UCH-L5 indeed cleaves Ub 
chains from the distal end, compelling evidence 
for an Ub-editing function for UCH-L5 has not
yet been provided, and no ortholog of UCH-L5 has 
been found in Saccharomyces cerevisiae.
DUBs and Chromatin Structure
An increasing body of evidence implicates dynamic 
histone ubiquitination in the regulation of tran-
scription and silencing, and even double-strand-
break formation during meiosis65. Although most 
histone proteins can be ubiquitinated, the dynam-
ics of H2B monoubiquitination are best under-
stood. In yeast, deubiquitination of H2B by the 
DUB Ubp10 is required for telomeric silencing. 
This in turn allows recruitment of the silencing fac-
tor Sir266. Interestingly, a second USP Ubp8 has 
been implicated in regulating H2B. In contrast to 
Ubp10, deubiquitination of H2B by Ubp8 corre-
lates with transcriptional activation67,68. At least at 
some sites of active transcription, Ub-H2B levels 
are high during activation and subsequently de-
crease in an Ubp8-dependent manner. Importantly, 
both the ubiquitination and deubiquitination of 
H2B are necessary for optimal transcription, indi-
cating a requirement for dynamic H2B modifica-
tion by Ub68.
Similar to yeast Ubp10, Drosophila 
USP7 interacts preferentially with silenced ge-
nomic regions, including telomeric domains, 
where it has been suggested to deubiquitinate
H2B and thereby contribute to Polycomb-mediat-
ed silencing69. In mammals, USP7 associates with 
HDM2, an E3 ligase critical for regulating p53 
turnover, and thereby inhibits degradation of both 
HDM2 and p5354,55. Indeed, different levels of 
USP7 can have opposite outcomes with respect to 
p53 stability. Intermediate inhibition of USP7 re-
sult in increased p53 degradation, whereas complete 
inhibition of USP7 enhances p53 stability. Interest-
ingly, a recent report has suggested that HDM2 can 
mediate H2B ubiquitination70. Together, these data 
suggest an attractive model in which HDM2/p53/
USP7 complexes mediate transcriptional repression 
by regulating H2B ubiquitination. 
DUBs and Endocytosis
Monoubiquitination and, at least in yeast, the at-
tachment of a K63-linked Ub dimer, play an im-
portant role in endocytosis of receptors and sorting 
of proteins71,72. After binding to ligands, receptor 
tyrosine kinases (RTKs) and adaptor proteins are 
monoubiquitinated at multiple sites, which trig-
gers their internalization. The RTKs are subse-
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quently either recycled or transported to lysosomes 
for destruction. The E3 ligase for many RTKs is 
the proto-oncogene Cbl, which can also induce 
proteasome-dependent degradation by stimulating 
K48 polyubiquitination73. Repeated addition of Ub 
or reduced deubiquitination may be the trigger for 
targeting to the lysosomal compartment, though 
exactly how ubiquitination determines this decision 
is unclear. Ub-interacting proteins like Hrs subse-
quently bind to the monoubiquitinated receptor 
and recruit protein complexes involved in budding 
of the endocytic vesicle.
DUBs are implicated in the endo-
cytic pathway at multiple levels and also play 
important roles in other types of intracellular 
traffic. In yeast, the DUB Doa4 acts to recycle
Ub at the late endosome to rescue Ub from destruc-
tion. Inactivation of Doa4 interferes with many 
Ub-related processes since it results in depletion of 
free Ub and many of the defects observed on Doa4 
mutant cells are restored upon expression of addi-
tional Ub74. The closest human relative of Doa4 is 
USP8, which binds the Hrs binding partner (Hbp) 
and inhibits EGF receptor (EGFR) endocytosis, 
suggesting that USP8 may act to regulate endocytic 
traffic75,76. Remarkably, a second Hrs interacting 
protein is AMSH, a JAMM domain DUB34. In-
hibition of AMSH results in the accumulation of 
endosomal Ub and promotes EGFR endocytosis 
thereby accelerating EGFR downregulation.
 Yet more DUBs are implicated in 
controlling endocytosis. In Drosophila, Fat fac-
ets (Faf; the homolog of human USP9X), deu- 
biquitinates Liquid facets (Lqf ), resulting in
enhanced Lqf activity77. Lqf and Faf play a role in 
Drosophila eye development by enhancing the in-
ternalization of a receptor implicated in cell pat-
terning, called Delta. In humans, Lqf homologs are 
known as epsins, adaptor molecules involved in the 
initial steps of endocytosis.
Ubiquitination and deubiquitina-
tion appears to be a common theme in vesicle 
dynamics; monoubiquitination plays a critical 
role in budding of some viruses. Additionally,
VCIP135, a OTU, has been impli-
cated in Golgi assembly after mitosis78.
Other Potential Roles for DUBs
Indications for the function of DUBs may come 
from various sources, including genetic screens in 
model organisms, interactome data, and domain- 
and signaling-motif predictions. Genetic screens in 
model organisms like the worm Caenorhabditis ele-
gans and the fruit fly Drosophila are pointing at new 
roles for DUBs in various pathways. For instance, 
screens in C. elegans for modulators of RNA interfer-
ence or longevity suggest an involvement of a USP
and a UCH79,80. In addition, a protein with both a 
USP and OTU domain (Duo-2) has recently been 
implicated in synapse function81. These studies 
further solidify the broad involvement of the Ub 
conjugation/deconjugation system in biological 
processes and will certainly spark research into the 
functions of the human DUB orthologs.
 Data derived from large-scale human 
protein-protein interaction experiments has impli-
cated a number of USPs in several signaling cas-
cades such as the TGF-β and NF-κB pathways. 
For instance, USP45 binds specifically to the phos-
phorylated TGF-β receptor in a mammalian two-
hybrid82. Similarly, USP11 and USP9 interact with 
the NF-κB transcription factors RelB and p100, 
respectively83. Although the significance of these in-
teractions remains to be determined, these findings 
suggest that DUBs may play a regulatory role in 
these pathways.
 Hints to the function of DUBs may be 
obtained from additional domains and signal mo-
tifs present in the primary amino acid sequence 
of these enzymes (Figure 3). For instance, USP7 
might be involved in specific signaling pathways as 
it contains a MATH (meprin and TRAF homol-
ogy) domain. These domains are found in members 
of the TRAF family of ring finger E3 ligases which 
mediates signaling via TNF receptors. Similarly, the 
JAMM2 protein might play a role in transcription 
and chromatin remodeling, as it contains domains 
(SWIRM and Myb DNA binding motif ) impli-
cated in these processes.
Regulation of DUBs
In contrast to many proteases, such as caspases 
that are translated as inactive precursors, DUBs are 
generally produced as active enzymes. Structural 
analysis has pointed out that the catalytic triad of 
UCHs and USPs only assume the active confirma-
tion when bound to Ub, thereby preventing spuri-
ous protease activity against other substrates. In ad-
dition, various studies show that a diverse array of 
mechanisms regulates DUB activity and additional 
ones are likely to be discovered.
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 In the case of at least two JAMM domain 
proteins (POH1 and CSN5), it appears that incor-
poration into higher-order protein structures (the 
19S proteasome and COP9 signalosome, respec-
tively) is required for peptidase activity46,63. Simi-
larly, accessibility of the enzymatic cleft of USP14 
appears to be regulated by activity of the 26S pro-
teasome, its resident complex60.
 Bre5, a cofactor for the yeast DUB Ubp3, 
is largely responsible for its in vivo activity toward 
Sec23, a protein involved in anterograde trans-
port between the endoplasmic reticulum and the 
Golgi compartment84. Bre5 does not bind directly 
to Sec23, suggesting that the interaction between 
Bre5 and Ubp3 regulates Ubp3 activity. Surprising-
ly, the human homolog of Bre5, G3BP1, inhibits 
the activity of USP10, at least in vitro, indicating 
that cofactors can either restrict or enhance protease 
activity (Figure 4B, right panel)85. A USP7 cofactor 
called GMPS that strongly augments USP7 activity 
was recently identified in Drosophila69. In addition, 
USP7 is regulated during apoptosis by cleavage 
by caspases. This cleavage presumably inactivates 
USP786.
 DUBs have frequently been found to be 
degraded by the proteasome, indicating that their 
abundance is an important regulatory mechanism 
(Figure 4B, right panel). Moreover, some DUBs 
have been reported to be transcriptionally regulated 
(Figure 4B, left panel), sometimes in a cell-cycle-
regulated manner (for example, USP1) or as part of 
a negative feedback loop (such as CYLD)87,88.
 In another case, inhibitory phosphory-
lation of CYLD after TNF-α stimulation is re-
quired for the accumulation of one of its pro- 
posed substrates, K63-ubiquitinated TRAF2.
Interestingly, this event does not appear to 
modulate the affinity of CYLD for TRAF2, 
suggesting that phosphorylation may direct-
ly regulate CYLD activity by an unknown
mechanism89.
Concluding Remarks
A large number of studies over the last decade have 
uncovered an unanticipated diversity of protein reg-
ulation by Ub and Ubl molecules. Nature has uti-
lized the versatility of Ub in almost any conceivable 
way. Strikingly, the ubiquitin conjugation/deconju-
gation system out competes the protein phosphory-
lation system in terms of diversity and complexity.
Although the reversal of ubiquitination by DUBs 
has been firmly established as a critical regulatory 
mechanism, we are only beginning to uncover the 
different mechanisms that control the activity of 
these enzymes.
 Remarkably, the Ub E3 ligases greatly 
outnumber the DUBs encoded in the human ge-
nome. This is in contrast to tyrosine kinases and 
phosphatases, which are roughly equal in number. 
One possible explanation is that we have not yet 
identified all DUBs or their associated cofactors 
that may determine specificity. Indeed, Serine/
Threonine kinases outnumber Serine/Threonine 
phosphatases, but a large variety of cofactors pro-
vide additional specificity to these phosphatases. 
It is also possible that many DUBs have poor sub-
strate specificity and regulate on average up to 10 
times more substrates than the average E3 ligase. 
However, most DUBs studied thus far appear to 
regulate a small number of targets. Another more 
likely explanation for the excess of E3 ligases could 
be that only a fraction of the targets that are ubiq-
uitinated are regulated by specific deubiquitina-
tion. For destruction mediated by K48 Ub poly-
mers, we would predict that many proteins are not 
deubiquitinated prior to arrival at the proteasome. 
Unless of course when you have made a mistake, 
why recycle a protein that you have decided to 
throw away? Possibly, only proteins that require 
extremely tight regulation, such as p53, require 
additional regulation by deubiquitination. In-
deed, other types of Ub-based modifications, like 
K63-linked polymers or monoubiquitin require
DUBs to “reset” the protein to its unmodi-
fied state and are thus more likely to be critically 
regulated by DUBs. Undoubtedly, future studies 
aided by detailed genomic annotation, structural 
information, and other new tools and methods 
to characterize this intriguing protein family will 
result in the demystification of these proteases.
Supplemental Data
Supplemental Data include one figure and one table 
and can be found with this article online at http://
www.cell.com/cgi/content/ full/123/5/773/DC1/.
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Abstract
High-throughput methods to produce a large number of soluble recombinant protein variants are 
particularly important in the process of determining the three-dimensional structure of proteins and 
their complexes. Here, we describe a collection of protein expression vectors for ligation-independent 
cloning, which allow co-expression strategies by implementing different affinity tags and antibiotic 
resistances. Since the same PCR product can be inserted in all but one of the vectors, this allows 
efficiency in versatility while screening for optimal expression strategies. We first demonstrate the 
use of these vectors for protein expression in Escherichia coli, on a set of proteins belonging to the 
ubiquitin specific protease (USP) Family. We have selected 35 USPs, created 145 different expression 
constructs into the pETNKIHis-3C-LIC-kan vector, and obtained 38 soluble recombinant proteins 
for 21 different USPs. Finally, we exemplify the use of our vectors for bacterial co-expression and for 
expression in insect cells, with USP4 and USP7 respectively. We conclude that our ligation-indepen-
dent cloning strategy allows for high-throughput screening for the expression of soluble proteins 
in a variety of vectors in E. coli and in insect cells. In addition, the same vectors can be used for co-
expression studies, at least for simple binary complexes. Application in the family of ubiquitin specific 
proteases led to a number of soluble USPs that are used for functional and crystallization studies.
Introduction
The sequences of viral, bacterial and eukaryotic ge-
nomes have been unravelled over the last decade, 
providing a large protein database in demand for 
structure–function analysis. To meet this challenge, 
an international effort to understand protein func-
tion was initiated, and pioneered by efforts such as 
the US-based ‘‘Protein Structure Initiative’’ (PSI), 
the Japan-based RIKEN Structural Genomics 
Initiative, and private–public open access consor-
tia pioneered by the Structural Genomics Center 
(SGC) and many others. In Europe, the SPINE 
project introduced high throughput proteomics in 
a wide collaborative platform, and SPINE-2-com-
plexesaimed to extend many of these methodolo-
gies to the study of macromolecular complexes. A 
direct consequence of such efforts was the rapid 
development of new high-throughput technologies 
for molecular cloning, expression and purification 
of recombinant proteins, that are crucial in the ef-
fort of determining the three-dimensional protein 
structures on a genomic scale1,2.
 Any structure determination project 
is dependent on the ability to obtain sufficient 
amounts of soluble recombinant protein. A differ-
ence of three amino acids between constructs can 
already improve either the protein solubility or 
significantly alter its propensity to crystallize3,4. It 
is therefore common practice to test many protein 
constructs, typically combinations of N- and C-ter-
minal truncations and assess them for the amount 
of protein expressed and solubility. The use of high-
throughput methods enables screening of multiple 
constructs in parallel, to quickly determine the con-
struct, which produces soluble recombinant protein 
and is more likely to crystallize.
 One technique for molecular cloning 
that was described two decades ago5 but has been 
popularized in the Structural Genomics field, is 
Ligation Independent Cloning (LIC). LIC is a 
procedure for the directional cloning of PCR prod-
ucts that is independent of restriction endonucle-
ases, DNA ligase or alkaline phosphatases. The LIC 
method takes advantage of the 3´→ 5´ exonucle-
ase activity of T4 DNA Polymerase to create very 
specific single-stranded overhangs in both the vec-
tor and in PCR products of the protein of inter-
est. When vector and insert are transformed into 
Escherichia coli cells, covalent bond formation at 
the vector-insert junctions occurs within the cell to 
yield circular plasmid and the resulting construct is 
ready for expression either in bacteria or in insect 
cells. Here, we first describe the procedures to de-
sign and produce a series of LIC applicable vectors 
for recombinant protein expression. All but one of 
the vectors accommodate the same PCR product: 
this allows to create in parallel a simple hexahisti-
dine tag construct, or a GST tag construct to facili-
tate solubility, or a Strep-tag II, or a His-tag fused 
to the Trigger Factor in a cold inducible system 
that has shown very promising results6. At the same 
time the target vectors have different antibiotic 
resistance combinations and/or origins of replica-
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tion (Fig. 1) making them possible for protein co-
expression experiments. The same PCR product 
can even be used for insertion in vector that can 
be used for protein production in insect cells. The 
only vector requiring a different PCR reaction is the 
his-SUMO2 vector: this peculiarity is necessary to 
take advantage of the SENP-2 protease property to 
leave no residual amino-acids after tag cleavage. To 
enable the high throughput design of PCR prim-
ers for these LIC reactions, the web server ‘Protein 
Crystallisation Construct Designer’ (ProteinCCD; 
http://xtal.nki.nl/ccd) has been designed7.
 To exemplify the use of our vector suite, 
we show our work in the study of the largest sub-
family of Deubiquitinating Enzymes (DUBs), the 
Ubiquitin Specific Protease (USP) family.
 DUBs are proteases that are capable of 
removing ubiquitin (Ub) from Ub conjugated pro-
teins by specifically hydrolyzing ester, thiol ester and 
amide bonds to the carboxyl group of Glycine-76 
of Ubiquitin. The large USP family comprises ap-
proximately sixty proteins, which are papain-like 
proteases that vary greatly in size. These USPs con-
tain three conserved regions surrounding the cyste-
ine, histidine and aspartate/asparagine residues that 
form the catalytic triad8,9. Only a small number of 
substrates have been identified and little is known 
about the substrate specificity and selectivity of the 
USP family. The large size of the USP family and its 
associated specificity opens up perspectives for its 
use as drug target.
 We present the expression testing for a 
large collection of USPs, using one of our vectors. 
Then, we show the use of a selection of our dif-
ferent bacterial expression vectors for single pro-
tein expression and co-expression studies using the 
minimal catalytic domain of one of the members 
of the USP family, USP4, which is formed by two 
domains, USP4-D1 and -D210. Finally we illustrate 
the use of an insect cell expression LIC vector for 
the production of another member of the USP fam-
ily, USP7.
Material and methods
The design and construction of the pETNKI-
LIC vector suite
An overview of all the vectors used in this study is 
shown in Fig. 1.
The pETNKI-His-3C-LIC-kan vector 
is engineered to express the target protein imme-
diately downstream of an N-terminal hexahistidine 
tag, followed by the human rhinovirus 3C prote-
ase (3C protease) cleavage site, enabling removal 
of all vector-encoded fusion sequences. This vector 
was based on the popular pET-28a expression vec-
tor (Novagen): the sequence between the NcoI and 
XhoI restriction sites of the original plasmid was 
replaced with the 5’CCATGGCACATCACCAC-
CACCATCACTCCGCGGCTCTTGAGGT
G C T C T T T C A G G G A C C C G G G T A C -
C A A G A A C A A A A A C TC ATC TC A G A A G
AGGATCTGTTGGTACCCGGGCTTCTCCTC-
GAG 3´ sequence. This sequence contains 
two KpnI restriction sites (bold) and the LIC 
sequences that are used to create the over-
hanging ends for the annealing reaction (ital-
ics). The 5’ sequence upstream the first KpnI
site encodes the 
MAHHHHHHSAALEVLFQ↓GPG  sequence 
(underlined; ↓  indicates  the  cleavage  site  for 
3C protease).
To create the pCDFNKI-StrepII-3C-
LIC-strep vector, pET52b (Novagen) was cut 
with XbaI and KpnI to obtain a 109 bp frag-
ment containing the StrepII-tag and 3C prote-
ase recognition site. This fragment was ligated 
into pETNKI-His-3C-LIC-kan that was cut
with XbaI and KpnI, to yield pETNKI-Stre-
pII-3C-LIC-kan. The resulting vector was cut 
with NcoI and XhoI to obtain a 84 bp fragment 
containing the LIC cassette. This fragment was
cloned into the pCDF-Ib expression vector (Nova-
gen) cut with the same enzymes.
To create the pGEXNKI-GST-3C-LIC-
amp vector, a PCR reaction was performed using 
the pETNKI-StrepII-3C-LIC-kan vector as tem-
plate to obtain a fragment containing the LIC cas-
sette that could be cloned into the pGEX-2T expres-
sion vector (GE Healthcare). The forward primer 
(50-CATAGGGATCCTCCGCGGCTCTTGAG-
GTG-30) contained a BamHI restriction site and 
the reverse primer (50-ATCCGAATTCTAAGT-
TATTGCTCAGCGG-30) contained an EcoRI 
site. The 250 bp PCR fragment was digested with 
BamHI and EcoRI and ligated into the pGEX-2T 
vector cut with the same enzymes.
To construct the pColdNKI-His-TF-3C-
LIC-amp vector containing a hexa-histidine-tagged 
Trigger Factor (TF) as a solubility tag, pETNKI-
His-3C-LIC-kan was digested with SacII and XhoI 
to obtain a 90 bp SacII-XhoI fragment containing
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the LIC cassette. This fragment was ligated into the 
pCOLD™ TF vector (Takara Bio Inc. Otsu, Japan), 
that was cleaved with the same enzymes.
To create the pET-NKI-His-SUMO2-
LIC-kan vector, a Quikchange reaction (Strata-
gene, CA) was performed with forward primer
C C A G C A G C A G A C G G G A G G G TA C C -
GGGCTCCGCCGCCAAGCTTGCGGCCG-
CACTCG and the corresponding reverse/comple-
ment oligonucleotide according to manufacturers 
instructions, using the SUMOPRO pSUMO2 
vector (LifeSensors, PA), which contains the
SMT3A gene in frame with a his-tag, as a template 
to introduce a LIC cassette. This is the only vector 
from this collection where different overhangs are 
required for the PCR fragment.
To create the pFastBac-NKI-His-3C-
LIC-amp vector the pETNKIHis-3C-LIC-kan 
cassette was PCR amplified and inserted in 
the baculovirus expression vector pFastBac-
HTb between the RsrII and HindIII restriction 
sites using the following primers: forward 5’-
G AG AC TC G G TC C G A A AC C ATG G C A -
CATCACCACCACCATCAC-3’ and reverse 
5’- ACTTAAGCTTCTCGAGGAGAAGCCC-
GGGTA -3’. The start ATG codon was main-
tained in the same position as in pFastBac-HTb.
Figure 1. A schematic diagram of the vectors in the NKI suite. Different features of the vectors allowing different affinity purification 
strategies, better induction mediated or tag mediated solubilisation, or co-expression experiments are indicated: Promotors: T7; cspA 
(Cold-shock protein) promoter; polH, polyhedrin. Tags: his, hexa-histidine tag; StrepII, Strep-tag; GST, GST-tag; his-TF, hexa-histidine 
tagged Trigger Factor; his-SUMO2, hexa-histidine SUMO2 tag. Protease site: 3C, Human Rhinovirus 3C prescission protease; SENP2, 
SUMO-specific protease. Origins of Replications: ColE1; CloDF13; PUC. Resistance markers: Kan, kanamycin; Amp, ampicillin; Strep, 
streptomycin. LIC cassette (LIC) and KpnI restriction sites to linearize the vector are indicated.
Preparation of Linear Plasmid DNA for LIC
An overview of the LIC cloning procedure is de-
picted in Fig. 2.
Any of these plasmids is transformed 
into an E. coli host strain like DH5a, amplified 
and retrieved via a midi or maxi plasmid prep kit 
(Qiagen). The vector DNA (10 µg) is then digested 
with KpnI for 2–3 h at 37°C in a 100 µL reaction 
volume and purified with a QIAquick spin column 
(Qiagen) according to the manufacturer’s protocol 
and eluted in 100µL TE buffer to achieve DNA 
concentration of ~100 ng/µL. The linearized vec-
tor DNA is then treated with T4 DNA Polymerase 
to create the single-stand overhangs as follows: 
In a sterile 1.5-ml micro-centrifuge tube 10 µl of 
linearized vector, 2 µl 10X T4 DNA Polymerase 
Buffer (NEB), 2 µl 25 mM dTTP, 1 µl T4 DNA 
Polymerase (NEB) and 5 µl Nuclease-free water are 
added to a final volume of 20 µl. The reaction is 
started by adding the enzyme and incubated at RT 
for 30 min. The T4 DNA Polymerase is inactivated 
by incubating at 75°C for 20 min. For the LIC 
annealing reaction 1 µl of vector prepared in this 
manner (~50 ng/µl) is annealed with each insert. 
Starting from the recommended 10 µg of vector, 
approximately 200 µl of final T4 treated solution is 
obtained, which is suitable for 200 LIC reactions.
ThesisVargas2.indd   55 9/28/2011   2:02:26 PM
56               CHAPTER 3
    3 
Production of gene products for LIC cloning
To amplify the target gene construct by PCR to cre-
ate the LIC insert, we typically use the high-fidelity 
polymerase Pfu from Stratagene. A main require-
ment here is that the polymerase used needs to be 
one with minimal activity for the addition of non-
templated 30 nucleotides. For all vectors (except 
pETNKI-His-SUMO2-LIC-kan) the 50-end of 
the primers must contain the CAGGGACCCGGT 
sequence upstream of the forward PCR primer 
and CGAGGAGAAGCCCGGTTA sequence 
upstream of the reverse primer (which includes a 
TAA stop codon). For the pETNKI-His-SUMO2-
LIC-kan vector the 50-end of the forward PCR 
primer must contain the CCAGCAGCAGAC-
GGGAGGT sequence upstream of the primer fol-
lowed by the sequence of the gene of interest; the 
GGCGGCGGAGCCCGTTA sequence is needed 
upstream at the 5’-end of the reverse primer. Im-
portantly, the SUMO2 tag can be removed from 
the target protein after treatment with SENP2 pro-
tease, leaving no extra amino acid residues at the 
N-terminus of the sequence of the target protein.
To prepare DNA fragments for the T4 
DNA Polymerase treatment, the dNTPs from the 
PCR product are removed with a spin column kit 
(QIAquick PCR purification kit) and the purified 
PCR products are eluted in TE buffer (10 mM Tris–
HCl, 0.1 mM EDTA, pH 8.0). In a sterile 1.5-ml 
microcentrifuge tube (or microwell plate to enable 
high throughput production) 0.2 pmol of purified 
PCR DNA (measured in a Nanodrop1000 by Ther-
moScientific), 2 µl 10X T4 DNA Polymerase Buffer 
(NEB), 2 µl 25 mM dATP and 1 µl T4 DNA Poly-
Figure 2. A schematic overview 
of the LIC cloning procedure. 1) 
Cleavage of the different expres-
sion vectors with KpnI (except for 
the pETNKI-HisSUMO2-LIC). 
2) Treatment of the cleaved vector 
with T4 DNA polymerase in pres-
ence of dTTP. 3) Generation of 
PCR fragment of gene of interest 
flanked with specific LIC sequences. 
4) Treatment of the LIC PCR frag-
ment with T4 DNA polymerase 
in presence of dATP. 5) Annealing 
and ligation of insert into expres-
sion vector. The sequence of KpnI 
cleavage site is indicated in pink, the 
LIC sequence is indicated in blue for 
the vector and brown for the PCR 
insert, and the gene of interest is in-
dicated in green.
merase (NEB) are added to a final volume of 20µL. 
The reaction is started by adding the enzyme and 
incubated at RT for 30 min. The T4 DNA poly-
merase is inactivated by incubating at 75°C for 20 
min.
Annealing the vector and the LIC insert
For each construct, 1 µl vector (50 ng/µl) and 2 
µl insert (0.02 pmol) prepared as above are as-
sembled in a sterile reaction plate. The reactions are 
incubated at RT for 5 min, and stopped by add-
ing 1 µl of 25 mM EDTA. Typically, half of the 
annealing reaction (2 µl) is transformed into Nov-
aBlue competent cells that are plated onto LB agar 
plates containing the appropriate antibiotic. After 
overnight incubation at 37°C, two single colonies 
for each construct are picked and used for plas-
mid amplification, isolation and sequencing, using 
standard protocols. Alternatively, colonies contain-
ing the insert can be identified using colony PCR 
and sequence confirmation can be reserved for only 
constructs that produce soluble protein. It should 
also be noted that annealing reactions can be trans-
formed directly into the expression strain; or each 
half of the reaction can go to an expression strain 
and a DNA amplification strain respectively.
Testing different pETNKI-LIC vectors in medi-
um-throughput co-expression
To identify constructs likely to yield sufficient 
amounts of soluble protein for scale-up and pro-
tein purification, we first performed a small-
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scale protein expression and solubility screening. 
50 µl E.coli Rosetta2(DE3) or BL21(DE3) cells are 
transformed with 50 ng of plasmid in a Thermowell 
96-well PCR microplate (Corning, Inc.) and heat 
shocked for 40 s at 42°C in a water bath. After in-
cubation on ice for 2 min, 100 µl SOC medium 
is added to each well and the 96-well microplate 
is sealed with a silicone rubber mat (Costar) and 
incubated at 37°C for 1 h. The transformation 
reactions are plated out on 6-well LB agar plates 
(Falcon multiwell, Beckton Dickinson) contain-
ing the appropriate antibiotics. After overnight 
growth at 37°C, single colonies of each construct 
are picked and grown in 200 µl auto-induction me-
dia (ZYP5052, made in-house)11 (Studier, 2005) 
with appropriate antibiotics, in a 2 ml 96-deepwell 
block (Nunc) and sealed with Airpore tape sheets 
(Qiagen). The 96-deepwell block is incubated in 
a shaker at 300 rpm for 4 h at 37°C. When the 
cells reach an OD600 of about 2–3, typically after 
4 h, the temperature is lowered to 15°C for over-
night induction. For higher volume production (in 
our case for all vector comparison tests) 0.5 ml of 
overnight pre-culture was used to inoculate 50 ml 
LB medium (LB Broth (Miller) from Molecular
Dimensions Limited) with corresponding antibiot-
ics in 250 ml baffled flasks and grown at 37°C until 
OD600 of 0.8 units is reached. Since USP4 con-
tains two zinc finger motifs, prior to induction we 
supplement the media with 12,5 µl 1M ZnCl2 (250 
mM), a practice we know to be beneficial based on 
prior experience. Finally, we added 25 µl 1M IPTG 
(500 mM) to induce protein production and the 
cells were grown overnight at 15°C.
For high throughput testing, cells 
are collected by centrifuging the 96-deepwell 
block at 4000 rpm for 15 min. All liquid han-
dling steps are done by hand with a multi-chan-
nel pipette (Matrix Technologies). The pellet 
in each well is resuspended with 200 µl lysis
buffer (50 mM Tris–HCl pH8.0, 200 mM NaCl, 
5 mM imidazole, 0.1% Triton X-100, 2 mM 
β-mercaptoethanol, 200 U Lysozyme (Novagen)). 
The 96-deepwell block containing the cell suspen-
sion is shaken at 800 rpms for 20 min at room 
temperature using the thermomixer (Eppendorf ). 
When the cell extract is clear, 10 µl of MagneHis 
Ni2+-beads (Promega), are added to each well. 
After 5 min the Magnetight HT96 stand (Nova-
gen) is used to pull down the MagneHis beads to 
remove unbound proteins. The MagneHis beads
are washed 3 times with 50 µl wash buffer (50 mM 
Tris–HCl pH 8.0, 200 mM NaCl, 5 mM imidaz-
ole & 2 mM β-mercaptoethanol). Protein elution 
from the MagneHis-beads is done by adding 20 µl 
elution buffer (wash buffer containing 500 mM im-
idazole) to each well and incubating the 96-deep-
well block for 10 min at room temperature. The 
MagneHis-beads are finally pulled down with the 
magnetic stand and the eluted proteins removed 
and analyzed on SDS–page gels. 
For higher volume testing (in our case for 
all vector comparison experiments and co-expres-
sion tests), cells are harvested by centrifugation and 
resuspended with 3 ml lysis buffer (25 mM Hepes 
pH7.5, 150 mM NaCl, 10 mM Imidazole, 5 mM 
β-mercaptoethanol and protease inhibitor tablet). 
The cells are broken by subjecting the cell suspen-
sion to a 10 s pulse with a pause of 20 s after each 
pulse for a total of 2 min using the Misonics soni-
cator S-4000 at 40% maximum setting. The cell 
lysate is centrifuged at 13,200 rpm for 25 min at 
4°C. The resulting supernatant is incubated with 
100 µl of corresponding resin (Talon resin (Clon-
tech) for His-tag, Glutathione Sepharose resin (GE 
Healthcare) for GSTtag and Strep Tactin resin 
(Novagen) for StrepII-tag) for 15 min at 4°C. The 
resin is washed with 2 times 5 mL lysis buffer and 
the protein is eluted from the beads with elution 
buffer (lysis buffer containing 300 mM Imidazole 
or 25 mM glutathione or 2.5 mM desthiobiotin). 
Samples of total cells, supernatant cell lysate and 
eluate are analysed on an SDS–PAGE gel.
Scale-up of expression and protein purification 
of USP8
As in the small scale expression trials, the E. coli host 
Rosetta2(DE3) was used for the large scale protein 
expression. 5 ml of overnight pre-culture was used 
to inoculate 500 ml autoinduction media in 3L 
baffled flasks and grown at 37°C until OD600 of 
2–3 units was reached. The temperature was low-
ered to 15°C for overnight induction. Cells were 
harvested by centrifugation and resuspended in 200 
ml lysis buffer (50 mM Tris–HCl pH8.0, 150 mM
NaCl, 10 mM imidazole, 5 mM β-mercaptoethanol 
and 1 mM PMSF). The cells were broken by sub-
jecting the cell suspension to a 10 s pulse with a 
pause of 30 s after each pulse for a total of 5 min 
using the Misonics sonicator S-4000 at 80% maxi-
mum setting. The broken cell lysis was centrifuged
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at 48,000 g (J-26XP Avanti Centrifuge, Beckman 
Coulter) for 30 min at 4°C to remove cellular debris 
and unbroken cells. The resulting supernatant was 
incubated with washed 2 ml Talon metal affinity 
resin (Clontech, Inc., Palo Alto, CA) for 20 min at 
4°C and the beads were then washed with 200 ml 
lysis buffer. The beads were eluted with 20 ml lysis 
buffer containing 400 mM imidazole. The eluted 
sample was diluted 10–15 times with 50 mM Bis-
Tris pH6.5. The diluted sample was applied to a 
5 ml Poros S column equilibrated with buffer A 
(20 mM BisTris pH6.5, 10 mM NaCl and 5 mM 
β-mercaptoethanol) and bound protein was eluted 
with buffer A containing 1 M NaCl using a 60% 
gradient in 20 column volumes. Peak fractions were 
pooled and concentrated by ultrafiltration using an 
Amicon Ultra centrifugal unit (Millipore) and ap-
plied to a Superdex 75 16/60 gel filtration column 
(GE Healthcare) equilibrated with buffer contain-
ing 25 mM Tris–HCl pH8.0, 150 mM NaCl and 
5mM β-mercaptoethanol. Peak fractions from the 
gel filtration column were pooled and concentrated 
in an Amicon Ultra centrifugation unit to a concen-
tration of 10 mg/ml. The concentrated protein was
flash frozen in liquid nitrogen and stored at -80°C. 
Small-scale test expression in insect cells
The production and isolation of the recombinant 
bacmid and the infection of the P0 culture is per-
formed as described in the Invitrogen Bac-to-Bac 
Baculovirus Expression System manual. 25 ml of 
Sf-9 insect cells at 106 cells/ml concentration is 
infected with 1 ml of P0 culture medium and let 
grow for 72 h.
Cells are harvested by centrifugation and 
resuspended with 10 ml lysis buffer (20 mM Hepes 
pH 8.0, 150 mM NaCl and protease inhibitor tab-
let). The cells are lysed by sonication in an ice bath 
for 30 s (5 s pulse with a pause of 40 s) using the 
Misonics sonicator S-4000 (at 50% maximum set-
ting) and the lysate centrifuged at 48,000g (J-26XP 
Avanti Centrifuge, Beckman Coulter) for 25 min 
at 4°C. The supernatant is purified on column us-
ing 200 µl of Chelating Sepharose Fast Flow resin 
loaded with Ni2+. Samples of lysate, supernatant 
and elution are analysed on a SDS–PAGE gel.
Table 1
Summary of the high-throughput cloning and protein expression screen.
Table 2
Medium-throughput testing of different NKI-LIC vectors in single and co-expressions of USP4-D1 and 
USP4-D2 (c: cloned, E: expression, S: soluble).
Table 1
Summary of the high-throughput cloning and protein expression screen.
Target name Targets Constructs 
designed
Constructs 
cloned
Soluble 
proteins (%)
Soluble 
targets
Human USPs 35 176 145 37 (26%) 21 (60%)
Single expression
C E S C E S
pETNKI-His-SUMO2-LIC-kan    
pCDFNKI-StrepII-3C-LIC-strep    
pCOLDNKI-His-TF-3C-LIC-amp    
pGEXNKI-GST-3C-LIC-amp    
Co-expression
pETNKI-His-SUMO2-LIC-kan (D1)
pCDFNKI-StrepII-3C-LIC-strep (D2)
pGEXNKI-GST-3C-LIC-amp (D1)
pCDFNKI-StrepII-3C-LIC-strep (D2)
pCOLDNKI-His-TF-3C-LIC-amp (D1)
pCDFNKI-StrepII-3C-LIC-strep (D2)
USP4-D1 USP4-D2
USP4-D1 & D2
E S






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Figure 3. SDS–PAGE assessment of co-expression trials for USP4-D1 and USP4-D2 domains in different NKI-LIC E.coli expression 
vectors. T: total cells; S: supernatant; E: elution. * indicates the D1 fusion protein and • indicates the D2 fusion protein.
Results and discussion
Evaluation of the pET-NKI vectors suite
The pETNKI-His-3C-LIC-kan vector was tested 
using a set of proteins that we have successfully 
produced previously in our lab. First, we used our 
method to clone two different proteins and analyzed 
96 colonies from each. The number of clones with-
out an insert was less than 6%, an acceptable rate of 
false positives to allow high throughput approaches. 
Expression levels were comparable to other vectors 
previously used in our lab. The pETNKI-His-3C-
LIC-kan vector has thereafter been used success-
fully to produce well over one thousand expression 
constructs of different proteins in our lab. In the 
next section we describe its specific application to 
the study of the USP family. 
 Based on the success of the pETNKI-
His-3C-LIC-kan system in our lab as well as in oth-
er labs, we have created a complementary suite of 
vectors (Fig. 1) which enable expression of different 
fusion proteins and which also allow production of 
protein complexes using co-expression strategies. To 
evaluate these vectors, we used as a test system the 
catalytic domain of the deubiquitinating enzyme 
USP4 (USP4CD) that is made by two domains, 
D1 and D2, which assemble together to make 
USP4CD. Neither D1 nor D2 could be obtained 
as a soluble protein when expressed individually 
as hexahistidine-tagged fusion proteins. However, 
upon co-expression of the two domains, a soluble 
protein complex could be isolated10. For our vector 
evaluation experiment, D1 was fused to different N-
terminal affinity and solubility tags (His-SUMO2-, 
GST- and His-TF- tag), whereas D2 was fused only 
to a StrepII affinity tag. We expressed each protein 
individually or in different D1-D2 co-expression 
combinations (Fig. 3, Table 2). For the compari-
son of expression experiments we did not apply any 
other normalization or optimization, other than 
using identical culture conditions and volumes in 
all cases. For His-SUMO2- and GST- D1 fusion 
constructs, only partially soluble protein could be 
obtained within the individual expression tests, 
whereas a fair amount of soluble D1 was obtained 
when fused to the His-TF-tag. For strepII-tagged 
D2 protein alone, only a minor portion of the ex-
pressed protein appeared in the soluble fraction.
However, when D2 was co-expressed together 
with the D1 constructs, a significant amount of 
soluble D2 could be co-eluted when D1 was puri-
fied via affinity purification (either Talon beads for 
the his-tag or glutathione Sepharose beads for the 
GST-tag), demonstrating the presence of a soluble 
D1-D2 complex. Co-expression improved the solu-
bility of the D1 fragments in all cases. Using the 
pETNKI-His-SUMO2-LIC-kan and pCDFNKI-
StrepII-3C-LICstrep vectors, D1 and D2 were also 
expressed in similar amounts, representing a stoi-
chiometric ratio of 1:1 as physiologically expected 
for D1 and D2 being the two parts that constitute 
USP4CD. These results suggest that the NKI-LIC 
vector suite can be used to produce soluble proteins 
and protein complexes when used in co-expression 
experiments.
 The utility of affinity tags has been 
previously shown to be of great use for purify-
ing recombinant proteins12. However, most tags 
come with their own advantages and disadvan-
tages. For example, the use of immobilized metal-
ion affinity chromatography (IMAC) sometimes 
yields insufficiently pure proteins and does not 
enhance the protein solubility13, while the af-
finity media are very cheap. In contrast, the 
StrepII-tag displays increased specificity and re-
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sults to more pure protein, but the affinity resin 
is very expensive, while it does not improve pro- 
tein solubility14. The GST-, SUMO2- and TF-tags 
have been developed to aid in protein solubility 
and folding6,15,16. Furthermore, the SUMO2-tag 
has been shown to also increase the level of protein 
expression and solubility. However, also for these 
tags there are disadvantages: the GST-tagged re-
combinant protein tends to form dimers, SUMO2 
is mostly constrained to E.coli, since SUMO prote-
ases that are present in eukaryotes may cleave the 
fusion protein during expression, and all these tags 
often result in finally insoluble protein after they are 
cleaved. Providing a vector suite where the utility of 
each tag can be tested experimentally easy and with 
minimal cost (no additional PCR products need-
ed, with the exception of the SUMO2 tag vector) 
makes the choice of this vector suite particularly ap-
pealing. Combining different tags with different or-
igins of replication and antibiotic resistance enables 
co-expression experiments with the same vectors.
Application to the USP family
The cDNA of 35 different USPs were collected and 
176 constructs were designed (Table 1 and Supple-
mentary Table 1). Initial constructs design was 
enabled by studying existing crystal structures of 
USP catalytic domains (USP7, 1nb8; USP2, 2hd5; 
USP8, 2gfo; USP14, 2ayo)17-20 and also based on 
sequence alignment21, secondary structure predic-
tion22 and protein disorder prediction23. Addi-
tional constructs were designed if a link to cancer 
was found in literature for a specific USP or when 
a positive but insufficient hit for protein expres-
sion was identified. These constructs included the 
full length protein as well the additional domains 
found outside the catalytic domain predicted by 
SMART8,24 with variations at the C- and N-termi-
nal ends of the predicted domains. Although PCR 
problems precluded the amplification of a signifi-
cant number of constructs (30 out of 176), once 
PCR products were made, all but one of them have 
been successfully cloned into the pETNKI-His-3C-
LIC-kan vector. The high throughput protein ex-
pression and solubility screening of 145 different 
constructs resulted in 26% of the constructs giving 
soluble protein for 21 different USPs. Large scale 
protein production is ongoing to verify whether 
these constructs can produce soluble protein in 
amounts suitable for structural studies. In Fig. 4
Figure 4. Large scale protein expression and purification profile 
of the catalytic domain of USP8CD on SDS–PAGE gel. Lane 1, 
total cells; lane 2, pellet; lane 3, supernatant; lane 4, flow through 
of washing Talon resin; lane 5, washed Talon resin; lane 6, eluted 
USP8CD from Talon resin; lane 7, eluted USP8CD of anion
exchange column; lane 8, eluted USP8CD of gel filtration column 
Superdex75 16/60. * indicates the UPS8CD fusion protein.
we exemplify the large scale protein expression and 
purification of the catalytic domain of USP8.  
 From all constructs tried, 98 of them 
(68%) expressed recombinant His-tagged protein 
for 26 different USPs. Absence of protein expres-
sion in the remaining constructs was caused either 
by failure of transformation reactions or by low cell 
culture density during protein induction. Of the 
98 expressing constructs, 37 constructs produced 
soluble recombinant protein for 21 different USPs. 
In some cases only particular constructs were able 
to give soluble protein. For example, only one con-
struct of USP1 (Supplementary Table 1) expressed 
soluble protein. This construct lacks the first 29 
residues at the N-terminus of the protein, which 
were predicted to belong to a flexible loop22. The 
removal of this flexible region seemed to be neces-
sary for the soluble expression of USP1. Also for 
example, in USP21 the addition and removal of 
several residues at the N-terminal and C-terminal 
ends respectively, greatly enhanced expression 
and solubility compared to the in silico (SMART) 
predicted domain (Supplementary Table 1). 
USP7 was a particular USP family target that was 
not expressed in E.coli despite significant effort. For 
convenience we created a vector (pFastBacNKI-
His-3C-LIC-amp) to facilitate recombinant virus 
production for protein expression in insect cells, 
which could accommodate the exact same PCR 
product as the E.coli vectors we use. We show that 
this vector can be used straightforwardly for LIC
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cloning and will yield viruses that successfully me-
diated USP7 production in insect cells (Fig. 5).
 Initially, all constructs were designed 
based on the sequence alignment and comparison 
with the previously determined X-ray crystal struc-
tures of several catalytic domains of USPs. How-
ever, it is clear that designing and screening several 
different constructs for a particular USP should also 
be based on domain prediction, disorder predic-
tion and secondary structure prediction, which can 
greatly improve the protein expression and solubil-
ity. A tool to enable such studies has been developed 
partially based on this experience and is available 
from http://xtal.nki.nl/ccd7.
Potential for automation
All described steps were done with a manual multi-
pipette. However all these steps can be automated 
with the help of robotics25, in which the different 
steps such as cell lysis, affinity binding and elution 
of recombinant protein are interlinked. Moreover, 
the analysis of protein samples by running conven-
tional SDS–PAGE gels is time-consuming and la-
borious (e.g. pouring gels, pipetting samples, stain-
ing and destaining gels). Using other methods for 
rapid analysis of protein samples such as 96-well 
gels or microfluidics, might increase the throughput 
in the last step of identifying soluble recombinant 
proteins in the high throughput protein expression 
and solubility screening26,27.
Conclusions
We presented the procedures to create and use
Figure 5. SDS–PAGE assess-
ment of expression and pu-
rification of USP7 using the 
pFastBac-NKI-LIC vector in 
Sf9 insect cells. T: total cells; 
S: supernatant; E: elution.
a collection of vectors 
for protein expression, 
the ‘NKI-LIC suite’ 
which can all (but one) 
accommodate the same 
PCR product. Com-
bining different affinity 
and solubility tags with 
different antibiotic re-
sistance markers and origins of replication, this  en-
ables straightforward and convenient expres- sion 
strategies. The only vector not compatible with the 
exact same PCR product contains the small and sol-
uble SUMO2 protein fused to a His-tag for purifi-
cation purposes. This vector has the advantage that 
upon cleavage with the SENP protease, no residual 
residues are left at the N-terminus of the protein of 
interest. Finally, we show one vector that is suitable 
to initiate insect cell expression. We showcase the 
applicability of this strategy to a large collection of 
targets within the Ubiquitin Specific Protease Fam-
ily, one of the SPINE-2-complexes priority areas, 
which enabled the production of many soluble 
recombinant proteins, suitable for functional and 
structural studies. 
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Abstract
Ubiquitin-specific proteases (USPs) are papain-like isopeptidases with variable inter- and in-
tra-molecular regulatory domains. To understand the effect of these domains on USP activ-
ity, we have analyzed enzyme kinetics of a set of twelve USPs in presence and absence of modu-
lators using synthetic reagents. We synthesized all seven wild-type lysine-linked di-ubiquitins and 
provide the first comprehensive analysis comparing ubiquitin (Ub) chain preference. Our data 
reveal large variations in both the catalytic turnover and Ub binding between USPs and mod-
est preferences for di-Ub topoisomers. Interestingly, our data show that the preference of USP7 
for di-Ub topoisomers can be attributed to the binding affinity (KM) for the substrate, while the 
intermolecular activators UAF1 and GMPS mainly increase the catalytic turnover (kcat). To-
gether, this comprehensive kinetic analysis highlights the variability within the USP family.
Introduction
Since the 1980s, the post-translational modifica-
tion of proteins by Ub has been the focus of many 
studies due to their important roles in many cellular 
processes1,2. However, the processing and removal 
of Ub and thus reversal of the modification of target 
proteins is equally important and is carried out by 
De-ubiquitinating enzymes (DUBs).
 The human genome encodes nearly 100 
putative DUBs, belonging to at least five subfami-
lies of isopeptidases 3. The Ubiquitin-Specific pro-
teases (USP) family is the largest class of DUBs, 
with more than sixty members3,4. USPs are cysteine 
proteases that use a papain-like mechanism to hy-
drolyze the isopeptide bond between the carboxy 
terminus of Ub and the ε-amine of the target lysine. 
 USPs are variable both in size and their 
modular domain architecture, which can include 
substrate binding domains, ubiquitin-like (UBL) 
domains and other protein-protein interaction do-
mains3,5 (Figure 1A). They share a common papain-
like fold, but the catalytic domains can have large 
insertions6, possibly directly affecting activity, Ub 
binding or localization as seen in USP47, USP58, 
USP149 and CYLD10. Additionally, some USPs 
need structural rearrangements to bind their sub-
strate and catalyze hydrolysis11-15.
 USPs are often found in large protein 
complexes and many interaction partners of USPs 
have been identified16. Although the function of 
most interaction partners is still unclear, some play 
a role in the modulation of USP activity. For ex-
ample, GMP synthetase (GMPS) interacts and acti-
vates USP717-19, whereas the WD40-repeat contain-
ing UAF1 activates USP1, USP12 and USP4620,21. 
 With its diversity of domain architec-
tures, internal insertions within the catalytic do-
main and external modulators, the USP family ap-
parently requires different levels of regulation. This 
poses a number of unanswered questions. For in-
stance, what is the variability of the activity between 
the catalytic domains and the full-length proteins? 
Are there preferences for Ub-chain types and does 
this change in the presence of external modulators?
 To address these questions, we have de-
veloped and produced22 chemical tools, and used 
these to characterize a set of twelve USPs. This 
revealed variations of several orders of magnitude 
in catalytic turnover and Ub binding, and allowed 
characterizing intra- and inter-molecular activity 
modulation. Using synthetic di-Ub, we determined 
the chain preferences of all USPs against all seven 
lysine-linked topoisomers. This showed a modest 
chain specificity that was variable between USPs, 
but did not change in the presence of the modu-
lators. Kinetic analysis of the hydrolysis by USP7 
showed that there is no additional Ub binding site, 
suggesting that the chain preferences are achieved 
by steric hindrance.
Results
Protein cloning, expression and purification
After protein expression trials23, we identified 
constructs suitable for large-scale protein expres-
sion of twelve different USPs in either E.coli or 
in Sf9 insect cells (Figure 1A). In this study we 
could therefore include sixteen constructs con-
taining either the (almost) full-length constructs 
(USP1ΔN, USP7FL, USP11FL, USP12FL, 
USP16FL, USP25FL and USP46ΔN, with ΔN 
and ΔC denoting N- and C-terminal truncations 
respectively), or the catalytic domain (USP4CD, 
USP7CD, USP8CD, USP16CD, USP21CD, 
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Figure 1. Overview of the characterized USPs. A) Domain architecture of the USPs used in this study. The constructs used 
in this manuscript are highlighted with corresponding residue numbers and expression system. B) Final purification product of 
the USP constructs shown on SDS-PAGE gel. An asterisk indicates the expressed USP. USP7FL has an N-terminal GST tag.
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USP30CD and USP39CD) (Figure 1A and B). Ad- 
ditionally, we expressed and purified two known 
USP activity modulators: UAF121 and GMPS19. 
Cloning, expression and purification protocols are 
provided in the materials and methods section.
Large variations in both catalytic turnover and 
Ub binding
Although USP family members share a homologous 
catalytic domain, many contain insertions within 
their catalytic domain or have additional domains 
that could influence their activity6,7 (Figure 1A). To 
study these effects, we determined the kinetic pa-
rameters of all the USPs. To this end, we produced 
a minimal synthetic Ub substrate with fused at its 
C-terminus the small molecule 7-amino-4-methyl-
coumarin (UbAMC)22,24. The UbAMC substrate is 
a widely used reagent to assay DUB activity. Upon 
hydrolysis by the USP, the free AMC reporter mole-
cule produces a fluorescent signal, which allows for a 
direct read-out of activity. Since this universal DUB 
substrate contains an AMC moiety instead of the 
endogenous USP target, it is suitable for comparing 
the relative activity among the USP family mem-
bers. With this substrate, we observed variations 
of several orders of magnitude in both KM and kcat 
between the USP constructs (Figure 2 and Supple-
mental Figure S1)). Our data are in agreement with 
earlier reports for USP1, USP4, USP7, USP8 and 
USP397,11,21,25,26. Based on their KM and kcat values, 
the USPs could be classified in three groups (Figure 
2D). Group 1 represents the USPs, whose activity is 
very limited due to a low kcat (USP1ΔN, USP4CD,
Figure 2. Kinetic parameters using UbAMC. A and B) The Michaelis-Menten curves for the different USPs obtained by 
determining the initial rates (V0) at different UbAMC concentration. B) shows the USPs with intra-molecular modulation. 
C) Overview of the kinetic parameters (kcat, KM and Kcat/KM) for the different USPs. D) Activity classification of USPs, based 
on kinetic parameters, where group 1 represents the USPs with the lowest activity; group 2 contains USPs with intermediate 
activity and group 3 contains the USPs with the highest activity. Dashed lines link the catalytic domains with the corre-
sponding full length USPs. Solid lines show the effect of intra-molecular activating and inhibiting domains. 
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2B,D). Since it is a Ub binding domain, the effect 
of the zinc-finger could be more prominent in poly-
Ub processing28, which might add up to a bigger 
difference than observed here. USP39CD also con-
tains a ZnF-UBP domain, but it is unlikely that this 
will lead to enzymatic activation since USP39CD 
does not have the catalytic residues.
 Overall, this shows that several intra-
molecular domains are able modulate USPs. The 
modulation can affect KM (USP4), kcat (USP16), or 
both (USP7), and both inhibitory and activating 
domains are found in USPs. Together, this creates 
an additional layer of regulation on the catalytic ac-
tivity of USPs.   
Some USPs show small preference for di-Ub 
topoisomers 
Most studies of DUB specificity have focused on 
processing K48- and K63-linked poly-Ub. How-
ever, since the additional linkages serve equally 
important cellular functions, we synthesized all 
seven lysine-linked di-Ub topoisomers22 and we 
used them in a qualitative assay to assess all linkage 
preferences of the panel of USPs (Figure 3 and Sup-
plemental Figure S2). In agreement with the kinetic 
parameters from the UbAMC assay, the USPs from 
group 1 showed very little activity; USP8CD from 
group 3 is the most active USP, and most USPs 
from group 2 show an intermediate activity. How-
ever, there were two clear changes. Where USP7 
was amongst the most active USPs in the UbAMC 
assay, now it shows an intermediate activity. In con-
trast, USP21CD showed intermediate activity in 
the UbAMC assay, but is very active in the di-Ub 
assay and displays activities almost matching the 
most active USP; USP8CD.
 The USP family seems to be rather pro-
miscuous compared to other DUB families. For 
example, Cezanne29 (K11), OTUB130,31 (K48) and 
TRABID32 (K29) from the OTU family display 
strong linkage preferences for di-Ub topoisomers. 
However, figure 3 shows that the differential activ-
ity of the USPs is smaller. All the active USPs from 
this study hydrolyze all di-Ub topoisomers. Never-
theless, there are clear differences in efficiency. For 
instance, most USPs have difficulties in hydrolyzing 
K27- and, to a lesser extent, K29-linked di-Ub. For 
example, USP7 has limited activity towards hydro- 
lyzing K27- and K29-linked di-Ub. In contrast, the 
K6, K11, K48 and K63 Ub topoisomers are hydro-
USP12, USP30CD, USP39CD and USP46ΔN). 
The “intermediate” group 2 contains the USPs that 
show moderate activity (USP4-D1D2, USP11FL, 
USP16CD, USP16FL, USP21CD and USP25FL), 
and group 3 contains very active USPs (USP7FL, 
USP7CD-HUBL and USP8CD). 
 As expected, group 1 contains USP-
39CD. It shows no activity, since it lacks the cata-
lytic cysteine and histidine residues3. Group 1 also 
contains USP1ΔN, USP12FL and USP46ΔN, all 
three known to have low activity, which is enhanced 
by the external modulator UAF120,21. Interestingly, 
also USP30CD shows very little activity. However, 
to date there is no known activator for USP30CD, 
although several interaction partners have been 
identified16.
 In contrast, group 3 represents the most 
active USPs, and contains both USP8CD and 
the USP7 constructs with activating C-terminal 
HAUSP UBL (HUBL) domain17. Interestingly, 
USP8CD has an unusual high KM, which is pos-
sibly due to an inserted α-helix in the catalytic do-
main, which is suggested to stabilize the observed 
closed conformation11. However, this is compen-
sated by a very high catalytic turnover, rendering it 
a very active USP overall. 
Intra-molecular modulation of USP activity
Not only do we observe differences in enzymatic 
behavior between the USPs, but we also observe 
differential effects of intra-molecular domains on 
the activity of the (minimal) catalytic domains in 
USP4, USP7 and USP16 (Figure 2B). 
 We recently showed that USP4 contains 
a UBL domain inserted in its catalytic domain 5 
(USP4CD; Figure 1A),  which inhibits the activ-
ity of USP4CD (group 1; Figure 2B,D). The pres-
ence of this UBL domain in USP4CD increases the 
KM and is therefore less active than the minimal 
catalytic domain USP4-D1D27 (group 2; Figure 
2D). In contrast, both kcat and KM are affected in 
USP7, where the minimal catalytic domain (group 
1) shows far less activity than the full-length en-
zyme (group 3). Here, the activity of USP7 is 
modulated by its HUBL domain which is essential 
for both activity and Ub binding in vitro and in 
vivo17,25,27. The activity of USP16CD is modulated 
by the zinc-finger Ub specific protease (ZnF-UBP). 
Surprisingly, the activity is enhances by increas-
ing catalytic turnover, rather than the KM (Figure
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lyzed relatively efficiently. Another clear example is 
USP4, for which K63-linked di-Ub is a better sub-
strate than K48-linked di-Ub7,33. Apparently, some 
USPs seem to prefer specific di-Ub isoforms. 
 We wondered whether the intramo-
lecular modulating domains in USP4, USP7 and 
USP16 change the linkage preferences. However, 
this does not seem to be the case. The different 
USPs respond differently to modulation by in-
ternal domains, analogous to what was observed 
with UbAMC (Figure 3 and Supplemental Figure 
S2 B,C). However, no change in linkage pref-
erence was seen between catalytic domain and 
longer constructs, showing that the modulation
Figure 3. Di-Ub topoisomer preference for the different USPs. A) Ubiquitin (1UBQ) showing all lysines. B) Overview of a time-course 
using all seven different di-Ub topoisomers (5 µM) (K6, K11, K27, K29, K33, K48 and K63) for the active USPs (75 nM). Samples from 
each time-point (0, 5, 10, 30, 60, 180 min) were analyzed on coomassie stained SDS-PAGE gels. 
effects are substrate independent mechanisms.
 Overall, this shows that USPs can hydro-
lyze all Ub lysine-linked di-Ub topoiso- mers, but 
with differences in efficiency. Moreover, these dif-
ferences are preserved in the presence of the intra-
molecular activity modulators.
In the case of USPs, isopeptide-linked Ub is not 
representative for di-Ub 
To explain the Ub linkage preference, we might not 
need full-length di-Ub34. To test this in an activity 
assay, we designed and synthesized a panel of fluo-
rescence polarization-based (FP) di-Ub mimics. In
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these reagents, TAMRA-labeled Ub peptides were 
linked via an isopeptide linkage to the carboxy-
terminus of wild-type full-length mono-Ub35 (Fig-
ure 4A and Supplemental Figure S3)). Therefore, 
in contrast to the peptide linkage in UbAMC, 
these FP-reagents use the natural isopeptide link-
age. The proximal Ub is represented by 14-mer 
peptides, each representing one of the seven lysines 
of Ub (Figure 3A and 4A, Table). In addition, the 
di-peptide (KG) was prepared to serve as a mini-
mal substrate. Mass spectrometry and SDS-PAGE 
analysis of these new Ub substrates showed that 
the synthesis was successful for all eight different 
TAMRA labeled isopeptide-linked Ub FP-reagents 
(Supplemental Figure S3F).
 As a proof of principle, we used the 
minimal ´KG´ FP-reagent to determine the ki-
netic parameters of USP4-D1D2 (Figure 4B and 
Supplemental Figure S3H). With this reagent we 
determined KM (293 nM) and kcat (0.07 s
-1) values 
similar to the kinetic parameters obtained using 
UbAMC. Only the kcat is higher, possibly due to 
the difference in the chemical nature of the linkage, 
since the FP-reagents contain a natural isopeptide 
linkage in contrast to the UbAMC reagent. How-
ever, since the KM values are similar, both represent 
comparable Ub reagents.
 In the di-Ub time course assay, we ob-
served linkage preferences of USP4-D1D2 and 
USP7; e.g. USP7 prefers the hydrolysis of K6- 
over K27-linked di-Ub, and USP4-D1D2 prefers 
K63- over K48-linked di-Ub (Figure 3B). Although
Figure 4. Kinetics of di-Ub hydroly-
sis. A) Schematic view of N-terminal 
TAMRA labeled ubiquitin peptide 
(K6) conjugated with ubiquitin. Table 
shows the peptide sequences used with 
the corresponding residue numbers for 
the different types of ubiquitin linkag-
es. The conjugated lysine is highlighted 
in red. B) Michaelis-Menten curves for 
USP4-D1D2 (top) and USP7FL (bot-
tom) were obtained using the TAMRA 
labeled ubiquitin peptides in a FP 
hydrolysis assay. The curves for USP7 
could not be fitted. 
difficult to fit for USP7, 
with our FP-reagents we 
ob served no difference in 
activity for either USP4-
D1D2 or USP7, and therefore could
not recapitulate the preferences observed in the 
di- Ub assay (Figure 3B and Supplemental Figure 
S3G). This shows that these FP reagents do not 
contain the required information to mimic di-Ub 
for USPs (Figure 4C and Supplemental Figure S3).
The proximal Ub does not contribute, but rather 
hinders binding to USP7
Since the FP-reagents were not sufficient to repro-
duce the observed linkage preference, we used full-
length di-Ubs to determine the kinetic parameters 
directly. We determined KM and kcat of the hydroly-
sis of all seven lysine linked di-Ubs by USP7, using 
initial rate experiments that monitored the appear-
ance of mono-Ub (Figure 5). These experiments 
showed that the linkages that are efficiently hydro-
lyzed by USP7 (K6, K11, K33, K48 and K63) have 
similar kinetic behavior (Figure 5B). Interestingly, 
the KM and kcat values are similar to the minimal 
substrate UbAMC, which contains only a single Ub 
moiety. This suggests that there is no induced bind-
ing or catalysis effect by the proximal Ub moiety. 
 In the initial di-Ub assay, two linkages 
(K27 and K29) showed a clear delay in hydrolysis by 
USP7 (Figure 3). This was nicely reproduced in this 
kinetic di-Ub assay. Interestingly, there was hardly 
any change in kcat, but rather the KM increased far 
above the concentrations used in our assays. This 
suggests that the preference for the di-Ub topoiso-
mers arises from steric hindrance, rather than an
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Figure 5. Michaelis-Menten kinetics of di-Ub hydrolysis by USP7. A Representative western-blot Michaelis-Menten analysis di-Ub 
hydrolysis USP7. Assay performed using 2-fold dilutions of the di-Ub starting at 15 µM for 5 minutes at 37 degrees. B. Michaelis-
Menten analysis for USP7FL for di-ubiquitin hydrolysis. Initial rate (V0) of di-Ub conversion into mono-Ub was determined at different 
substrate concentration from Western Blots shown in A. The conversion to mono-Ub was quantified using the di-Ub signal corrected for 
conversion. C. and D. Michaelis-Menten analysis of USP8/21CD (C) and USP11 (D). 
additional binding site for the proximal Ub moiety. 
Therefore, the binding of some linkages to the cata-
lytic domain is impaired, resulting in lower activity. 
Intermolecular activation of USPs by UAF1 and 
GMPS only affects kcat
Besides their intrinsic activity, some USPs are acti-
vated by intermolecular modulation. For example, 
USP1, USP12 and USP46 are activated by the 
WD40-repeat containing UAF1, and USP7 is acti-
vated by GMPS17,19-21. Here, we used the UbAMC 
assay to quantify this activation (Figure 6A,B and 
Supplemental Figure S4). In agreement with previ-
ous data, we observe mainly a kcat increase (7-fold) 
of USP1ΔN activity in the presence of UAF1. The 
USP1 used in this work has a mutation in the self-
cleavage site (Gly671,672Ala)21. UAF1 also activates 
USP12FL and USP46ΔN, where the kcat is increased 
by 66- and 70-fold, respectively. Also in the case of 
USP7 we observed a kcat increase (5.5-fold) in the 
presence of its modulator GMPS. Interestingly, in 
contrast to variable modulation invoked by internal
domains (Figure 2D), intermolecular modulation is 
achieved mainly by an increase in the catalytic turn- 
over rather than in substrate binding (Figure 6B). 
 To investigate whether this activation 
also induces new linkage preferences of these USPs, 
we repeated the di-Ub assay in the presence of 
UAF1 or GMPS (Figure 6C). As expected from the 
UbAMC kinetics, USP1ΔN shows limited activity 
in the absence of UAF1, while USP12FL and US-
P46DN show no activity. However, in the presence 
of UAF1, the activity of all three USPs is increased, 
albeit not to the same level. In complex with their 
activators, USP1ΔN and USP7CD-HUBL show 
most activity, but no change in chain type prefer-
ence by UAF1 or GMPS. This agrees well with an 
activation mechanism that only increases kcat, but 
does not induce binding, which should translate in 
changing KM values.
Discussion
In this study, we used chemical reagents to de-
termine the kinetic parameters of substrate inde-
K6 K11 K27 K29
K33 K48
Ub
2
Ub
K63
Ub
2
Ub
Ub
2
Ub
Ub
2
Ub
Ub
2
Ub
Ub
2
Ub
Ub
2
Ub
A
B
k cat /K M [M
-1 s -1 ]
K6 0.81 ± 0.08 6.3 ± 1.5 1.29 *105
K11 1.04 ± 0.33 16.1 ± 8.3 0.65 *105
K27 1.19 ± 0.19
K29 1.28 ± 0.39
K33 1.12 ± 0.21 12.3 ± 4.1 0.91 *105
K48 1.26 ± 0.3 10.4 ± 4.7 1.21 *105
K63 1.07 ± 0.31 18.4 ± 8.3 0.58 *105
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Figure 6. Intermolecular USP activity modulation is achieved by increasing kcat. A) Kinetic parameters (kcat, KM and Kcat/KM) using 
UbAMC as substrate for USP1ΔN, USP12FL and USP46ΔN in presence of UAF1 and USP7CD-HUBL in presence of GMPS. B) 
Alternative representation of the kinetic parameters comparing the USP activity between the USPs and in the presence of their modulator. 
C) Activity modulation by UAF1 and GMPS towards all seven di-Ub topoisomers. Samples from each time-point (0, 5, 10, 30, 60, 180 
min) were analyzed on coomassie stained SDS-PAGE gels.
activity can be affected by structural rearrangements 
in both Ub binding sites and active sites, as shown 
by structural studies11,12. Secondly, intra-molecular 
domains of USPs can modulate the DUB activity, 
as seen here for USP4, USP7 and USP16. External 
modulator proteins can further regulate the activ-
ity of the USP by enhancing its activity, as seen for 
USP1, USP7, USP12 and USP46 (Figure 6A,B).
 Here we report a few cases where intra-
molecular modulators regulate the USP catalytic 
efficiency: either insertions within or additional do-
mains outside the catalytic domain. For both USP7 
and USP16 the enzymatic behavior is regulated by 
intra-molecular domains (the HUBL and ZnF-UBP 
domain, respectively) outside the catalytic domain, 
resulting in the increase of the activity. Addition-
ally, variations in kinetics can be induced by (large) 
insertions in the catalytic domains themselves, as 
demonstrated for USP4, where a UBL containing 
insert is inhibiting the catalytic efficiency7. These 
variations and intra-molecular modulations result 
in the unique activity of each USP. 
 For the last decade, the focus on DUB 
specificity has been on K48- and K63-linked poly-
Ub chains. However, different Ub linkage topoiso-
pendent activity of 12 USPs, their di-Ub linkage 
preference and characteristics of both intra- and 
intermolecular activity modulation. We observe 
large variations in both the catalytic turnover (kcat) 
and Ub binding (KM) between USPs, which can of 
the DUBs so far has been tested for all Ub link-
ages, some DUBs show remarkable specificity. For 
example the OTU protease DUBA41 is K63-spe-
cific, OTUB130,31 is K48-specific, while AMSH42 
a small preference for individual di-Ub topoiso- 
GMPS can activate USPs by increasing their cata-
lytic turnover (kcat). Additionally, the USPs have 
a small preference for individual di-Ub topoiso- 
mers. We show that in USP7 there is no additional 
Ub binding site, but rather that the differences 
in hydrolysis of the topoisomers are achieved by 
hindering binding (KM) sterically. The combined 
data provide insights in the variation in the bio-
chemical behavior of the USP enzyme family.
 Based on their specific catalytic effi-
ciency (Figure 2), the USPs can be classified into 
three groups: (1) a group of USPs showing very low 
DUB activity, (2) an ´intermediate´ group and (3) 
USPs that exhibit high activity. This variability in 
activity can be explained in several ways. First, the 
A Ck
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mers can result in different cellular fates, some of 
which are very specific36-38 and others requiring a 
minimal chain length to invoke its function39,40. 
Our study presents the first complete and com-
prehensive study on di-Ub preference of all seven 
linkages for USP family members. Although none 
of the DUBs so far has been tested for all Ub link-
ages, some DUBs show remarkable specificity. For 
example the OTU protease DUBA41 is K63-spe-
cific, OTUB130,31 is K48-specific, while AMSH42 
and BRCC343 both from the JAMM/MPN+ fam-
ily are K63-specific. Next to CYLD10, the USPs 
do not have strict chain-type specificity, but rather 
have preferences. Kinetic studies on USP7 showed 
us that there is no proximal S1’ Ub binding site 
to induce Ub topoisomers preference, but rather 
the proximal Ub moiety induces steric constraints 
for binding to the USP in the case of K27 or K29 
linkages. However, it is possible that linkage speci-
ficity is increased when using longer Ub chains. 
 Overall, the hydrolysis efficiency of the 
USPs towards K6-, K11-, K48- and K63-linked Ub 
was higher than for K27- and, to a lesser extent, 
K29- and K33-linked di-Ub. These residues localize 
in distinct regions on Ub (Figure 3A). The lysine 
residues involved in the easiest hydrolyzed linkages 
(K6, K11, K48 and K63) are in the β-sheet or loops. 
In contrast, the lysine residues of the more difficult 
linkages (K27, K29 and K33) are positioned on the 
other side of the Ub molecule, and are all in the α1-
helix. Additionally, K27 is barely accessible, which 
possibly induces a steric constraint, resulting in the 
lower activity. This interesting bi-polar behavior 
needs future investigation. 
 Previous studies suggested that Ub-pep-
tide reagents were sufficient to mimic di-Ub and 
discriminate between  topoisomers in binding34. 
However, in our activity assays with the FP Ub-
peptide reagents, we observed no difference be-
tween Ub linkages. This suggests that the peptides 
do not contain enough information to mimic the 
proximal Ub for the USPs. Nevertheless, they may 
be sufficient for DUBs from families with more 
pronounced Ub specificity and be useful tools in 
those cases. In addition, the ‘KG’ FP-reagent might 
prove a good alternative for UbAMC, as the ki-
netic parameters are similar, while it contains the 
natural isopeptide linkage, which is not present in 
UbAMC. 
 This study confirmed that two known 
intermolecular USP activity modulators UAF1 and
GMPS activate USP1, USP12, USP46, and USP7 
respectively. This activation is mainly by increasing 
the kcat. However, the biological roles of the UAF1 
and GMPS activation are distinct. UAF1 activa-
tion is almost essential for USP activity of USP1, 
USP12 and USP46. This resembles the Ubp8 
activation by Sgf1114,15. Surprisingly, USP12 in 
complex with UAF1 is still not very active, possi-
bly requiring additional partners, like WDR2044. 
In a different manner, GMPS hyper-activates 
USP7, by allosterically stabilizing the active state 
of the enzyme induced by the HUBL domain17. 
Besides a general activation, the GMPS activity 
modulation most likely has additional substrate 
specific roles, as it induces H2B de-ubiquitination.
 Although the function of an increasing 
number of USPs is elucidated, they still represent 
a relatively uncharacterized enzyme family. To aid 
in the biochemical understanding of these enzymes, 
we here report the large variations in kinetics and 
intra-molecular modulation (kcat and KM), the mod-
est but surprising differential activity towards the 
seven di-Ub topoisomers (KM), and a characteriza-
tion of the activation by intermolecular interactions 
(kcat). 
Significance
Ubiquitination is a dynamic process, which is in-
volved in numerous key cellular processes. The re-
moval of the Ub molecules is an integral part of 
this process, and is carried out by Deubiquitinating 
enzymes (DUBs). These are increasingly recognized 
as interesting drug targets. However, to date we 
lack the markers to predict the biochemical behav-
ior based on sequence alignments and therefore a 
need exists for comprehensive kinetic studies. This 
is where chemical tools that allow fast and accurate 
read-outs will contribute to answer these biological 
questions. In this study, we designed and produced 
several of such chemical reagents to determine the 
kinetics and di-Ub linkage preferences of twelve 
USPs. Despite the homologous catalytic domain, 
the kinetic data underline the large variability with-
in the USP family, and the intra- and intermolecu-
lar activity modulators create an additional layer of 
regulation. 
 In addition this study for the first time re-
ports the linkage preference of twelve USPs against 
all seven-lysine linked di-Ubs. Kinetic analysis of 
the hydrolysis of the di-Ub topoisomers, suggest 
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that within the USP family the preferences are in-
duced by steric hindrance, rather than the induced 
binding, as seen in other DUB families.
 Together, this data provides insight in 
the biochemical behaviour in the USP family, and 
validates the chemical tools that now also can be 
applied in characterizing other DUB families. 
Material and Methods
General
General reagents were obtained from Sigma Al-
drich, Fluka and Acros and used as received. Sol-
vents were purchased from Biosolve or Al- drich. 
Peptide synthesis reagents were purchased from 
Novabiochem. USP25 cDNA was provided by Erik 
Meulmeester and Frauke Melchior.
General plasmids and proteins
Di-Ub moieties were produced as previously de-
scribed22. USP4CD (aa 296-954), USP4-D1D2 
(aa 296-490/766-932), USP8CD (aa 776-1110), 
USP11FL (aa 1-920), USP16FL (aa 1-823), US-
P16CD (aa 193-823), USP21CD (aa 211-565), 
USP30CD (aa 65-500), USP39CD (aa 222-565) 
and USP46ΔN (aa 8-366) are cloned into the 
pETNKI-LIC vector for expression in bacteria as 
described23. USP1ΔN (aa 21-785 self-cleavage site 
glycine 671 and 672 are mutated to alanine), USP-
7FL (aa 1-1102), USP12FL (aa1-355) and STREP-
TEV-UAF1 (6-677) are cloned into the pFastBac-
HTb vector for expression in insect cells. Both 
USP7CD-HUBL (aa 208-1102) and USP7CD (aa 
208-560) are cloned into the pGEX vector17 and 
USP25FL is cloned in the pET11a vector45. Codon 
optimized full length USP7 and GMPS cDNA was 
obtained from DomainEx (Cambridge, UK). Both 
were amplified by PCR and subcloned (SpeI/NotI) 
into a pFastBac vector (Invitrogen) containing an 
N-terminal GST tag (BamHI/SpeI) and Prescis-
sion Protease cleavage site. cDNA for USP11 and 
USP16 were obtained from ImaGenes (Berlin, Ger-
many).
Protein expression and purification 
As specified in figure 1, the USPs were expressed 
in both E.coli and insect cells and purified as de-
scribed17,23. GMPS was expressed and purified as 
before17.USP constructs and GMPS cloned both 
in bacterial and baculovirus expression vector are 
expressed and purified as described17,23. Depending
on the type of vector, the tag was removed with ei-
ther TEV or the HRV 3C protease. Bacmids were 
prepared following the manufacturer’s guidelines. 
USP1, USP12 and UAF1 were produced using 
Sf9 and Sf21 insect cell expression. Infection was 
done using a low-MOI infection protocol46. The 
cells were harvested 72 hours after a baculovirus 
induced growth arrest was observed. USP46 was 
produced in E.coli. USP1, 12, 46 and UAF1 were 
purified using Ni2+ sepharose (GE Healthcare) 
in 20 mM Hepes (pH 7.5), 150 mM NaCl, 0.1 
mM PMSF, and 0.1 mM DTT followed by elu-
tion using imidazole. His-tag was removed by 
overnight cleavage with TEV protease whilst dia- 
lyzing to remove imidazole. Uncleaved product 
was removed with Ni2+ sepharose. Size exclusion 
chromatography was performed using a Superdex 
200 or 75 column (GE Healthcare), equilibrated 
against buffer containing 10 mM Hepes [pH 7.5], 
100 mM NaCl and 1 mM DTT. All proteins were 
concentrated to ~10 mg/ml and stored at -80°C.
UbAMC assay
Kinetics were determined as described before7. 
UAF1 and GMPS were added in a 1:1 stoichiom-
etry. USP concentration varied between 1 and 100 
nM, depending on relative activity. In order to cal-
culate the kinetic parameters for the hydrolysis of 
UbAMC, curves obtained by plotting the measured 
enzyme initial rates (v) versus the corresponding 
substrate concentrations ([S]). These were subject-
ed to nonlinear regression fit using the Michaelis–
Menten equation V = (Vmax · [S]) ⁄ ([S] + KM) (eqn 
1), where Vmax is the maximal velocity at saturat-
ing substrate concentrations and KM the Michaelis 
constant. The kcat value was derived from the equa-
tion kcat = Vmax ⁄ [Eo] (eqn 2) where [Eo] is the total 
enzyme concentration. Experimental data was pro-
cessed using Prism 5.01 (GraphPad Software, Inc.).
Di-Ub assay
Di-Ub hydrolysis reactions were performed at 37°C 
in 50 mM Hepes buffer at pH 7.5, with 100 mM 
NaCl, 1 mM EDTA, 5 mM dithiothreitol and 
0.05% (w⁄v) Tween-20 with constant enzyme con-
centration (75 nM). When indicated UAF1 was 
added in a 2-fold excess (150 nM) and GMPS in 
a 1:1 stoichiometry. Reactions were stopped by ad-
dition of SDS loading buffer and followed by SDS-
PAGE analysis. For the kinetic analysis, the reaction 
mixture was pre-heated to 37 °C degrees before 
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adding USP7. Samples were run on a 12% Bis-Tris 
NuPage gel (duplicates on one gel), and western 
blots were performed with anti-Ub antibody (Santa 
Cruz; P4D1).  The ChemiDoc system (Biorad) was 
used to read the chemiluminence  signal and sub-
sequent quantification of mono-Ub was done using 
the quantification tools of ImageLab (Biorad) using 
the non-saturated di-Ub signal (corrected for con-
version to mono-Ub). Experimental data was pro- 
cessed using Prism 5.01 (GraphPad Software, Inc.).
Solid Phase Peptide Synthesis (SPPS) of the 
TAMRA thiolysine peptides
SPPS was performed on a Syro II MultiSyntech Au-
tomated Peptide synthesizer using standard 9-flu-
orenylmethoxycarbonyl (Fmoc) based solid phase 
peptide chemistry at 25 µmol scale, using fourfold 
excess of amino acids relative to pre-loaded Fmoc 
amino acid Wang type resin (0.2 mmol/g, Applied 
Biosystems). The following protected amino acids 
were used during Ub peptide synthesis: Fmoc-L-
Ala-OH, Fmoc-L-Arg- (Pbf )-OH, Fmoc-L-Asn 
(Trt)-OH, Fmoc-L-Asp (OtBu)-OH, Fmoc-L-Gln 
(Trt)-OH, Fmoc-L-Glu (OtBu)-OH, Fmoc-Gly-
OH, Fmoc-L-His (Trt)-OH, Fmoc-L-Ile-OH, 
Fmoc-L-Leu-OH, Fmoc-L-Lys (Boc)-OH, Fmoc-
L-Met-OH; Fmoc-L-Phe-OH; Fmoc-L-Pro-OH; 
Fmoc-L-Ser (tBu)-OH; Fmoc-L-Thr (tBu)-OH, 
Fmoc-L-Tyr (tBu)-OH, Fmoc-L-Val-OH. Fmoc-
5S- (methyldisulfanyl)- (L)-Lys (Boc)-OH was syn-
thesized as described previously22. 
The coupling procedure starts off with single cou-
plings in N-methylpyrrolidon (NMP) for 45 min 
using PyBOP (4 equiv) and DiPEA (12 equiv) in 
a total volume of 750 µL. Followed by the removal 
of Fmoc with 20% piperidine in NMP for 2×2 and 
1×5 min. Finally the procedure ends with NMP 
wash steps after each coupling (3×) and deprotec-
tion (5×).
The resin was washed with diethylether and dried 
under high vacuum. Next, the polypeptide se-
quence was detached from the resin and deprotect-
ed by treatment with TFA/H2O/Phenol/iPr3SiH 
90.5/5/2.5/2 v/v/v/v for 2.5 h. After washing the 
resin with 3×1 mL TFA, the crude protein was pre-
cipitated with cold Et2O/n-pentane 3:1 v/v. The 
precipitated protein was washed 3× with diethyl-
ether, the pellet was dissolved in a mixture of H2O/
CH3CN/HOAc (65/25/10 v/v/v) and finally lyo-
philized. All peptides were analyzed by LC-MS and 
purified by RP-HPLC when necessary.
LC-MS
LC-MS measurements were performed on a Waters 
2795 Seperation Module (Alliance HT), equipped 
with a Waters 2996 Photodiode Array Detector 
(190-750nm), Phenomenex Kinetex C18 column 
(2.1×50, 2.6 µm) and LCTTM Orthogonal Ac-
celeration Time of Flight Mass Spectrometer. Sam-
ples were run using two mobile phases: A = 0.1% 
formic acid in water and B = 0.1% formic acid in 
acetonitrile. Flow rate = 0.8 mL/min, runtime = 6 
min, column T = 40 °C. Gradient: 0 − 0.5 min: 
5% B; 0.5 − 4 min: 5% to 95% B; 4 − 5.5 min: 
95% B. Data processing was performed us- ing 
Waters MassLynx Mass Spectrometry Soft-ware 
4.1 (deconvulation with Maxent1 function).
Ligation of Ub to the peptides followed by des-
ulphurization
Schematic overview of reaction scheme and final 
yields can be found in Supplemental Figure S3. A 
mixture of 4-mercaptophenylacetic acid (MPAA, 
100 mM) and TCEP (50 mM) in 6M Guanidin-
ium ∙HCl (1 mL, pH 7) was added to Ub-MesNa 
thioester (5 mg, prepared according to the proce-
dure described previously 22). To this the TAMRA 
thiolysine peptide (100 µL of a 20 mM stock solu-
tion in DMSO) was added and the whole mixture 
was incubated at 37 °C. After overnight incubation, 
all low-molecular weight material was removed us-
ing a 3 kDa cutoff spin-column (Amicon Ultra) 
in four centrifuge cycles. The crude material was 
taken up in 6M Guanidinium∙HCl, 0.1M sodium 
phosphate (4 mL, pH 6.5) and to this was added 
TCEP (187 mg) and glutathione (30 mg), after 
which the pH of the mixture was adjusted to pH 
6.5 by addition of 1M NaOH. Next, the mixture 
was degassed with argon, after which radical initia-
tor VA-044 was added. The mixture was incubated 
at 37 °C overnight. All constructs were purified by 
RP-HPLC and analyzed by LC-MS and gel electro-
phoresis and were obtained as purple solids.
C18 RP-HPLC
Purification by RP-HPLC was performed on a Shi-
madzu system equipped with a LC-20AT liquid 
chromatography pump, CTO-20A column oven 
(T = 40 °C), SPD-20A UV/VIS detector (detection 
simultaneously at 230 nm and 254 nm), RF-
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10AXL fluorescence detector (ex/em = 540/600 
nm) and an Atlantis Prep T3 column (10×150 mm, 
5 µm). Samples were run using two mobile phases: 
A = 0.05% trifluoroacetic acid in water and B = 
0.05% trifluoroacetic acid in acetonitrile. Flow rate 
10AXL fluorescence detector (ex/em = 540/600 
nm) and an Atlantis Prep T3 column (10×150 mm, 
5 µm). Samples were run using two mobile phases: 
A = 0.05% trifluoroacetic acid in water and B = 
0.05% trifluoroacetic acid in acetonitrile. Flow rate 
= 7.5 mL/min, runtime = 30 min. Gradient: 0 – 6 
min: 5% to 10% B; 6.5 – 26 min: 25% to 47% 
B; 26.5 – 29.5 min: 95% B. Pure fractions were 
pooled and lyophilized.
Isopeptide linked Ub FP  hydrolysis assay
FP assays were performed on a PerkinElmer Wallac 
EnVision 2010 Multilabel Reader with a 531 nm 
excitation filter and two 579 nm emission filters. 
The confocal optics were adjusted with TAMRA-
KG (synthesized by SPPS as described above) and 
the G factor was determined using a polarization 
value for TAMRA-KG (25 nM) of 50 mP. The as-
says were performed in “non binding surface flat 
bottom low flange” black 384-well plates (Corning) 
at room temperature in a buffer containing 20 mM 
Tris·HCl, pH 7.5, 5 mM DTT, 100 mM NaCl, 1 
mg/mL 3-[ (3-cholamidopropyl) dimethylammo-
nio] propanesulfonic acid (CHAPS) and 0.5 mg/
mL bovine gamma globulin (BGG). Each well had 
a volume of 20 µL. Buffer and enzyme were predis-
pensed and the reaction was started by the addition 
of substrate. Kinetic data was collected in intervals 
of 2.5 or 3 min. From the obtained polarization val-
ues (P) the amount of processed substrate (Pt) was 
calculated with to the following equation47: S = S0 
– S0 · ( (Pt - Pmin) / (Pmax - Pmin)), where Pt is the po-
larization measured (in mP); Pmax is the polarization 
of 100% unprocessed substrate (determined for 
every reagent at all used substrate concentrations); 
Pmin is the polarization of 100% processed substrate 
(determined for every linkage at all used substrate 
concentrations by measuring the mP value for the 
corresponding deubiquitinated TAMRA-peptide, 
which were synthesized by SPPS according to the 
procedure describes above); S0 is the amount of 
substrate added to the reaction. From the obtained 
Pt values the values for initial velocities were calcu-
lated, which were used to determine the Michaelis-
Menten constants. All experimental data was pro-
cessed using Ms Excel and Prism 4.03 (GraphPad
Software, Inc.).
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Supplemental Table S1. Related to Figure 1. Comparison with published UbAMC kinetics.
Supplemental Figure S1. Re-
lated to Figure 2. Exemplary 
raw data of UbAMC hydroly-
sis by USP7CD-HUBL. Meas-
urements were done using a five 
minute interval. The signal was 
stable for at least one hour.
k cat 
[s -1 ]
K M 
[μM]
k cat /K M 
[x10 3  M -1  s -1 ]
Reference
USP1FL 0.014 1.4 10.2 Cohn et al. (2007)
USP1FL+UAF1 0.26 0.7 371 Cohn et al. (2007)
Ubp8/SAGA 0.17 1.5 110 Samara et al. (2011)
USP2CD 0.62 2.5 250 Zhang et al. (2011)
USP2CD 0.14 0.55 252 Renatus et al. (2006)
USP7FL 3.56 17.5 203 Fernandez-Montalvan et al. (2007)
USP7CD 0.077 44.2 1.7 Fernandez-Montalvan et al. (2007)
USP7CD-HUBL 0.805 22.8 35 Fernandez-Montalvan et al. (2007)
USP8CD 2.4 10.2 235 Avvakumov et al. (2006)
USP21CD 0.041 0.26 158 Ye et al. (2011)
USP25FL 0.12 5 24 Meulmeester et al. (2008)
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Supplemental Figure S2. Related to Figure 3. Di-Ub assay for inactive USPs and comparison USP7CD versus USP7CD-HUBL. A 
and B) Di-Ub assay for USP12FL, USP39CD, USP46FL, USP7CD, USP16CD and USP30CD. Time-course using all di-Ub topoiso-
mers (5 µM) (Linear, K6, K11, K27, K29, K33, K48 and K63) for USPs (75 nM). Samples from each time-point (0, 5, 10, 30, 60, 180 
min) (A) and (0, 10, 30, 60 min) (B) were analyzed on coomassie stained SDS-PAGE gels. C) Di-Ub assay USP7CD versus USP7CD-
HUBL. Time-course using all di-Ub topoisomers (5 µM) (Linear, K6, K11, K27, K29, K33, K48 and K63) for USP7 constructs (10 µM 
and 75 nM). Samples from each time-point (0, 10, 30, 60 min) were analyzed on coomassie stained SDS-PAGE gels.
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Supplemental Figure S3. Related to Figure 4. Synthesis, LC-MS of FP reagents, exemplary raw data and Michaelis-Menten curves 
of USP4 and USP7. A. Ligation of Ub to the peptides. B. Peptide sequence, molecular weight and typical yield of the reaction. C. 
Coomassie staining and fluorescence scan of SDS electrophoresis analysis of the FP-reagent. D. Kinetic parameters of USP4-D1D2 using 
the FP-reagents. E. Exemplary data of hydrolysis of FP reagents.
Figure and legend continue on next page 
Linkage type Peptide sequence MW (Da) Yield 
K G  TAMRA-K (Ub)G  9162 1.3 m g  (25% ) 
K 6 (U b  1-14) TAMRA-M Q IF V K (Ub)T LTG K T IT  10540 0 .8  m g (16% ) 
K 11 (U b 4-17) TAMRA-FV K T LT G K (Ub)T IT LE V  10509 1 .0  m g (18% ) 
K 27 (U b 20-33) TAMRA-S D T IE N V K (Ub)A K IQ D K  10548 0 .5  m g (10% ) 
K 29 (U b 22-35) TAMRA-T IE N V K A K (Ub)IQ D K E G  10532 1 .8  m g (30% ) 
K 33 (U b 26-39) TAMRA-V K A K IQ D K (Ub)E G IP P D  10497 1 .7  m g (28% ) 
K 48 (U b 41-54) TAMRA-Q R LIF A G K (Ub)Q LE D G R  10590 0 .6  m g (12% ) 
K 63 (U b 56-69) TAMRA-LS D Y N IQ K (Ub)E S T LH L 10620 1 .6  m g (32% ) 
 
A
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D
M Ub KG K6 K11 K27 K29 K33 K48 K63M Ub KG K6 K11 K27 K29 K33 K48 K63
Fluorescence (ex/em 550/590)CBB staining
3
6
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38
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USP4-D1D2
 k cat [s -1] K m  [nM ] k cat/K m  [M -1 s -1] 
K G  0 .068  ± 0 .006  271 .8  ± 43 .2  2 .51 ×10 5 
K 6  0 .157  ± 0 .015  1532  ± 256  1 .03 ×10 5 
K 11  0 .060  ± 0 .001  229 .2  ± 16 .0  2 .61 ×10 5 
K 27  0 .038  ± 0 .001  150 .1  ± 11 .4  2 .56 ×10 5 
K 29  0 .060  ± 0 .002  299 .7  ± 20 .5  1 .99 ×10 5 
K 33  0 .048  ± 0 .002  330 .5  ± 31 .6  1 .46 ×10 5 
K 48  0 .044  ± 0 .001  165 .5  ± 11 .7  2 .65 ×10 5 
K 63  0 .047  ± 0 .001  220 .7  ± 12 .2  2 .12 ×10 5 
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Figure and legend continued from previous page.
Supplemental Figure S3. Related to Figure 4. Synthesis, LC-MS of FP reagents, exemplary raw data and Michaelis-Menten curves 
of USP4 and USP7. F. LC-MS spectra of the FP-reagents. G. Michaelis-Menten analysis of USP7 hydrolysis of the FP reagents. Data 
could not be fitted with an exponential Michealis-Menten curve. 
Figure and legend continue on next page
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Supplemental Figure S3. Related to Figure 4. Synthesis, LC-MS of FP reagents, exemplary raw data and Michaelis-Menten curves 
of USP4 and USP7. H. Michaelis-Menten analysis of USP4 hydrolysis of the FP reagents. Kinetic pararameters are in (D).
Supplemental Figure S4. Related to Figure 6. Curves of the Michaelis-Menten analysis of the UAF1 and GMPS modulation. The 
Michaelis-Menten curves for the different USPs obtained by determining the initial rates (V0) at 2-fold serial dilutions of UbAMC.
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Abstract
USP4 is a member of the ubiquitin-specific protease (USP) family of deubiquitinating enzymes that 
has a role in spliceosome regulation. Here, we show that the crystal structure of the minimal catalytic 
domain of USP4 has the conserved USP-like fold with its typical ubiquitin-binding site. A ubiquitin-
like (Ubl) domain inserted into the catalytic domain has autoregulatory function. This Ubl domain can 
bind to the catalytic domain and compete with the ubiquitin substrate, partly inhibiting USP4 activ-
ity against different substrates. Interestingly, other USPs, such as USP39, could relieve this inhibition.
Introduction
Post-translational modification by the small, highly 
conserved ubiquitin (Ub) protein has an essential 
role in the regulation of many cellular processes 
in eukaryotes1,2. In this process, the carboxy-
terminus of Ub forms an isopeptide with lysines 
on the target proteins, or on Ub itself, to form 
poly-Ub chains. The activity of the conjugating 
enzymes E1–E2–E3 is actively balanced through 
hydrolysis by deubiquitinating enzymes (DUBs)2-
6. Deregulation of the ubiquitination pathway can 
lead to cancer and neurodegenerative diseases7,8.
More than 100 putative DUBs are known so far, 
belonging to five subfamilies of isopeptidases. The 
Ub-specific protease (USP) family is the largest, with 
more than 60 members in the human genome5,6,9. 
USPs share a papain-like catalytic domain and crys-
tal structures show a conserved catalytic core that un-
dergoes conformational changes on Ub binding10-15.
USPs are variable in size with modular domain archi-
tecture including, for example, TRAF-like, DUSP 
or Znf domains5,6. Sequence analysis predicted the 
presence of Ub-like (Ubl) domains in 17 different 
USPs16. Integrated Ubl domains are stretches of 45–
80 amino acids that share the b-grasp fold of Ub, 
but often have poor sequence conservation among 
subfamilies17,18. The Ubl domains in the USP fam-
ily are located amino-terminally, within or C-termi-
nally to the catalytic domain. Structural studies of 
the N-terminal Ubl domain of USP14 confirmed 
the Ubl-fold (Protein Data Bank (PDB): 1WGG) 
and showed involvement in proteasome binding 
that promotes the DUB activity of USP1412. Simi-
lar to USP14, USP4 has a Ubl domain N-terminal 
of its catalytic domain, but it has an additional 
Ubl domain embedded in the catalytic domain.
USP4 was previously known as ubiquitous nuclear 
protein (UNP)19. Identified as a proto-oncogene 
related to Tre 2/Tre 17 (USP6), USP4 shows a con-
sistently elevated gene expression level in small cell 
tumours and lung adenocarcinomas, suggesting 
that it may have a possible causative role in neo-
plasia20. Besides possible roles in Wnt signalling21 
and recruitment to the A2A receptor22, USP4 is re-
cruited to the spliceosome by complex formation 
with Sart323. Here, it preferentially deubiquitinates 
K63-linked chains on the U4 component Prp3. 
Another component of the spliceosome com-
plex is the catalytically inactive USP3923,24, which 
controls the messenger RNA levels of Aurora B25.
Here, we report on the crystal structure of the cata-
lytic domain of USP4 without the internal Ubl do-
main, and show how this Ubl domain acts as an au-
toregulatory domain that partially inhibits catalytic 
activity by competitive inhibition.
Results
Identification of USP4-D1D2
To gain insight into the structure and function of 
USP4, we expressed and purified the USP4 cata-
lytic domain (amino acids 296–954, Fig 1A) in 
Escherichia coli. To improve the chances for crys-
tallization, we used limited proteolysis. After treat-
ment with thermolysin, two fragments—domain 1 
(D1) and 2 (D2)—were obtained, which copurified 
on size exclusion chromatography and together re-
tained DUB activity (supplementary Fig S1A,B on-
line). We identified the composition of D1 and D2 
using mass spectrometry and N-terminal sequenc-
ing (supplementary Fig S1C online) and com-
pared them against a multi-sequence alignment of
USP family members. This showed that the prote-
ase treatment removed an insertion between Leu 
481 and Leu 766 (supplementary Fig S2 online), 
yielding a minimal catalytic domain consisting of 
an enzymatically active complex of two fragments: 
USP4–D1D2.
Structure of the USP4–D1D2 catalytic domain
We crystallized and determined the USP4–D1D2 
structure by molecular replacement using the
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USP8 catalytic domain (PDB: 2GFO) as the search 
molecule, and refined it to 2.4Å resolution with 
an R/Rfree of 0.178/0.21 and good geometry (Fig 
1B; supplementary Table S1 online). There are six 
molecules of USP4–D1D2 per asymmetrical unit, 
with a pairwise root-meansquare deviation of ap-
proximately 0.7Å over 344 residues using the PISA.
Similar to crystal structures of other USPs, the cata-
lytic domain of USP4–D1D2 resembles an extend-
ed right hand comprising three domains: Fingers, 
Thumb and Palm (Fig 1B; supplementary Fig S3 
online). The D1 fragment contains the Thumb do-
main and part of the Fingers domain with the Cys 
box (amino acids 303–320) and QQD box (amino 
acids 390–403) of the active site, whereas the D2
Figure 1. The catalytic domain of USP4–D1D2. A) Domain architecture of USP4 and fragments expressed. B) Crystal structure of 
USP4–D1D2 catalytic domain in cartoon representation, with secondary structure elements labeled. D1 and D2 are coloured as in (A). 
Catalytic triad and the cysteines (yellow) coordinating zinc (grey sphere) are shown in stick representation. C and D) Superposition of six 
non-crystallographic symmetry-related copies in the asymmetrical unit showing flexibility in (C) the zinc-finger ribbon and (D) blocking 
loops, BL1–3. BL, blocking loop; Ub, ubiquitin; Ubl, ubiquitin-like; USP, ubiquitin-specific protease.
fragment completes the active site with the His 
box (amino acids 864–885, 894–903, 915–922) 
and makes the remaining part of the Fingers and 
the Palm9 (supplementary Fig S2 online). Like 
other USP structures10,12-15, except USP711, the 
catalytic triad is in a catalytically competent con-
figuration, wherein His 711-ND1 is 3.2Å away 
from Cys 311-SG and His 711-ND2 is hydro-
gen bonding with Asp 898-OD1 (2.7Å; Fig 1B).
 The zinc-finger ribbon observed in 
USP2 and USP8 is present in USP4 (Fig 1B,C). 
The Zn2+ ion brings together the D1 and D2 
domains, tetrahedrally coordinated by cyste-
ines on anti-parallel β-strands β1 and β2 in D1, 
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Figure 2. Insert inhibits the DUB activity of USP4CD. (A–C) The full-length USP4 catalytic domain (A) is much less active than (B) 
USP4–D1D2 or (C) USP4 fusion in deubiquitinating K63 di-Ub (Coomassie-stained SDS–PAGE gels). D) Quantification of mono-Ub 
in K63 di-Ub cleavage assays. The intensity of the mono-Ub band is plotted against time. E) The inhibitory effect of the insert is observed 
in a Ub-AMC assay. On comparing Kcat/KM between USP4CD and D1D2, we observed a 90 times lower enzyme efficiency for the insert 
containing USP4CD. F) Inhibition of USP4–D1D2 in trans in Ub-AMC assays at different Ubl-insert concentrations (5, 15, 45 and 
90 µM) can be jointly fit as a competitive inhibitor. SDS–PAGE, SDS–polyacrylamide gel electrophoresis; Ub, ubiquitin; Ub-AMC, 
ubiquitin-7-amido-4-methylcoumarin; Ubl, ubiquitin-like; USP, ubiquitin-specific protease.
and b4 in D2. This zinc-finger ribbon in the Fin-
gers domain seems to be in the contracted ‘closed-
hand’ configuration seen in USP8 that blocks ac-
cess of Ub to its binding site10. A similar role was 
assigned to the two Ub-binding surface loops 
(BL1 and BL2) in USP1412 that block the ac-
tive site, but relocate on Ub binding. In USP4, 
both loops (Fig 1D)—as well as a third blocking 
loop (BL3) that hinders access of the C-terminal 
tail of Ub to the binding pocket—are observed.
Superposition of the six non-crystallographic sym-
metry-related molecules of USP4–D1D2 shows 
that both the zinc-finger ribbon and the three 
blocking loops show flexibility (maximal Cα dis-
placement 4Å; Fig 1C,D), which is in agreement
 
with their role in activation10,12. 
The insert inhibits deubiquitinating activity
We compared the catalytic activity of the USP4 cat-
alytic domain with and without the large insert, by 
using in vitro deubiquitinating assays. In these assays 
we followed the hydrolysis of K63- and K48-linked 
di-Ub into mono-Ub (Fig 2A,B; supplementary 
Fig S4A,B online). We observed that K63 di-Ub is 
more efficiently degraded than K48, in agreement 
with the role of USP4 in splicing23. Interestingly, 
quantification (Fig 2D; supplementary Fig S4D 
online) shows that USP4–D1D2 without insert is 
more efficient at degrading both di-Ubs than the
A UblD1 D2USP4CD
Ub
 M    -    0   
Ub2-K63
 min
D1 D2B USP4CD-D1D2
 M    -    0 
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E
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intact catalytic domain (13.5 µM) was weaker than 
that for USP4–D1D2 (0.20 µM), leading to ap-
proximately 90-fold lower catalytic efficiency over- 
all (kcat/KM) for USP4CD than for USP4–D1D2.  
 As the insert seems to inhibit the DUB 
activity of USP4, we tested whether it could do 
so in trans. We expressed and purified the insert 
(amino acids 483–765) and added it in increasing 
amounts to USP4–D1D2 in the Ub-AMC assay 
(supplementary Fig S5A online). We observed that 
the insert slows deubiquitination by USP4–D1D2. 
To investigate whether this reduction in DUB ac-
tivity is due to molecular crowding, we repeated
Figure 3. Ubiquitin competes with the insert or Ubl-domain for binding to USP4–D1D2. (A–C) Interaction of Ub and the insert 
fragments with USP4–D1D2 was studied by SPR experiments. Top: (A) GST-tagged Ub, (B) GST-insert and (C) GST-Ubl domain were 
immobilized on anti-GST antibodies coupled to a CM5 Biacore chip and USP4–D1D2 was flowed over the chip at different concentra-
tions. Bottom: Langmuir binding curves. D) Competition experiment with immobilized GST insert on USP4–D1D2 with varying con-
centrations of Ub. A one-site competition binding model was fitted (Ki = 1.4 µM). E) The interaction of Ub with USP4–D1D2 (left) and 
with full-length USP4CD (right) were studied by ITC analyses. Thermodynamic values for USP4–D1D2 (ΔH = -14.3 kcal/mol and ΔS 
= -16.9 cal/mol/deg), for USP4CD (ΔH = -11.4 kcal/mol and ΔS = -10.0 cal/mol/deg). GST, glutathione S-transferase; ITC, isothermal 
titration calorimetry; Ub, ubiquitin; Ubl, ubiquitin-like; USP, ubiquitin-specific protease.
complete catalytic domain. When D1 and D2 are 
fused through a short linker, as found in USP7 (sup-
plementary Fig S2 online), their activity is similar 
to that of USP4–D1D2, showing that the cause of 
the activation is the lack of insert and not the chain 
break (Fig 2C; supplementary Fig S4C online). 
In Ub-7-amido-4-methylcoumarin (Ub-
AMC) assays the intact USP4 catalytic domain is 
also less active than USP4–D1D2 or the fusion 
protein. As only AMC is cleaved off, the inhibi-
tion is not dependent on the protein target. When 
analysed by Michaelis–Menten kinetic analysis (Fig 
2E) the Vmax values were similar, but the KM for the
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only fourfold less, compared to USP4–D1D2 in an 
isothermal titration calorimetry (ITC) experiment 
(Fig 3E). Although the exact Kds are slightly tighter 
in the ITC experiment, qualitative analysis of SPR 
experiments agrees with this assessment. Non-
specific binding at high concentrations precluded 
detailed fitting of these data (supplementary Fig S7 
online), but the curves show that binding of Ub to 
USP4CD has a slower off-rate than that of Ub to 
USP4–D1D2, and together with the Kd value also 
suggests that it has a slower on-rate. As the KM is de-
pendent on Kd and the binding rate, the combina-
tion of slow kinetics and slightly lower affinity ex- 
plains the differences in KM values. Apparently, the 
insert prevents rapid binding as well as rapid release 
of the Ub substrate, allowing competitive binding.
Finally we analysed whether the enzymatic activ-
ity is competitively inhibited by the addition of 
the insert in trans. We tested the enzymatic activ-
ity with varying inhibitor concentrations against 
a range of substrate concentrations (Fig 2F), and 
fitted the data against different inhibition mod-
els26. We found that the data were best explained 
by competitive inhibition with Ki = 47 µM.
Although this value is lower than expected on the 
basis of the binding data alone, it explains why 
the USP4CD is not completely inhibited in the 
continuous presence of the insert. It seems that
the in trans inhibition assay with USP4–D1D2 in 
the presence of either SUMO or BSA (supplemen-
tary Fig S6 online). Neither of these reduced DUB 
activity, confirming that the insert is intrinsi-cally 
able to inhibit the catalytic activity of USP4.
Competitive inhibition of the USP4 insert
We tested whether USP4–D1D2 would directly 
interact with the insert. In a surface plasmon reso-
nance (SPR; Fig 3B) experiment, we observed bind-
ing of USP4–D1D2 to the insert, with a Kd of 1.32 
µM after equilibrium fitting. This affinity closely 
resembled the affinity of USP4–D1D2 for Ub itself 
(Kd of 1.39 µM; Fig 3A).
Therefore, we tested whether the insert 
could compete with Ub for binding to USP4–
D1D2, and would therefore bind to the same bind-
ing site. In an SPR competition experiment we 
flowed USP4–D1D2 over a glutathione S-transfer-
ase (GST)-tagged insert in the presence of increas-
ing amounts of Ub (Fig 3D). We observed decreas-
ing binding of USP4–D1D2 to the GST-insert as 
the Ub concentration increased. The data could be 
fitted with a one-site competition binding model 
with a Ki of 1.4 µM, showing that the USP4 insert 
competes with Ub for binding to USP4–D1D2. 
Interestingly, the Kd of intact USP4CD for Ub is
Figure 4. USP39CD binds to the Ubl domain and increases the deubiquitinating-enzyme activity of USP4CD. A) Other USPs 
activate the DUB activity of USP4CD in trans in a Ub-AMC assay (USP39CD: 10, 20, 50, 100, 500 and 1,000 nM; USP8CD-mut: 
1,000 nM). B) USP39 and (C) USP8-mut bind to Ubl insert, in an SPR assay analogous to Fig 2B. DUB, deubiquitinating enzyme; 
GST, glutathione-S-transferase; mut, mutant; Ub, ubiquitin; Ub-AMC, ubiquitin-7-amido-4-methylcoumarin; Ubl, ubiquitin-like; USP, 
ubiquitin-specific protease. 
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additional conformational changes take place. 
One possibility is that the enzyme reaches a state 
after turnover that has lower affinity for the in-
sert, and is therefore not as effectively inhibited. 
The Ubl domain is sufficient for inhibition
The presence of a Ubl domain within the insert was 
predicted (supplementary Fig S2 online)16. To test 
whether the Ubl domain is sufficient for binding to 
the USP4 catalytic domain, we performed the SPR 
experiment with the purified Ubl domain (amino 
acids 483–571, Fig 1A) and found a Kd of 1.36 µM 
towards USP4–D1D2, which is similar to that for 
the complete insert (Fig 3C). This suggests that the 
Ubl domain is the functional part of the insert.
To test whether the Ubl domain can in-
hibit the DUB activity of USP4, we repeated the 
in trans inhibition assay with USP4–D1D2 in the 
presence of increasing amounts of the Ubl domain 
(supplementary Fig S6 online) and found that it 
provides inhibition equal to the insert. We there-
fore conclude that the Ubl domain is sufficient to
inhibit the DUB activity of USP4, through com-
petitive inhibition of Ub binding.
Regulation by other USP enzymes
As the Ubl domain seems to bind in the substrate 
Ub-binding site of USP4, we wondered whether 
other USP enzymes could also bind to the Ubl 
domain. We tested whether our Ubl domain con-
taining insert could bind to the catalytic domain of 
USP39 and USP8, and found similarly high affini-
ties as for USP4CD (Fig 4B,C).
Then, we analysed whether these 
DUBs could modulate USP4CD activ-
ity. We repeated the in trans Ub-AMC assay 
with USP4CD in the presence of the intrinsi-
cally inactive USP39CD or an inactive variant 
of the USP8 catalytic domain, USP8CD-mut
(Fig 4A). For both USPs we observe a mod-
est activation of USP4CD that was depen-
dent on the presence of the Ubl-containing in-
sert, as it does not increase the DUB activity of
USP4–D1D2 in this manner.
Figure 5. Model for Ubl domain inhibition on USP4. A) Structural model in which interaction of the Ubl domain with USP4CD 
inhibits the binding of Ub. B) Schematic model of the auto-inhibitory role of the Ubl domain in USP4. C) Other USP enzymes, such as 
USP39, may relieve the inhibition by binding to the Ubl domain. Ub, ubiquitin; Ubl, ubiquitin-like; USP, ubiquitin-specific protease.
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 Apparently, other USP enzymes can reg-
ulate USP4 activity by competing for binding to 
the Ubl domain. This effect could be larger when 
the USPs have further interactions. As USP39 
forms a stable complex with USP4 in cells23,24, it is 
a prime candidate for an activating role in vivo.
Discussion
We show that the predicted Ubl domain within a 
large insert embedded in the USP4 catalytic do-
main partially inhibits DUB activity by competing 
with Ub for binding. Superposition of the crystal 
structure of USP4–D1D2 and any Ubl domain on 
USP7 in complex with Ub-aldehyde (PDB: 1NBF), 
respectively, shows that the Ubl domain would fit 
like a Ub molecule into the hand of USP4–D1D2 
(Fig 5A), only requiring movements in the block-
ing loops and the zinc-finger ribbon. Hence, we 
propose a model in which the Ubl domain partly 
inhibits DUB activity through competitive inhibi-
tion by binding into the hand of USP4 and thus
preventing Ub substrate binding (Fig 5B).
 This function of an integrated Ubl do-
main is relatively new. The Ubl domains in protea-
somal shuttle factors Rad23 and Dsk2, as well as 
in Parkin and USP14, function in recruitment of 
ubiquitinated proteins to the proteasome12,27. Oth-
er Ubl domains regulate the enzymatic activities of 
immune-response inducible kinases such as IKKβ (a 
subunit of IkB kinase complex)28, or as PB1 (Phox 
and Bem1) domains, have a role in the regulation of
signal transduction in proteins such as P62, 
MEK5 and protein kinase C29,30. However,
all these Ubl-domain families have low sequence 
similarities, indicating that their functions are 
probably distinct between subfamilies.
The activity of USPs is regulated 
through an inactive conformation of the catalytic 
triad, as in USP7, or through a series of block-
ing loops or a blocking zinc-finger ribbon. USP4
seems to combine the blocking loops and zinc-fin-
ger ribbon with a fur-ther regulation through the 
Ubl domain.
 Whether Ubl domains provide a com-
mon regulation mechanism for the DUB activity of 
USPs is an interesting question for future research. 
A second Ubl domain is found within USP4, at its 
N-terminus. A recent crystal structure (PDB: 3JYU, 
amino acids 139–226) shows that this Ubl domain 
interacts extensively with the adjacent DUSP (do-
main in USP) domain (amino acids 27–125). This 
region of the protein is primarily important for in-
teraction with Sart323 and hence might not have 
this function.
 However, USP4 is not the only DUB 
with a Ubl fold within its catalytic domain. Se-
quence analysis by Zhu and co-workers identi-
fied an integrated Ubl fold within the catalytic 
do- main of USPs 6, 11, 15, 19, 31, 32 and 43, 
embedded in a larger insert, like in USP416.
In particular, USP11 and USP15 are closely related 
to USP4. This subgroup of USPs probably also reg-
ulates DUB activity through its Ubl domain.
The way in which Ubl-domain inhibition 
itself is regulated is an exciting question. One could 
imagine that further posttranslational modification 
by, for example, phosphorylation or acetylation 
would enable the release of the full activity of the DUB
enzyme. In addition, we have shown that binding 
partners such as USP39, can activate USP4 func-
tion by binding to the Ubl domain (Fig 5C). Al-
though the activation is modest (Fig 4A), this could 
be increased by further interactions, as observed in 
the spliceosome complex.
Whatever the mechanisms that are iden-
tified to regulate USP4 activation, it is clear that 
this type of internal regulation by a Ubl domain 
allows the creation of an extremely fast response ele-
ment to external signals.
Material and Methods
Plasmids and cloning
cDNA for human USP4 and USP8 was a gift from 
Hidde Ploegh and cDNA for USP39 was a gift 
from R. Medema. USP4CD (aa 296-954) and the 
D1 fragment (aa 296-490) of human USP4, US-
P39CD (aa 219-565) and USP8CD (aa 771-1118) 
were cloned using ligation independent cloning 
into pET-46 Ek/LIC vector (Novagen). The D2 
fragment (aa 766-932) of USP4 was cloned into 
the pET-NKI b/3C (Luna-Vargas, in prepara-
tion). The fused USP4-D1D2 was created by in-
serting aa 353-359 of USP7 (SIKGKNN) between 
residues Leu479 and Leu777. The USP4 insert (aa 
483-765), Ubl domain (aa 483-571) and Ub were 
cloned into pGEX-6P-1 (GE Healthcare). The US-
P8CD mutant was generated by site-directed muta-
genesis of the catalytic cysteine (C786A).
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Protein preparation
Purification of E2-25K31, Ubc13/Mms232 was as 
described. GST-tagged proteins were overexpressed 
in Escherichia coli strain Rosetta2(DE3)-T1R us-
ing IPTG (200µM) induction overnight at 15°C. 
Cells were lysed by microfluidizer into buffer 
A (50mM Hepes pH7.5, 150mM NaCl, 5mM 
β-mercaptoethanol, 1mM PMSF). The fusion pro-
tein was purified using glutathione sepharose resin, 
eluted, followed by removal of the GST-tag with 
3C protease and size-exclusion using HiLoad 16/60 
Superdex 200 (GE Healthcare). Peak fractions were 
concentrated to 10mg/ml in 25mM Hepes (pH7.5), 
200mM NaCl and 5mM β-mercaptoethanol.
D1 and D2 co-expression, other USP4 variants, 
USP39CD and USP8CD-mut were overexpressed 
as above, with 200µM ZnCl2 during induction and 
lysed in buffer A supplemented with 1mM ZnCl2 
and 10mM Imidazole. These His-tagged proteins 
were purified by a Co2+-affinity (Talon resin) step. 
Upon Imidazole elution the His-tag was removed 
by TEV cleavage at 4°C overnight during dialysis 
in buffer B (25mM Hepes pH7.5, 150mM NaCl, 
5mM β-mercaptoethanol). This was followed 
by POROS Q affinity chromatography and size-
exclusion using HiLoad 16/60 Superdex 200 (GE 
Healthcare), where the protein eluted as a mono-
mer. The peak fractions were concentrated to 5mg/
ml in buffer B.
Limited Proteolysis and protein identification
Purified USP4CD (9mg/ml) was incubated with 
Thermolysin (0.8units) for 1,5hr at room tem-
perature and subjected to size exclusion chro-
matography using Superdex75 16/60.  Fractions 
containing USP4-D1 and –D2 were subjected 
to LC-MS analysis. LC-MS measurements were 
performed on a system equipped with a Waters 
2795 Seperation Module (Alliance HT), Waters 
2996 Photodiode Array Detector (190-750nm), 
Waters Alltime C18 (2.1x100mm, 3µm), Waters 
Symmetry300TM C4 (2.1x100mm, 3.5µm) and 
LCTTM Orthogonal Acceleration Time of Flight 
Mass Spectrometer. Data processing was performed 
using Waters MassLynx Mass Spectrometry Soft-
ware 4.1 (deconvolution with Maxent 1 function).
N-terminal sequencing of USP4-D1 and –D2 were 
performed by AltaBioscience in Birmingham, Eng-
land.
Crystallization and structure determination of 
the USP4-D1D2
Crystals were grown overnight in sitting-drops mix-
ing 200nl USP4-D1D2 (~3.5mg/ml) with 200 nl 
100mM Bis-Tris propane [pH8.5], 25mM Na2SO4 
and 18% PEG3350 (w/v) at 19°C. Crystals were 
cryoprotected in mother liquor with 25% ethyl-
eneglycol. The crystals belong to the space group 
P212121 with six molecules per asymmetric unit 
(supplementary Table S1). Diffraction data were 
collected at the ESRF (Grenoble, France) beam- 
line ID14-2 and processed with MOSFLM33 and 
SCALA34. The structure was solved by molecu-
lar replacement with PHASER35 using USP8CD 
(PDB:2GFO) as search model. Iterative rebuilding 
and refinement were done with Coot36 and PHE-
NIX37 and BUSTER38. The structure was validated 
with MOLPROBITY39 and WHAT-CHECK40 and 
structure figures were generated using PYMOL41. 
Cysteine residue 311 in all chains have been chemi-
cally modified by β-mercaptoethanol.
Ub-AMC assay
UbAMC assays were done in 50mM Hepes [pH7.5], 
100mM NaCl, 5mM DTT, 0,05% Tween-20 and 
1mM EDTA and reaction progress was monitored 
with a Fluostar Optima plate-reader (BMG Tech) 
by the increase in fluorescence emission at 460nm 
(λex = 355nm) generated by Ub-AMC cleavage.
Quantitative activity (triplicate) and in trans inhibi-
tion (duplicate) assays or USP modulation assays 
(triplicate) were performed using Ub-AMC with 
10nM enzyme in 30 µl reaction volume in 384-
well plates and preincubated for 15 min at 21°C, 
for inhibition assays with Ubl insert and with other 
DUBs for modulation assays. Initial velocities 
against Ub-AMC concentration were computed to 
derive steady-state kinetic parameters using Graph-
Pad Prism5 (GraphPad Software Inc.). Non-linear 
fitting of four inhibition models was compared in 
GraphPad.
Di-ubiquitin assay
Di-Ub assays were performed in similar buf-
fer as in UbAMC assays at 37°C in 75µl re-
action volume. Aliquots (5µl) were stopped 
by addition of 4x SDS-sample loading buf-
fer and subjected to SDS-PAGE analysis on 
a 4-12% coomassie stained gel (Invitrogen).
K48 and K63 di-Ub substrates were produced 
and purified as described42. 75nM enzyme was
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incubated with 3 µM di-Ub, subjected to SDS–
polyacrylamide gel electrophoresis and image anal-
ysis, and quantitation was performed in duplicate 
with TINA 2.09 (Raytest Co.).
Surface plasmon resonance
SPR was performed on a Biacore T-100, with GST-
Ub, GST-insert and GST-Ubl domain immobilized 
on anti-GST antibodies coupled to a CM5 chip. 
Data (duplicate) were processed using BiaE- valu-
ation (GE Healthcare) and GraphPad Prism5. 
Quantitative binding analysis was done in dupli-
cate at 25°C on a Biacore T-100 instrument (GE 
Healthcare). GST fused Ub, insert and Ubl domain 
were immobilized on α-GST antibodies lysine-cou-
pled to a CM5 chip. USPs were injected in varying 
concentrations over the sensor chip at 30µl/min 
with a 120s association phase followed by a 10min 
dissociation phase. For the binding inhibition assay 
Ub was added in varying concentrations to USP4-
D1D2. Standard double referencing data subtrac-
tion methods were used before and equilibrium 
curve fitting with BiaEvaluation (GE Healthcare) 
and GraphPad software (GraphPad Software Inc).
Isothermal Titration Calorimetry
ITC experiments were performed with the VP-ITC 
Micro Calorimeter (MicroCal, Inc.) at 25°C. Stock 
solutions of USP4CD, USP4-D1D2 and Ub were 
prepared by dialysis of the purified proteins against 
a buffer containing 25mM Hepes pH8.0, 150mM 
NaCl and 5mM β-mercaptoethanol at 4°C and 
were degassed before use. The sample cell (1.8ml) 
contained USP4-D1D2 (10µM) or USP4CD 
(20µM) which was titrated with 100µM Ub or 
200µM Ub respectively using 16 injections. The in-
jections after saturation were used to determine the 
background signal. Corrected data were analyzed 
using software supplied by the ITC manufacturer 
to calculate the dissociation constant Kd and fitted 
with a one to one binding model.
Accession number
Atomic coordinates and structure factors have been 
deposited to the Protein Data Bank with accession 
number: 2Y6E
 
Supplementary information is available at EMBO 
reports online (http://www.emboreports.org).
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 Table SI Data collection and refinement statistics.
Data collection statistics Native
Wavelength (Å) 0.993
Space group P212121
Unit cell (Å) 110.5, 151.0, 178.7
Molecules per asymmetric unit 6
Resolution (Å)a 47.0 - 2.4 (2.53 - 2.4)
Rmerge (%) 8.8 (66.1)
<I/σ(I)> 11.0 (1.1)
Completeness (%) 94.9 (74.0)
Redundancy 3.4 (2.4)
Refinement
Rwork/Rfree (%) 17.5/21.3
Number of reflections 111078
Number of protein atoms 15775
Number of zinc ions 6
Number of waters 867
RMSD from ideal geometry
Bond lengths (Å) 0.009
d l ( )Bon  ang es ° 1.01
Ramachandran statisticb
(prefered/allowed/outliers)
1849 / 66 / 2
a Numbers in parentheses are for the highest-resolution shell
b Calculated using Molprobity
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Supplemental Figures
Supplemental Figure S1
Identification of USP4-D1D2. A) Limited prote-
olysis analysis of thermolysin cleavage on USP4CD 
at 37°C. Samples at different time-points were 
taken and analyzed on a SDS-PAGE gel. B) Proteo-
lytic sample of USP4CD was subjected to a size ex-
clusion chromatography and fraction samples were 
analyzed on a SDS-PAGE gel. C) Mass Spectrome-
try analysis and N-terminal sequencing determined 
the identity of the two fragments, D1 and D2.
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Supplemental Figure S2
Structure based multiple sequence alignment. Secondary structure elements are colored and labeled ac-
cording to structure of USP4-D1D2 in Figure 1. The internal Ubl is depicted as a yellow bar and the two 
black arrows indicate where the protease thermolysin cleaved in the catalytic domain of USP4. The catalytic 
triad residues are indicated with an asterisk. The four black triangles indicate the positions of the Cys resi-
dues coordinating the zinc ion.
α1 α2 α3 α4 α5
α6 α7 α8 β1
Ubiquitin Like Domainβ2 β3
α10β4 β5 β6 β7 β8 β9 β10 β11
α11β12 β13
α9
*
*
*
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Supplemental Figure S3
Overview and superposition of USP catalytic domain structures with USP4-D1D2. Comparison be-
tween catalytic domains depicted in cartoon representation of USP4-D1D2 (red-cyan), Ubp8 (brown, 
PDB: 3MM9), CYLD (orange, PDB: 2VHF), USP21 (marine blue, PDB: 3I3T), USP2 (yellow, PDB: 
2HD5), USP8 (purple, PDB:2GFO), USP14 (green, PDB: 2AYO) and USP7 (light pink, PDB:1NB8). 
The structures depicted in ribbon representation were superposed in Coot (RMSD of 2.1Å over 323 resi-
dues).
USP4-D1D2 [xx] Ubp8 [3MM9] CYLD [2VHF]
USP7 [1NB8]USP14 [2AYO]
USP2 [2HD5] USP8 [2GFO]USP21 [3I3T]
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Supplemental Figure S4
Deubiquitinating assay with K48 di-Ub as sub-
strate. A-C) The full-length USP4 catalytic domain 
(A) is much less active than USP4-D1D2 B) or 
USP4-fusion (C) in a deubiquitinating assay using 
K48 di-Ub as substrate on coomassie-stained SDS-
PAGE gels. D) Quantification of mono-Ub in K48 
di-Ub cleavage assays. The intensity of the mono 
Ub band is plotted against time
Supplemental Figure S5
In trans inhibition of USP4-D1D2 DUB activity. A) The inhibitory effect of the insert is observed in a 
Ub-AMC assay with increasing amounts of insert (5, 10, 25, 50 and 75µM). B) The Ubl domain (5, 10, 
25, 50 and 100µM) is sufficient to show this in trans inhibition.
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Supplemental Figure S7
Kinetic comparison of USP4-
D1D2 and USP4CD binding to 
Ub, Ubl and insert on SPR. Bind-
ing curve of 0.8 µM of USP4-
D1D2 and of 1 µM of USP4CD 
were normalized for maximum 
binding in order to compare off-
rates.
Supplemental Figure S6
The molecular crowding of high concentrations of 
SUMO or BSA (100µM) does not have an effect on 
USP4-D1D2 DUB activity.
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The USP family: small and multifunctional
More and more functional roles of USPs in impor-
tant biological cellular processes are being discov-
ered. Also the role they play in tumorigenesis is rec-
ognized in the ubiquitin field. Therefore members 
of the large USP family are being actively pursued 
as drug targets. 
 In chapter 2 a genomic and functional 
overview is given on the large family of deubiqui-
tinating enzymes encoded in the human genome. 
The analysis of the ENSEMBL human genome da-
tabase revealed 95 putative DUBs of which 79 are 
expressed in cells and display Ub/Ubl protease ac-
tivity. Compared to the number of E3 ubiquitin li-
gases, the DUBs are remarkably outnumbered. One 
possible explanation is that not all DUBs have been 
identified yet or their associated cofactors that may 
determine specificity. Another explanation is that a 
DUB may have different targets. For instance USP7 
seems to be able to deubiquitinate several different 
targets such as p53, Mdm2, PTEN, FOXO4 and 
H2B1-5. As already mentioned in chapter 1, USP4 
also has different targets e.g. the U4 spliceosome 
component Prp3, TAK1 and more recently the E3 
Ub ligase ARF-BP16-8. More USPs seem to have 
more than one target, like USP1 (targets FANCD2 
and PCNA)9,10, USP2 (fatty acid synthase and 
Mdm2)11,12, and CYLD (targets NEMO, TRAF-2 
and TRAF-6)13-15. Another explanation for the ex-
cess of E3 Ub ligases could be that only a fraction 
of the targets that are ubiquitinated are regulated 
by specific USPs. It is possible that only proteins 
that demand extremely tight regulation, such as 
p53 and H2A/B, require additional regulation by 
deubiquitination. Indeed p53 and H2A/B seem 
to have more than one USP for their deubiquiti-
nation, USP2, USP7, USP10 and USP3, USP16, 
USP21, USP22 respectively. Undoubtedly, future 
studies will uncover more about the functional roles 
of members of the USP family and why the E3 Ub 
ligases outnumber the DUBs.
High-throughput equals low-output
In order to understand and explain the molecular 
and biochemical function of USPs one should turn 
to structural molecular biology. Once the three-di-
mensional structure of a USP is determined it could 
General Discussion
help decipher basic principles of protein structure 
and assembly, mechanisms of biochemical reac-
tions and details of macromolecular interactions. 
As stated in chapter 1 only the crystal structures 
of the catalytic domain of several USP members 
and more recently of USP4 (chapter 5) have been 
solved. Despite the low sequence similarity the 
overall structure of the catalytic domain is highly 
conserved. The structures also reveal that the cata-
lytic activity of USPs is regulated by substrate- or 
scaffold-induced conformational changes. It will be 
very interesting to determine full-length USPs and 
see how their additional domains interact with the 
catalytic domain. In the process of determining the 
three-dimensional protein structures it is important 
to produce a large number of soluble recombinant 
protein variants. In chapter 3 a set of protein ex-
pression vectors for ligation-independent cloning 
is described and their use for protein expression in 
E.coli on 35 different members of the USP fam-
ily. Out of 145 different expression constructs, 38 
soluble recombinant proteins for 21 different USPs 
were obtained. Looking more carefully, the level of 
protein solubility amongst the 21 USPs differ sub-
stantially. An explanation for this solubility differ-
ence could be the use of high-throughput methods. 
The protein expression and solubility screening was 
done in 96-well blocks and working with small vol-
umes one can easily make a mistake in the different 
steps such as cell lysis, affinity binding and elution 
of recombinant protein. The use of robotics in au-
tomating these different steps can help substantially 
in identifying the correct construct that gives high 
protein expression and solubility. 
 Most of the constructs that give solu-
ble protein for the 21 different USPs are either 
representing the catalytic domain only or with 
variations at the N- and C-terminal ends of the 
catalytic domain. The expression of the full-length 
protein of only two USPs (USP16 (823aa) and 
USP46 (366aa)) was possible in E.coli. Interest-
ingly, the USP12 construct which has high se-
quence similarity with USP46 did not give soluble 
protein in the E.coli expression system. However 
expressing the USP12 construct in the Sf9 insect 
cell expression resulted in a high yield of soluble 
full-length protein (chapter 4). It looks like the 
Sf9 insect cell expression system might be a more
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suitable system for expressing the full-length USP 
protein. Indeed when testing the pFastBac- NKI-
LIC vector in Sf9 insect cells, the construct for full-
length USP7 gave high yield of soluble protein. 
 Another way of improving the expression 
and solubility of the USPs is the use of synthetic 
genes containing optimized codons. In E.coli the 
protein expression is maximized by using codons 
corresponding to tRNA’s that retain amino acid 
charging during starvation16. The expression and 
solubility of USP7 in E.coli for instance has been 
greatly improved by using synthetic genes (chapter 
4).
 Although the development and the use 
of high-throughput methods did not achieve the 
desired results in getting a large number of USP 
constructs giving soluble protein in large amounts, 
the use of these high-throughput methods are now 
well established and the ligation-independent clon-
ing using the pET-NKI vectors is currently the stan-
dard method in our lab. Furthermore, the number 
of USPs that we finally could obtain was used for 
the characterization in chapter 4.  
USPs look similar, but behave differently
Even though many studies show the vital role of 
a number of USPs in important cellular pathways 
and the implication in tumorigenesis, not much 
is known about the proteases themselves in terms 
of enzyme kinetics and preference for ubiquitin-
chain type. We have tried to address these topics by 
characterizing a set of twelve USPs using synthetic 
tools including all seven di-ubiquitin topoisomers 
(chapter 4). 
 The analysis of the enzyme kinetics 
showed that there are large differences in DUB 
activity amongst the twelve USPs. Based on their 
KM and kcat values, these USPs can be grouped in 
three classes: the inactive, the intermediate and the 
very active group. Future studies will show whether 
these three classes still hold true after characterizing 
the enzyme kinetics for the rest of the USP family. 
It seems that the USP family doesn’t show any real 
preference for a certain ubiquitin-chain type, but 
rather show a modest differential activity towards 
the seven di-ubiquitin topoisomers which was vari-
able between USPs. 
 Many USPs have additional domains and 
internal insertions within the catalytic domain and 
some USPs are known to have external modulators 
that regulate the DUB activity. As shown for USP7 
and USP16, both show increased DUB activity 
in the presence of their additional domains (the 
HUBL and ZnF-UBP domain, respectively). The 
ZnF-UBP domain of USP16 enhances the DUB 
activity by increasing the kcat. This activation of 
DUB activity has been previously shown for USP5 
as demonstrated by Reyes-Turcu et al.17. They show 
that binding of free Ub to the ZnF-UBP domain 
enhances the USP5 DUB activity in vitro. Besides 
USP16 and USP5, several other USPs (USP3, 
USP44, USP45 and USP49) have a similar ZnF-
UBP domain. It is possible that enhancement 
of USP activity following free ubiquitin binding 
would be a general regulatory mechanism18.  The 
activity of USP7 is modulated by its HUBL domain 
which affects both the KM and kcat. Despite a clear 
difference in DUB activity, no change in ubiquitin-
chain type preference was seen between the catalytic 
domain and full-length of USP7 and USP16. Inter-
estingly, our data show that the preference of USP7 
for di-ubiquitin topoisomers can be attributed to 
the binding affinity (KM) for the substrate.
 A similar enhancement of DUB activity 
by increasing the kcat is seen for USP1, USP12 and 
USP46 in presence with their external modulator, 
the WD40-repeat containing UAF1. Also for USP7 
the kcat is increased by adding its external modula-
tor GMPS. Similar to the HUBL and ZnF-UBP 
domain, both external modulators do not seem to 
affect the preference for ubiquitin-chain type.  
 Because of the important cellular roles of 
several USPs, their DUB activity must be tightly 
regulated. Several studies have revealed that kinases 
play an important role in USP control and a num-
ber of USPs, such as USP7, USP16 and USP44, are 
activated by phosphorylation19-22. It seems that the 
DUB activity of USPs is further regulated by intra-
molecular modulating domains (HUBL and ZnF-
UBP) and by intermolecular modulators (GMPS 
and UAF1). The identification of new intra- and 
intermolecular modulators for other USPs will be 
interesting and challenging for future studies and 
will unveil whether they also can affect the prefer-
ence for ubiquitin-chain type.
  
New role for the Ubl domain
The knowledge about functions for the Ubl do-
mains in USP family members is limited. Only 
one example has been described which is the Ubl 
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domain located at the N-terminus of the catalytic 
domain of USP14. It functions as an anchor for 
recruitment to the proteasome where USP14 is ac-
tivated23. Very recently Faesen and co-workers show 
the crystal structure of five Ubl domains located C-
terminal of the catalytic domain of USP724. Here 
the first three Ubl domains seem to be required as 
a docking station for the intermolecular modulator 
GMPS, while the last two Ubl domains apparently 
are responsible for activating USP7. This activa-
tion is achieved by interacting with the Cys-loop 
and position the catalytic triad in a catalytic com-
petent configuration. Finally in chapter 5, a new 
role for the Ubl domain in USPs is described. The 
Ubl domain of USP4 located within the catalytic 
domain plays a role as the internal inhibitor of the 
DUB activity of USP4. The Ubl domain inhibits 
USP4 activity by binding to the catalytic domain 
with similar affinity as for ubiquitin and thereby 
preventing ubiquitin substrate binding.  
 It seems that the Ubl domain in USPs can 
have different functions: recruiting, activating and 
inhibiting DUB activity. These functions might be 
a common feature in USPs as similar Ubl domains 
have been identified in a large number of USPs25. 
Interestingly, the Ubl domains which recruits, acti-
vates and inhibits are each located differently with 
respect to the catalytic domain. The recruiting Ubl 
domain of USP14, the activating Ubl domain of 
HAUSP and the inhibiting Ubl domain of USP4 
are located respectively N-terminal, C-terminal and 
internal of the catalytic domain. Whether the loca-
tion of the Ubl domain in respect of the catalytic 
domain plays an important role in Ubl function is 
an interesting question. 
 Interestingly, the inhibitory role of the 
Ubl domain within the USP4 catalytic domain 
can be blocked by USP39 through binding to 
the Ubl domain, thus activating USP4 function. 
The interaction between USPs opens up a new 
door for USP regulation. Looking at the domain 
architecture of the USP family containing ubiqui-
tin binding domains and Ubl domains, it is very 
likely that other USPs can interact with each other 
and possibly alter USP function. Indeed recently, 
Maertens et al show the interaction between USP7 
and USP11 and how they regulate the ubiquitina-
tion status of several components of the Polycomb 
repressive complex 126,27. How they interact re-
mains unclear, but as USP11 looks very similar in 
domain architecture as USP4 with Ubl domains,
it is possible that USP7 binds to USP11 through 
one of its Ubl domains. Or USP11 binds to one of 
the HUBL domains of USP7 and thereby altering 
each others function. Future research into Ubl do-
mains should be conducted to investigate whether 
the Ubl domains predicted in other USPs have 
similar or might display new functions.
Concluding remarks 
In the last decade the importance of DUBs as a key 
regulatory step in ubiquitin-dependent pathways 
and as an important factor in tumorigenesis, have 
been increasingly recognized. Although many excit-
ing studies on DUBs are ongoing, there is still a long 
way to go before we fully characterize this intrigu-
ing protease family. The largest subfamily of DUBs, 
the USP family, has been the focus of this thesis. We 
have seen that USPs, even in small number com-
pared to the E3 ubiquitin ligases, are multifunc-
tional in that they have more than one target. We 
have also seen that a subset of USPs displays a large 
variation in DUB activity with no real preference 
for a ubiquitin-chain type. Furthermore, the USP 
activity not only is regulated on the level of phos-
phorylation, but it also involves inter- and intramo-
lecular modulators. Finally, a new inhibitory role for 
the integrated Ubl domain in the catalytic domain 
of USP4 has been described. Hopefully, the experi-
ments and data shown in this thesis will contribute 
to the further understanding of the USP family. 
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SUMMARY
Since the discovery of ubiquitin (Ub), it is in-
creasingly apparent that Ub mediated events 
are critical in cell proliferation. In the last 
several decades much attention is placed on 
the ubiquitination pathway and recently the 
role of deubiquitinating enzymes (DUBs) in 
the reverse pathway is being recognized as im-
portant regulators of these processes. There is 
also a growing recognition of DUBs that are 
mutated in human cancers making them in-
teresting drug targets. To better understand 
these DUBs, this thesis focuses on the struc-
tural and functional aspects of the largest sub-
class of DUBs, the ubiquitin-specific protease 
(USP) family.   
Chapter 2 gives a genomic and func-
tional overview of the DUB family and de-
scribes the five different subclasses. Describing 
examples of the cellular roles of USPs in differ-
ent pathways with known protein substrates, 
it shows that eventhough the USP family is 
relatively small, the USP family member is 
multifunctional by having more than one 
substrate. It also shows how some important 
substrates such as p53 and H2A/B requires ad-
ditional regulation by having more than one 
USP for their deubiquitination.
In order to better understand the 
molecular and biochemical roles of USPs, 
soluble protein is required for both crystal-
lographic and biochemical studies. To obtain 
soluble protein, one must produce and screen 
a large number of DNA constructs. In chap-
ter 3 the development and the use of the pET-
NKI-LIC vectors as high-throughput methods 
to obtain DNA constructs, which results in 
high protein expression and improves protein 
solubility, is described. Ligation-independent 
cloning (LIC) using the pET-NKI-LIC vec-
tors is currently the standard method in our 
lab and the implementation of LIC for a large 
number of USPs, resulted in a number of sol-
uble USP proteins.  
Chapter 4 shows the enzymatic 
characterization of the obtained soluble USPs 
using synthetic substrates including all seven 
lysine-linked di-ubiquitins. The analysis shows 
that the USPs behave differently in terms of
DUB activity and that based on their kinet-
ic behaviour they can be grouped into three 
classes: the inactive, the intermediate and the 
very active group. Furthermore, we provide 
the first comprehensive analysis comparing 
the Ub chain preference and show that USPs 
display a modest activity towards the seven 
di-ubiquitin topoisomers which was variable 
amongst the USPs and that this Ub chain-
type preference in the case for USP7 can be 
attributed to the binding affinity (KM) for its 
substrate. Finally, the existence of intermolec-
ular modulating domains (HUBL and ZnF-
UBP) and intramolecular modulators (GMPS 
and UAF1) help regulate the DUB activity of 
USPs by mainly increasing the catalytic turn-
over (kcat).
In chapter 5 the three-dimensional 
crystal structure of minimal catalytic domain 
USP4-D1D2 is shown and a new role for the 
Ubl domain embedded within the catalytic 
domain of USP4 is described. The crystal 
structure of the USP4 catalytic domain has 
the conserved USP-like fold with its typical 
Ub binding site. Our findings show that the 
integrated Ubl domain acts as an intermo-
lecular modulating domain that inhibits the 
DUB activity of USP4. This inhibitory func-
tion of the integrated Ubl domain is induced 
by binding to the catalytic domain of USP4 
with similar affinity as for Ub and thereby pre-
venting Ub substrate binding. Interestingly, a 
binding partner of USP4, USP39 is able to 
bind to the same Ubl domain and relieve the 
inhibition.
 Together the work presented in 
this thesis illustrates how complex and di-
verse the function and the regulation are of 
this relative small USP family. Hopefully this 
work gives interesting leads for future studies 
and helps contribute into the understand-
ing of the intriguing DUB family, the USPs. 
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SAMENVATTING
Sinds de ontdekking van ubiquitine (Ub), 
wordt het steeds duidelijker dat Ub gemedi-
eerde gebeurtenissen belangrijk zijn in de cel 
proliferatie. In de laatste decennia is er veel 
aandacht besteed aan de ubiquitinering route 
en onlangs is de rol van deubiquitineringsen-
zymen (DUBs) in de omgekeerde route er-
kend als belangrijke toezichthouders van deze 
processen. Er is ook een toenemende erken-
ning van DUBs die gemuteerd zijn in mense-
lijke kankers, waardoor ze interessant zijn als 
drug targets. Om deze DUBs beter te begrij-
pen, concentreert dit proefschrift zich op de 
structurele and functionele aspecten van de 
grootste subgroep van DUBs, de ubiquitine-
specificieke protease (USP) familie.
 Hoofdstuk 2 geeft een genomisch 
en functioneel overzicht van de DUB familie 
en beschrijft de vijf verschillende subgroepen. 
Door voorbeelden te beschrijven van cellulaire 
rollen van USPs in de verschillende routes 
met bekende eiwit substraten, laat hoofdstuk 
2 zien dat de USP familie leden, ondank het 
kleine aantal, multifunctioneel zijn door meer 
dan één substraat te hebben. Verder wordt ook 
beschreven dat sommige belangrijke substra-
ten zoals p53 en H2A/B extra regulatie verei-
sen door meer dan één USP voor hun deubi-
quitinering te hebben.
 Om beter inzicht te krijgen in de 
moleculaire en biochemische rollen van USPs, 
is oplosbaar eiwit nodig voor zowel de kris-
tallografische en biochemische studies. Om 
oplosbaar eiwit te verkrijgen, moet men een 
groot aantal DNA constructen produceren en 
screenen. In hoofdstuk 3 worden de ontwik-
keling en het gebruik van de pET-NKI-LIC 
vectoren beschreven. Deze vectoren worden 
gebruikt als hoge-doorstroom methodes om 
DNA constructen te verkrijgen die kunnen 
leiden tot hoger eiwit expressie en betere eiwit 
oplosbaarheid. Ligatie-onafhankelijke klone-
ring (LIC) door middel van de pET-NKI-LIC 
vectoren is tegenwoordig de standaard metho-
de in ons lab en de implementatie van LIC op 
een groot aantal USPs resulteerde in een aantal 
oplosbare USP eiwitten.
 Hoofdstuk 4 laat de enzymatische
karakterisatie van de verkregen oplosbare USPs 
zien door gebruik te maken van de syntheti-
sche substraten inclusief alle zeven lysine-ge-
koppelde di-ubiquitines. De analyse laat zien 
dat de USPs zich anders gedragen in termen 
van DUB activiteit en dat gebaseerd op hun 
kinetisch gedrag ze in drie groepen verdeeld 
kunnen worden: de inactieve, de gemiddelde 
en de zeer actieve groep. Bovendien geven we 
de eerste uitgebreide analyse waarin de voor-
keur voor een Ub keten wordt vergeleken. We 
laten ook zien dat de USPs een gemiddelde 
activiteit vertonen tegenover de zeven di-ubi-
quitine topoisomeren. De activiteit is variabel 
tussen de USPs en de Ub keten-type voorkeur 
in het geval van USP7 is toe te schrijven aan 
de bindingsaffiniteit (KM) voor zijn substraat. 
Tenslotte laat hoofdstuk 4 zien dat het bestaan 
van intermoleculaire modulerende domeinen 
(HUBL en ZnF-UBP) en intramoleculaire 
modulatoren (GMPS en UAF1) in USPs mee-
helpen aan de regulatie van de DUB activiteit 
door voornamelijk de katalytische omzetting 
(kcat) toe te laten nemen. 
 In hoofdstuk 5 wordt de driedi-
mensionale kristal structuur van het minimale 
katalytische domein USP4-D1D2 getoond en 
wordt een nieuwe rol voor het Ubl domein dat 
geïntegreerd is in het katalytische domein van 
USP4, beschreven. De kristal structuur van 
het USP4 katalytisch domein heeft het gecon-
serveerde UPS-lijkende vouwing met zijn ty-
pische Ub bindingsplaats. Onze bevindingen 
laten zien dat het geïntegreerd Ubl domein 
als een intermoleculaire modulerende domein 
functioneert door de DUB activiteit van USP4 
te inhiberen. Deze inhiberende functie van het 
geïntegreerde Ubl domein wordt tot stand ge-
bracht door in het katalytische domein van 
USP4 te binden met eenzelfde affiniteit als 
voor Ub en hierdoor wordt Ub substraat bin-
ding voorkomen. Verder is het interessant dat 
USP39, een bindingspartner van USP4, aan 
hetzelfde Ubl domein kan binden en hiermee 
de inhibitie van het Ubl domein opheft.
 Tezamen illustreert het werk gepre-
senteerd in dit proefschrift, hoe complex en 
divers de functie en de regulatie van deze re-
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latieve kleine USP familie zijn. Hopelijk geeft 
dit werk interessante aanknopingspunten voor 
toekomstige onderzoeken en draagt het bij in 
het begrijpen van deze intrigerende DUB fa-
milie, de USPs.
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LIST OF ABBREVIATIONS
DNA  deoxyribonucleic acid
Ub  ubiquitin
Ubl  ubiquitin-like
Da  Dalton
E1  ubiquitin activating enzyme
E2  ubiquitin conjugating enzyme
E3   ubiquitin ligase
UBA1  ubiquitin-like modifier activating enzyme 1
MgATP   magnesium adenosine triphosphate
RING  Really Interesting New Gene
HECT  Homologous with E6-associated protein C-Terminus
URM1  ubiquitin related modifier 1
ATG12  autophagy related protein
Nedd8  neural precursor cell expressed, developmentally down-regulated 8
SUMO  small ubiquitin-like modifier
FAT10  ubiquitin like protein
ISG15  interferon-stimulated ubiquitin like protein
LC3  ubiquitin like protein
Cys  cysteine
Ser  serine
Thr  threonine
UBD  ubiquitin-binding domain
ZnF-UBP zinc finger ubiquitin-specific protease
UIM  ubiquitin-interacting motif
UBA  ubiquitin-associated
UCH  ubiquitin C-terminal hydrolase
USP  ubiquitin-specific protease
OTU  ovarian tumor 
JAMM  JAB1/MPN/MOV34 
PCNA  proliferating cell nuclear antigen
K  lysine
ERAD  endoplasmic-reticulum-associated-degradation
UFD  ubiquitin fusion degradation
BRCA1  breast cancer 1
BARD1  BRCA1-associated RING domain protein 1
Ufd2  ubiquitin chain elongation enzyme
LUBAC  linear ubiquitin chain assembly complex
NF-κB  nuclear factor kappa-light-chain-enhancer of activated B cells
Ile  isoleucine
Kd  dissociation constant 
TRAF  TNF receptor associated factor
RAP80  receptor associated protein
NEMO  NF-κB essential modulator
ABIN  A20-binding inhibitor of NF-κB
UBAN  ubiquitin-binding in ABIN and NEMO
IΚΚ  ΙκΒ kinase
TNF-α  tumor necrosis factor-α
SAGA  Spt-Ada-Gcn5 acetyltransferase
Akt  kinase
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IκB  inhibitor of NF-κB
TNF-α  tumor necrosis factor α
IL-1  interleukin 1
IKK  IκB kinase
SCF  Skp, cullin, F-box containing 
RIP  ribosome inactivating protein
HR  homologous recombination
UBE2T  ubiquitin conjugating enzyme
HERC2  HECT domain and RCC1-like domain containing protein 2
RNF8  Ring finger protein 8
RNF168  Ring finger protein 168
RIDDLE  radiosensitivity, immunodeficiency, dysmorphic features and learning difficulties
Ubc13  ubiquitin conjugating enzyme 13
53BP1  p53 binding protein 1
UPS  Ubiquitin-proteasome system
CYLD  cylindromatosis (turban tumor syndrome)
Wnt  wingless int
TGFβ  transforming growth factor beta
BCL-2  B-cell lymphoma 2
MCL1  myeloid cell leukemia 1
Mdm2  murine double mutant 2
COP1  caspase recruitment domain-containing protein 1
Pirh2  p53-induced ring-h2 domain
ARF-BP1  alternate reading frame-binding protein 1
HAUSP  herpesvirus associated ubiquitin-specific protease
PTEN  phosphatase and tensin homolog
Asp  aspartate
Asn  asparagines
DUSP  domain in USPs
Rad23  UV excision repair protein 23
Dsk2  ubl/ub associated containing protein
SG  structural genomics
RIKEN  Rikagaku Kenkyusho (institute of physical and chemical research)
PSI  protein structure initiative
SGC  structural genomics consortium 
SPINE  structural proteomics in Europe
NMR  nuclear magnetic resonance
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